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AIM 
 
The aim of this PhD project was to investigate the control of expression of ST3Gal-I 
(and C2GnT1) in breast cancer and to determine the involvement of COX-2 in the 




Aberrant glycosylation is a common phenotypic change observed in malignancy. 
Changes in mucin-type O-glycosylation in breast cancer can result in the expression of 
truncated core 1-based sialylated glycans rather than core 2-based glycans found in the 
normal gland. This is partly due to changes in the expression of glycosyltransferases. 
C2GnT1 expression, the glycosyltransferase that initiates branching in normal 
mammary epithelial cells, can be decreased in tumour cells while, in contrast, the 
expression of the sialyltransferase ST3Gal-I, which causes chain termination, increases 
in breast cancer. 
When dendritic cells mature, prior to migration to lymph nodes, their O-glycosylation 
changes by decreasing C2GnT1 expression and increasing ST3Gal-I expression. This 
can be controlled by PGE2, the major product of COX-2. The project described in this 
thesis investigated the control by PGE2/COX-2 of ST3Gal-I and C2GnT1 expression in 
breast carcinomas. Importantly, COX-2 is normally only expressed during inflammation 
but is found to be upregulated by many carcinomas including those of the breast. 
In the breast cancer line T47D, mRNA expression of ST3Gal-I was induced by PGE2, 
resulting in increased sialyltransferase activity. Induction of COX-2 in the MDA-MB-231 
breast cancer cell line also resulted in increased expression of ST3Gal-I and increased 
sialylation of the ST3Gal-I substrate. This effect on sialylation could be reversed by the 
selective COX-2 inhibitor celecoxib. The use of siRNA to knock-down COX-2 and the 
over-expression of COX-2 in MDA-MD-231 confirmed the involvement of COX-2 in the 
upregulation of ST3Gal-I. Moreover, analysis of the expression of ST3Gal-I and COX-2 
in 78 primary breast cancers showed a significant correlation between the two 
enzymes.  
COX-2 expression in breast cancer has been associated with poor prognosis. Thus 
these results suggest the intriguing possibility that some of the malignant characteristics 
associated with COX-2 may be via the influence that COX-2 exerts on the glycosylation 
of tumour cells. 
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ST3Gal-I is a glycosyltransferase overexpressed in breast cancer that is involved in 
tumorigenesis (Burchell et al.1999, Picco et al. 2010). This chapter will firstly describe 
breast cancer and the role of glycosylation in this disease, in which the different classes 
of glycans will be discussed with a particular focus on O-glycans and ST3Gal-I structure 
and function.  
COX-2 is the target of NSAIDs (anti-inflammatory non steroidal drugs) (Minghetti, 2004) 
and its mechanism and regulation in inflammation and cancer will be discussed. The 
final section will show glycosylation involvement in inflammation and possible 
interactions between ST3Gal-I and COX-2. 
 
 
1.2 Breast Cancer. 
 
1.2.1 The epidemiology of breast cancer. 
 
Breast cancer is the most common form of malignant disease among women in 
Western countries, and it is second to lung cancer as the cause of cancer death. The 
frequency of this disease varies widely between countries and is about five times higher 
in North America than in Japan. Wide risk variations occur also within some countries. 
For example, within Italy the risk in the North is twice than the South and in Israel, Jews 
have a risk of breast cancer about four times higher than non-Jews. The increasing 
rates of disease in “low risk countries” (especially in Asia and in Africa) and the 
changing rates of disease for migrants indicate that environmental factors, such as 
diets with a high intake of meat, cheese and milk, lack of physical activity, exposure to 
mutagens (radiations) and obesity, have a strong influence on the aetiology of breast 
cancer. Other factors that influence the risk of breast cancer include age at menarche 
and menopause, age at first live birth, and other variables related to pregnancy and 
lactation. These risk factors suggest that hormones play an important role in the 
aetiology of breast cancer. This hypothesis can be demonstrated by studies on 
hormone levels and on the modest increase of breast cancer risk associated with long-
term use of hormone replacement therapy (Beral, 2003). 
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            According to a report published in the BMJ, breast cancer mortality has dropped over 
the past two decades in many European countries. This study was carried out on breast 
cancer mortality for all women and by age group (<50, 50-69, and ≥70 years) and it was 
found that England and Wales had the second greatest reduction in mortality. However 
in central European countries mortality has not declined but showed an increase during 
the same period (Autier et al. 2010).  
             
             
1.2.2 Histopathology of breast cancer and classification. 
 
The two major classifications of breast cancer are ductal and lobular carcinoma. 
Traditionally it was thought that ductal carcinoma starts in the ducts, that move milk 
from the lobules to the nipple, and lobular carcinoma starts in lobules, that produce milk 
(Pubmed Health- http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001911/).  
Breast cancer can also be classified as carcinoma in situ and invasive cancer. 
Carcinoma in situ is defined as being confined within an intact basement membrane in 
which the lumen can become filled with cancer cells. Carcinoma in situ may become 
invasive, but the transition between these two stages is not well understood (Cichon et 
al. 2010). An extensive effort is being placed on defining markers that could identify 
carcinoma in situ that develops into invasive carcinoma.   
In invasive ductal carcinoma the basement membrane is ruptured and the tumour cells 
invade the stroma. In advanced breast carcinoma, cancer cells invade the dense and 
fibrous stroma and the sorrounding area (see figure 1.1) (Kalluri et al. 2006). Malignant 
cells can metastasize initially through the lymph nodes or directly via the bloodstream. 
Metastatic breast cancer may affect almost any organ in the body, especially lungs, 
liver, bone, brain, and skin. There are about 20 histological examples of invasive breast 
carcinoma (including medullary type, mucinous carcinoma, papillary carcinoma, tubular 
carcinoma, adenoid cystic carcinoma, secretory carcinoma, inflammatory carcinoma), 
but invasive ductal (IDCs) and invasive lobular carcinomas (ILCs) account for 90% of all 
breast tumours (Bertucci et al. 2009).  
Breast cancer is also classified by stage and grade. Staging refers to the severity of  
the cancer, basing this evaluation on three parameters: the extent of the tumor (T), the 
extent of spread to the lymph nodes (N), and the presence of distant metastasis (M). 
This system is called TNM, acronym for tumour, nodes and metastasis. A number is 
added to each letter to indicate the size or extent of the primary tumor and the extent of 
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cancer spread. Most tumors can be described as stage 0, stage I, stage II, stage III, or 
stage IV. This system has been accepted by the International Union Against Cancer 
(UICC) and the American Joint Committee on Cancer (AJCC). For example, breast 
cancer classified as T3 N2 M0 refers to a large tumor that has spread outside the 
breast to nearby lymph nodes but not to other parts of the body.  
 
 
















Figure 1.1 Different stages of mammary ductal carcinoma progression (Kalluri et al. 2006 
Nature Reviews Cancer 6, 392-401). 
 
 
Tumor grade is a system to classify cancer cells in terms of differentiation and how 
abnormal appearance of the cells. This evaluation can be done at the microscope by a 
pathologist. There are four degrees of severity: Grades 1 (well differentiated), 2 
(moderately differentiated), 3, and 4 (undifferentiated tend to grow rapidly and spread 
faster). The Grading system is different for each type of cancer (American Joint 
Committee on Cancer, 2002).  
Breast cancers can also be classified by their estrogen receptor status (ERα) as being 
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1.2.3 Molecular classification of breast cancer. 
 
In 2001 Sorlie & Perou reported a study of gene expression on dissected human breast 
cancers. This study provided a new classification of tumours based on their gene 
expression which was also associated with prognosis. A total of 85 cDNA microarray 
experiments, representing 78 cancers, 3 fibroadenomas, and 4 normal breast tissues, 
were analyzed by hierarchical clustering using a 476 cDNA intrinsic clone set. From this 
paper and a subsequent paper from the same group (Sorlie et al. 2003), five main 
subgroups of breast cancer were identified (see figure 1.2).  
These consist of: 
 
1. Luminal A (ER+ve and PR+ve, HER-2-ve, low Ki67) 
2. Lumimal B (ER+ve, some can be HER-2 positive, high Ki67) 
3. HER-2 positive (ER-ve, PR-ve HER-2+ve) 
4. Basal  









Figure 1.2 Gene expression patterns of 85 experimental samples analyzed by hierarchical 
clustering. The tumour specimens were divided into five subtypes based on differences in gene 
expression (dark blue: luminal subtype A, light blue: luminal subtype B, purple: ERBB2, red: 




The five molecular subsets of breast cancer defined by gene expression profiling are 
shown in figure 1.2 (Sorlie et al 2003).  
Surrogate immunohistochemical markers such as the expression of estrogen receptor 
α (ER α), progesterone receptor (PR), HER2, EGFR and cytokeratins 5/6 (CK5/6), can 
be used to classify tumours (Blows et al. 2010, Ali et al. 2011). Using these markers, 
breast cancers have been classified into molecular subtypes and defined as luminal A 
(ER or PgR positive, HER2 negative, EGFR negative, cytokeratins 5/6 negative); 
luminal B (ER positive or PR positive, HER2 negative or positive, CK5/6 positive or 
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EGFR positive), basal phenotype (ER negative and PR negative, HER2 negative, 
CK5/6 positive or EGFR positive) or triple negative (ER negative, PgR negative, HER2 
negative).  
These subtypes have distinctive behavioural characteristics and responses to therapy. 
Thus, the molecular classifications of breast cancer can be used for prognostic and 
predictive evaluation. Statistically, patients with the ER positive phenotype receiving 
endocrine therapy have the best survival, although resistance to therapy develops in 
many patients. Triple negative breast cancer patients (ER negative, PR negative, HER-
2 negative) have a poor prognosis and specific targeted therapy is not available. Triple 




















Figure 1.3 Kaplan–Meier plot of disease-specific survival (truncated at 15 years) for ten 
subgroups in the discovery cohort. Each cluster is indicated with a different colour. The 
number of samples at risk is indicated as well as the total number of deaths (in brackets). The 
two groups with worst disease specific survival probability are marked with an arrow (Curtis et al. 
2012, Nature; 486, 346–352).  
 
 
Recently, within this broader classification of subtypes, other molecular features, which 
relate to prognosis, have been identified (Curtis et al. 2012). Using a large cohort of 
2,000 breast tumours, ten subgroups were identified with distinct clinical outcomes (see 
figure 1.3). Importantly within this study a cohort of ER positive luminal epithelial 
cancers have been identified (on the basis of acquired somatic copy number 
aberrations and gene expression profiling) as having a very bad outcome (Curtis et al. 
2012) unexpected for ER positive breast cancer patients. This group is represented by 
the green line (Intclust 2) in figure 1.3. From figure 1.3 Intclust 5 (brown line) seems to 
have a worse disease specific survival probability compared to intclust2 (green line). 
Intclust 5 is composed of ERBB2 enriched and luminal cases. These patients were 
features it may be possible to derivemore robust patient classifiers.We
show here, for the first time, that subtype-specific trans-acting aberra-
tions modulate concerted transcriptional changes, such as the TCR
deletion-mediated adaptive immune response that characterizes the
CNA-devoid subgroup and the chromosome 5 deletion-associated cell
cycle program in the basal cancers.
The integrated CNA-expression landscape highlights a limited
number of genomic regions that probably contain driver genes,
including ZNF703, which we recently described as a luminal B specific
driver11, as well as somatic deletion events affecting key subunits of the
PP2A holoenzyme complex andMTAP, which have previously been
under-explored in breast cancer. The CNA-expression landscape also
illuminates rare but potentially significant events, including IGF1R,
KRAS and EGFR amplifications and CDKN2B, BRCA2, RB1, ATM,
SMAD4, NCOR1 and UTX homozygous deletions. Although some of
these events have low overall frequencies (,1% patients) (Figs 2,
Supplementary Fig. 15 and Supplementary Tables 22–24), they may
have implications for understanding therapeutic responses to targeted
agents, particularly those targeting tyrosine kinases or phosphatases.
Finally, because the integrative subgroups occur at different
frequencies in the overall population, focusing sequencing efforts
on representative numbers from these groups will help to establish
a comprehensive breast cancer somatic landscape at sequence-level
resolution. For example, a significant number (,17%, n5 167 in the
discovery cohort) of breast cancers are devoid of somatic CNAs, and
are ripe for mutational profiling. Our work provides a definitive
framework for understanding how gene copy number aberrations
affect gene expression in breast cancer and reveals novel subgroups
that should be the target of future investigation.
METHODS SUMMARY
All patient specimens were obtained with appropriate consent from the relevant
institutional review board. DNA and RNA were isolated from samples and
hybridized to the Affymetrix SNP 6.0 and Illumina HT-12 v3 platforms for
genomic and transcriptional profiling, respectively. A detailed description of
the experimental assays and analytical methods used to analyse these data are
available in the Supplementary Information.
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Figure 5 | The integrative subgroups have distinct clinical outcomes.
a, Kaplan–Meier plot of disease-specific survival (truncated at 15 years) for the
integrative subgroups in the discovery cohort. For ea h cluster, the umber of
samples at risk is indicated as well as the total number of deaths (in
parentheses). b, 95% confidence intervals for the Cox proportional hazard
ratios are illustrated for the discovery and validation cohort for selected values
of key covariates, where each subgroup was compared against IntClust 3.
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features it may be possible to derivemore robust patient classifiers.We
show here, for the first time, that subtype-specific trans-acting aberra-
ti ns m dulate concerted transcriptional changes, such as the TCR
deletion-mediated adaptive immune response that characterizes the
CNA-devoid subgroup and the chromosome 5 deletion-associated cell
cycle program in the basal cancers.
The integrated CNA-expression landscape highlights a limited
number of genomic regions that probably contain driver genes,
including ZNF703, which we recently described as a luminal B specific
driver11, as well as somatic deletion events affecting key subunits of the
PP2A holoenzyme complex andMTAP, which have previously been
under-explored in breast cancer. The CNA-expression landscape also
illuminates rare but potentially significant events, including IGF1R,
KRAS and EGFR amplifications and CDKN2B, BRCA2, RB1, ATM,
SMAD4, NCOR1 and UTX homozygous deletions. Although some of
these events have low overall frequencies (,1% patients) (Figs 2,
Supplementary Fig. 15 and Supplementary Tables 22–24), they may
have implications for understanding therapeutic responses to targeted
agents, particularly those targeting tyrosine kinases or phosphatases.
Finally, because the integrative subgroups occur at different
frequencies in the overall population, focusing sequencing efforts
on representative numbers from these groups will help to establish
a comprehensive breast cancer somatic landscape at sequence-level
resolution. For example, a significant number (,17%, n5 167 in the
discovery cohort) of breast cancers are devoid of somatic CNAs, and
are ripe for mutational profiling. Our work provides a definitive
framework for understanding how gene copy number aberrations
affect gene expression in breast cancer and reveals novel subgroups
that should be the target of future investigation.
METHODS SUMMARY
All patient specimens were obtained with appropriate consent from the relevant
institutional review board. DNA and RNA were isolated fro samples and
hybridized to the Affymetrix SNP 6.0 and Illumina HT-12 v3 platforms for
genomic and transcriptional profiling, respectively. A detailed description of
the experimental assays and analytical methods used to analyse these data are
available in the Supplementary Information.
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enrolled before the general availability of Trastuzumab and when treated with this drug 
the disease survival increased. 
 
 
1.3 Glycobiology in breast cancer. 
 
Breast cancer can be affected by changes in posttranslational modifications (PTM) of 
proteins that occur during neoplastic transformation. As well as being important for 
biomarker detection, understanding PTM changes that drive or contribute to oncogenic 
progression will allow development of agents that inhibit these specific PTMs (Krueger 
et al. 2006).  
Glycosylation is one of the most common and important modification of proteins and 
lipids. It is defined as the reaction during which saccharide units are covalently attached 
to the target structures (proteins or lipids) and then, sequentially elongated and 
branched. Changes in the composition of glycans, added to glycoproteins and 
glycolipids, are common events in malignancy (Hakomori et al. 2002) and these 
changes can affect the course of the disease (see figure 1.4). The change in 
glycosylation can affect cell-cell interaction and signaling, adhesion properties 
(important for invasion of the tumour and metastasis) and, very importantly, tumour 
interaction with the immune system (Ohtsubo et al. 2006). These changes have been 
reported in numerous studies (Burchell et al. 2001; Hakomori et al. 2002; Ohtsubo et al. 
2006;). The changes of glycosylation in malignancy can result in a) the appearance of 
novel structures, b) the persistence of incomplete or truncated structures, c) the 
accumulation of precursors, and d) loss of expression or excessive expression of 
certain structures. Changes in the first few branches in the normal biosynthesis can 
affect the relative amount of one class of structures, causing the dominance of another. 
According to Potapenko et al., glycans are classified in four main groups that differ in 
their target attachment and the type of saccharides comprising the mature structure: N-
linked glycans, O-linked glycans, glycosaminoglycans (GAGs) (including 
glycosphingolipids (GSLs) and glycophosphatidylinositol (GPI) anchors) and 
polysaccharides (glycans without lipid or protein backbone) (Potapenko et al. 2010). 
The N-linked, O-linked glycans and GAGs, are attached to polypeptide chains (but also 
to lipids). The N-linked glycans are considered to be a co-translational modification. 
Glycosphingolipids are considered the majority of glycolipids. Glycosylation pathways 
have been better defined in the last decades, partly due to the cloning of the enzymes 
involved (glycosyltransferases) (Furukawa et al. 2001; Marth, 1996). These enzymes 
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are type II transmembrane proteins with a short cytoplasmic tail, a transmembrane 
domain and a catalytic domain facing into the Golgi lumen. There are more than 100 
glycosyltransferases involved in all processes and they are grouped into families, based 
on the type of sugar they transfer (galactosyltransferases, sialyltransferases, 
fucosyltransferases, N-acetylgalactosaminyltransferase) (Paulson et al. 1989). The 
number in the nomenclature of the glycosyltransferases represents the linkage, the 
























Figure 1.4 Glycosylation mechanism in carcinogenesis. This figure illustrates six important 




This thesis focuses on the change of expression of glycosyltransferases in O-linked 
glycosylation seen in breast cancer. The following sections will explain briefly 
glycosphingolipids, N-glycans and O-glycans in physiological conditions. Then mucin 
type O-linked glycosylation and its changes in cancer will be described in more detail. 
The Consortium for Functional Glycomics (CFG) has established a symbol system with 
coloured geometric shape, for each sugar, illustrated in figure 1.5. In the next figures 
these symbols will be used. 
 
in this pathway are catalyzed by transferases which are
encoded by a gene family termed ALG (asparagine-linked gly-
cosylation). Among its members are ALG14, encoding an en-
zyme responsible for transferring the second GlcNAc
saccharide to the GlcNAc-P-P-Dol; ALG3 coding for a transfer-
ase that attaches the second a1,3 mannose to the glycan pre-
cursor immediately after its flipping to the inner layer of ER
membrane, as well as two transferases (ALG8 and ALG10
genes) which add two terminal glucose residues to the precur-
sor prior to its attachment to a polypeptide. All of these
showed higher transcript levels in breast carcinomas in com-
parison to normal breast tissue in at least one of the investi-
gated data sets (Tables 1 and 2B; Supplementary material:
Table 3).
Additionally, several factors other than transferases them-
selves may impact efficiency of these reactions and thus pro-
gression along the pathway, including availability of
substrate. During this early stage of the N-glycan synthesis
pathway three substrates are used, namely UDP-Glc, UDP-
GlcNAc and GDP-Man. Both enzymes involved in their metab-
olism and solute carriers are therefore of relevance. Examples
of genes encoding these are PMM1, PMM2 and SLC35A3. The
former two code for enzymes that convert mannose-6-P to
mannose-1-P. Mannose-1-P is then in turn converted to
GDP-Man which serves as substrate for the sequential addi-
tion of the 9 mannose residues to the N-glycan precursor.
SLC35A3 is a solute transporter for another substrate, UDP-
GlcNAc (Figure 2B). Our analysis demonstrated elevated ex-
pression levels of SLC35A3 and PMM2 in malignant samples
compared to cancer-free tissue. PMM1, however, was down-
regulated in breast carcinomas.
2.2. Core fucosylation of N-glycans
Cores of N-glycans may be decorated with various sugar moi-
eties along their passage through Golgi. The most common
modification of the N-glycan core in mammals is the a1,6
fucosylation of the GlcNAc residue bound to asparagine
(Figure 2C). Core fucosylation is of special interest due to its
ability to modulate growth and development through altering
functional properties of integrins (Figure 1, and ). It has for
example been shown that core decoration by a1,6 fucose of
certain motifs of the a3b1 integrin complex is essential for
its association and activity (Zhao et al., 2008). In breast cancer
patients an increase in core fucosylation of N-glycans for the
circulating alpha-1-proteinase inhibitor (API) has previously
Figure 1 – Glycosylation in carcinogenesis. Glycosylation plays a principal role in a number of cellular processes of key importance for
carcinogenesis. Two metastasizing carcinoma cells are illustrated, entering distant tissue through the blood stream. Six important processes for
cancer development and progression ( – ) influ nced by various glycosyl tion types are indicated; growth receptors (especially EGFR and TbR)
are influenced by N-glycosylation in concert with galectins; growth factors and other signaling molecules may have elevated concentrations,
filtered or sequestered by glycosaminoglycans and O-glycosylated mucins; cell–cell adhesion might be mediated either directly by for example
glycosynapses consisting mainly of glycosphingolipids – or, more importantly, indirectly by modulation of integrins and cadherins by N-linked
glycosylation; O-glycosylated mucins, both secreted and membrane-bound, may constitute a physical barrier or act on specific leukocyte
receptors thereby modulating immune system response towards the malignant cells; N-linked glycosylation may enhance motility of transformed
cells by regulating int grin fu ctionality; adhesion to endothelium can be mediated by a number of mechanisms, cluding binding of Lewis
antigens by endothelial selectins.
M O L E C U L A R O N C O L O G Y XXX ( 2 0 1 0 ) 1 – 2 1 3
ARTICLE IN PRESS
Please cite this article in press as: Ivan O. Potapenko et al., Glycan gene expression signatures in normal and malignant breast
tissue; possible role in diagnosis and progression, Molecular Oncology (2010), doi:10.1016/j.molonc.2009.12.001
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Figure 1.5 Monosaccharide symbols (Varki et al. 2009, Proteomics 2009, 9, 5398–5399) 






A glycolipid consists of one or more monosaccharide residues covalently linked to a 
hydrophobic moiety, such as an acylglycerol, a sphingoid or a prenyl phosphate. In 
mammals the majority of glycolipids are glycosphingolipids (GSLs), a large and widely 
varying family of amphipathic lipids, based on the ceramide N-acylsphingoid lipid 
moiety (Kolter et al. 2002). Glycosphingolipids are present in cellular membranes 
(typically in the plasma membrane) and they play a role in organizing role in the cell 
membrane, in cell–cell recognition, cell–matrix interactions, and cell surface receptor 
and messaging, in the association with certain cell membrane receptors (eg. the 
tyrosine phosphorylation of the EGF receptor is specifically down-regulated by adding 
the ganglioside GM3) (Varki et al. 2009).  
Glycosphingolipid synthesis starts on the cytosolic face of the ER with the formation of 
ceramide (that consists of sphingosine-2-amino-4-octadecene-1,3-diol- and a fatty 
acid). Ceramide then crosses the endoplasmatic reticulum (ER) membrane and causes 
two possible reactions that lead to the formation of the core of all mammalian GSLs: 
Galactosylceramide (GalCer) and Glucosylceramide (GlcCer). The enzymes involved in 
these reactions are ceramide glucosyltransferases (Merrill et al. 2002). The GalCer 
undergoes few reactions (like sulphation that generates sulphatides) and its extention is 
limited. Since GalCer is expressed in specific cell types, like oligodendrocytes, 
Schwann cells, epithelial cells of renal tubules and the gastrointestinal tract, it has been 
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Coming soon: Enhanced version of the Glycosyltransferase database. For more
information, click here. 
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Table 1.1 Nomenclature for classification of glycosphingolipids based on Glc-Cer. The 
abbreviations and the partial structure with the sugar position is illustrated in the table (Merrill 
and Sandhoff, 2002).  
  
 
On the other hand, the next step for GlcCer is the formation of lactosylceramide 
(LacCer) by adding a β4-linked galactose residue. Unlike GalCer-derived GSLs, 
hundreds of structures can be generated from the GlcCer core including: 1) 
neolactoseries and lactoseries, that begin with the addition of a β1,3-GlcNAc or β1,4-
GlcNAc respectively 2) globoseries that are distinguished by the addition of an α1,4-
Gal; 3) gangliosides, glycolipids that are characterized by one (GM1, GM2, GM3), two 
(GD1a, GD1b, GD2, GD3), three (GT1b) or four (GQ1) sialic acid residues (Yu et al. 
2011) (figure 1.6).  
The class of gangliosides is the most common among glycosphingolipids. The name 
ganglioside was first applied by Ernst Klenk in 1942 to lipids isolated from ganglion cells 
of brain (Yamakawa et al.1996) and gangliosides are indeed mainly present in the 
central nervous system. All gangliosides (with an exception for GM4) are synthesized 
from LacCer and continue down through two pathways: the asialo pathway (also called 
the o-pathway) through the addition of a GalNAc residue, or the “ganglioside proper” 
pathway (a-, b-, and c- pathways as shown in figure 1.6) through the addition of one or 
more sialic acid residues (Maccioni et al. 1999). The addition of the sialic acids is 
performed by sialyltransferases. The first sialyltransferase that synthesizes the GM3 
structure is the ST3GAL5, by addition of a α3-sialic acid to LacCer. The 
sialyltransferase ST8SIA1 can add one or two sialic acid to form GD3 and GT3. Further, 
an addition of a GalNAc to LacCer, GM3, GD3 and GT3 results in the formation of a 
GA2, GM2, GD2 or GT2 structures. The transferase catalyzing this step is coded by 
B4GALNT1 ((1) in figure 1.6). Then a Galactose is added by B3GALT4 creating GA1, 
GM1, GD1b and GT1c. The terminal galactose residues of GA1, GM1, GD1b and GT1c 
can be sialylated by transferases ST3GAL1/-2 (number 3 in figure 1.6) (resulting in 
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cisGM1, GD1a and GT1b structures) and ST6GALNAC6 (creating GD1a, GT1a and 
GQ1ba) in all but the c-series. 
Other sialyltransferases are involved in the formation of cis-GD1 like ST6GALNAC3 and 
ST6GALNAC5, but they are less specific (Varki et al. 2009). ST6GALNAC5 has been 
associated with brain metastasis in breast cancer patients as the product of this 
sialyltransferase enhances the adhesion of cancer cells to brain endothelial cells and 
their passage through the blood–brain barrier (Bos et al. 2009).  
Alterations of gangliosides structures have been found in different diseases like 
Alzheimer’s disease, Guillain-Barre syndrome but also in aggressive angiogenesis to 
support cancer growth. This suggests that gangliosides are important targets for 






























Figure 1.6 Ganglio-series glycosphingolipid synthesis pathway. The sialylltranferases 
involved in the pathway are indicated with numbers, because the same enzymes catalyze 
several steps of the pathway (modified from Varki et al. 2009, Essentials of Glycobiology-




N-glycans are a class of glycans covalently attached to asparagine with the consensus 
sequence of Asn-X-Ser/Thr by the N-glycosidic bond, GlcNAc β1-Asn. The N-glycans 
been fully elucidated. Some attention has also been devoted to
interactions between glycosphingolipids and immune
response. In this regard GM3 and GD3 have been proposed to
reduce cytotoxicity of NK-cells and peripheral blood leuko-
cytes, perhaps by influencing the arachidonic acid cascade
(Bergelson, 1993).
5.2. Glycosynapse
At least some of the biological effects GSLs convey are medi-
ated through a somewhat unusual mechanism, emergent im-
portance of which deserves a separate mention. It has been
known for some time that GSLs have a tendenc to aggregate
in cell membranes forming clusters (Tillack et al., 1983) with-
out recruitment of cholesterol. Such aggregates are necessary
for glycosphingolipids to exert some of their biological activi-
ties. The term ‘‘glycosynapse’’ was introduced to describe
such functional GSL aggregates (Hakomori Si, 2002). The aggre-
gates have been subdivided into several subtypes depending
on function and contents (Todeschini and Hakomori, 2008).
Their importance is thought to relate to their ability to convey
adhesion – between cells (Figure 1, ) as well as between cells
and extracellular matrix – and potential to associate to and
modulate a number of key receptors such as growth factor
receptors and integrins (Todeschini and Hakomori, 2008).
5.3. Desialylation
As previously noted, glycosphingolipids are abundantly deco-
rated by sialic acid residues where sialyltransferases are of
crucial importance. The degradation process of these struc-
tures mediated by sialidases is equally interesting. Currently
three sialidases are known, encoded by NEU1, -2 and -3, each
of which has a distinct cellular localization and thus differs
functionally (Miyagi et al., 2004). Some conflicting findings as
to the effects of sialidase over-expression in malignancy
have been published. Early work suggested that activity of
these enzymes was higher in transformed cells (Bosmann
and Hall, 1974; Schengrund et al., 1973; Usuki et al., 1988). A
more recent study demonstrated that high level of the plasma
membrane sialidase (NEU3) was linked to protection from
Figure 5 – Ganglio-series glycosphingolipid synthesis pathway. (For symbol explanation, see Figure 7) Key genes involved in the pathway are
indicated, and four have been denoted numerically to indicate that the sialyltransferases encoded by these genes catalyze several steps of the
pathway (modified from Varki et al., 2009).
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are classified in three subfamilies that share the main core sugar sequence, as shown 
in figure 1.5, but differ in the chain elongation: (1) oligomannose type, in which only 
mannose residues are attached to the core; (2) complex type, in which “antennae”, 
initiated by N-acetylglucosaminyltransferases (GlcNAcTs), are attached to the core; and 
(3) hybrid type, in which, on one side, mannose residues are attached to the Manα1–6 
arm of the core and, on the other side, one or two antennae are on the Manα1–3 arm 
(Varki et al. 2009).  
N-Glycans are involved in the proper folding of newly synthesized polypeptides in the 
ER and in the maintenance of protein solubility and conformation. If some proteins are 
incorrectly glycosylated, they fail to fold properly and they are consigned to degradation 
in proteasomes (Varki et al. 2009). 
The biosynthesis of N-glycans precursor is initiated by a family of transferases, 
encoded by the ALG (asparagine-linked glycosylation) gene family. The biosynthesis of 
N-glycans begins in the ER with the transfer of GlcNAc-P from UDP-GlcNAc by the 
enzyme GlcNAc-1-phosphotransferase to the lipid-like precursor dolichol phosphate 
(Dol-P). This reaction generates dolichol pyrophosphate N-acetylglucosamine (Dol-P-P-
GlcNAc). A second N-acetylglucosamine is added and the enzyme responsible for 
transferring the second GlcNAc saccharide to the GlcNAc-P-P-Dol is ALG14. 
Consequentially, five mannose saccharides, four mannoses and three glucoses are 
added to create the mature N-glycan precursor in the cytosol. Each step is catalyzed by 
a different ALG (asparagine-linked glycosylation): for instance ALG3 is a transferase 
that attaches the second α1,3 mannose to the glycan, and ALG8 and ALG10 add two 
terminal glucose residues to the precursor, prior to its attachment to a polypeptide. The 
precursor translocates across the ER membrane bilayer, so that the glycan becomes 
exposed to the lumen of the ER. At this stage, the precursor is transferred to a protein. 
The complex that transfers the 14-sugar glycan is called oligosaccharyltransferase 
(OST). At this point a sequential removal of glucose and mannose by ER glucosidase 
and mannosidase trims the glycan to Man5GlcNAc2 that can be branched by the Mgat 
family of GlcNAc-transferases. Up to four branches can be added to this glycan by 
Mgat1, -2, -4 and 5. Cores of N-glycans may be modified with other sugar moieties 
along their passage through the Golgi. The main core modification of the N-glycan in 
mammals is the α1,6 fucosylation of the GlcNAc residue bound to asparagine (Varki et 
al. 2009).            
N-glycosylation changes occur in cancer. One of the most common interesting changes 
in malignancy affects Mgat5, mannosyl (α-1,6-glycoprotein-β-1,6-N-acetyl-
glucosaminyl-transferase). The growth of mammary tumours and metastases in mice, 
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deficient in Mgat5, crossed with polyomavirus middle T oncogene, were considerably 
less in the Mgat5−/− mice than in the controls expressing Mgat5 (Granovsky et al. 2000). 
The β1,6 branch, initiated by the Mgat5 transferase, may be elongated by a 
polylactosamine chain. Increase of expression of Mgat5 causes accumulation of 
polylactosamine chains (potentially recognized by galectins-see section 1.8) with 
consequential polyfucosylation and sialyl Lewisx production (potentially recognized by 
the selectins-see section 1.8.2 selectins). Galectins are a family of lectins that bind β-
galactosides and affect a variety of physiological and pathological processes, including 
cancer (Yang et al. 2008). The β1,6 branching by Mgat5 creates a different 
conformation from the normal outer antennae of N-glycans and can cause changes in 
the adhesive property and in the motility of a cancer cell (Saito et al. 1994). For 
instance, it was shown that exogenous galectin-3, added to Mgat5+/+ epithelial 
mammary tumor cells, isolated from Mgat5-deficient mice crossed with mice expressing 
the PyMT oncogene cells, recruits conformationally active α5β1-integrin to fibrillar 
adhesions, increases F-actin turnover and activates FAK and PI3K (Lagana et al. 
2006).  
Epidermal growth factor (EGFR) and transforming growth factor-b (TbR) receptors 
present β1,6 branching by Mgat5, which, in concert with the galectin family does not 
allow the endocytosis of these receptors and thus facilitate their retention at the cell 
surface (Partridge et al., 2004). So, Mgat5 can control cytokine signaling involving 
these receptors, which are key factors in epithelial–mesenchymal transition (Partridge 
et al., 2004).  
The change in expression of the glycosyltransferase GlcNAcT-III has been reported in 
certain tumors. GlcNAcT-III (coded by MGAT3 gene) is responsible for addition of a 
bisecting branch that competitively inhibits Mgat5 (Gu et al. 2004). Homotypic cadherin 
adhesion is influenced by  Mgat3 glycosylation (Iijima et al. 2006). The glycosylated E-
cadherin enhanced cell-cell aggregation and, in this way, it suppresses metastasis into 
melanoma cells (Yoshimura et al. 1996). Mgat3 transferase, in most cases, is 
correlated to inhibition of motility and reduction in malignancy (Bhaumik et al., 1998). 
The bisecting branch, created by Mgat5 and Mgat3, is involved in a more elaborate 
network of interactions that is still not fully understood.Potapenko et al. showed through 
expression data that the expression of other enzymes, like MGAT2, MGAT4A, 
B4GALT3 involved in the anabolic steps and MAN2A1 (involved in the catabolic steps), 
is changed in breast cancer. 
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1.3.3 O-glycosylation. 
 
In contrast to the N-glycans, which are synthesized by en-bloc transfer of a high-
mannose-type oligosaccharide to the asparagines residues within the polypeptide, O-
glycans are linked to the hydroxyl groups of serines and threonines of a protein and the 
sugars are added individually and sequentially. Other than in O-GlcNAc and O-Man 
type O-linked glycosylation, the addition of each sugar is catalyzed by the action of 
specific resident Golgi glycosyltransferases (Burchell et al. 2001). The various type of 
O-glycosylation are listed in table 1.2. 
 




a) O-linked GlcNAc. 
 
O-GlcNAcylation is an abundant posttranslational modification and consists of the 
incorporation of an O-linked β-N-acetylglucosamine (O-GlcNAc) linked to the hydroxyl 
group of a serine or threonine residue. O-GlcNAcylation is found on numerous 
cytoplasmic and nuclear proteins and in contrast to other O-glycosylation, the 
modification consists of a single O-linked-N-acetylglucosamine (Holt et al. 1986). The 
enzyme involved in the addition of O-GlcNAc is an O-GlcNAc transferase (OGT), while 
the enzyme that catalizes its removal is called D-N-acetylglucosaminidase (O-
GlcNAcase). O-GlcNAc is dynamic and its half life is very short. It has been observed 
that O-GlcNAc–containing proteins are phosphoproteins (Wells et al. 2001) and mass 
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with phosphorylation-mediated signalling (Hu et al. 2010). The difference is that 
phosphorylation is catalyzed by hundreds of distinct kinases (Venter et al. 2001), while 
there is only one transferase (OGT) and the beta-D-N-acetylglucosaminidase (OGA) 
encoded by single highly conserved genes (Shafi et al. 2000). Wells et al. supported 
the idea that O-GlcNAc transferase and the serine/threonine phosphatases PP1β and 
PP1γ, enzymes that remove phosphate from proteins, form stable and active 
complexes (Wells et al. 2001). 
GlcNAcylation is not only found in normal biological function, but also in some diseases 
like neurologic disorders and diabetes. In diabetes many proteins involved in the 
phosphoinositide-3-kinase/AKT signaling cascade, are GlcNAcylated and the 
modification induces insulin resistance (Issad et al. 2010). A decrease in O-
GlcNAcylation and consequent hyperphosphorylation of tau at the majority of the 
phosphorylation sites has been observed In patients with Alzheimer's disease. This 
causes tau to aggregate into the paired helical filaments that constitute the visible 
neurofibrillary tangles, characteristic of the disease. In an animal model of starved mice 
with Alzheimer’s disease, it was seen that the decrease of tau O-GlcNAcylation was 
probably induced by deficient brain glucose uptake metabolism (Liu et al. 2004). 
GlcNAcylated proteins are also involved in cancer. Tumor-associated proteins, like c-
Myc, are GlcNAcylated on Thr58, which competitively inhibits phosphorylation. This 
event suppresses the proteasome-mediated degradation of c-Myc (Chou et al. 1995). 
The p53 protein (tumor suppressor protein important for the prevention of cancer 
formation) is GlcNAcylated at Ser149 and this blocks ubiquitin-dependent proteolysis 
and stabilizes p53 (Yang et al. 2006). A report from Gu et al. showed that 
GlcNAcylation was significantly enhanced in metastatic lymph nodes of breast cancer 
compared to their corresponding primary tumor tissues. These results also suggest that 
GlcNAcylation might be a potential target for the diagnosis and therapy of breast cancer 
(Gu et al. 2010). 
 
 
b) O-linked mannose.  
 
The incorporation of mannose to Ser and/or Thr of a protein is known as O-mannosylat 
ion. O-α-Man was identified in yeast in the 1960s. Today it is known that most of the 
proteins in yeasts and fungi are substantially O- mannosylated (de Groot et al. 2005; 
Strahl-Bolsinger et al. 1999). Furthermore in mammals, O-mannosylation is found on 
proteins like α-dystroglycan (α-DG) from nerves and muscles (see figure 1.7) (Chiba et 
al. 1997; Sasaki et al. 1998), chondroitin sulfate proteoglycans (Finne et al.1979), and, 
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most recently, on neuron-specific protein tyrosine phosphatase, receptor type, zeta 1 
(PTPRZ1, also known as RPTPβ) (Abbott et al. 2008). A GDP-Mannose is transferred 
to dolichol-phosphate forming Dol-P-Man (Sharma et al. 1974) by a family of O-
mannosyltransferases (PMTs). An α-D-mannosidic linkage is formed through invertion 
of the anomeric configuration of the mannose through a putative flippase machinery. 
The PMT family is formed by three subfamilies PMT1, PMT2, and PMT4 (Girrbach et al. 
2000). Coexpression of the POMT1 and POMT2 proteins and the formation of their 
complex are crucial for mannosyltransferase activity (Manya et al. 2004). Differently 
from most other O-glycosylation reactions (that take place exclusively in the Golgi 
apparatus), O-mannosylation occurs in the ER (Haselbeck et al. 1983). After 
mannosylation of the target protein, further extension of the O-linked mannose residue 
takes place in the Golgi apparatus. The vast majority of mammalian O-mannosyl 
glycans represent variations of the tetrasaccharide Neu5Acα2–3Galβ1–4GlcNAcβ1–
2Manα1–Ser/Thr with different lengths (e.g., asialo) and variable fucose (α1,3-linked to 
GlcNAc) contents. The presence of mannose in the muscles and nerves and its role in 
α-dystroglycanopathies are not known. Tran et al. published a few months ago that the 
presence and specific location of O-Man can determine the site of O-GalNAc addition 
on α-DG, so the absence of proper O-mannosylation can alter the O-GalNAc addition. 
This plays a central role in the α-dystroglycanopathies (Tran et al. 2012). 
 
 
                                                                                          
Figure 1.7 Glycosylation of α-dystroglycan. Sequential O-glycosylation pathway of α-
dystroglycan within the cellular organelles.  
 
 
The most-studied O-mannosylated protein in humans is α-DG, that is an essential 
component of the dystrophin-glycoprotein complex (DGC) in skeletal muscles. Most 
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defects in α-DG are associated with impaired O-mannosylation. Mutations in six 
glycosyltransferase genes, including the human POMT1, POMT2, and POMGnT1, have 
been identified to cause various α-dystroglycanopathies. Mutations in either POMT1 or 
POMT2 occur in about 20% of all cases of α-dystroglycanopathy patients. These 
diseases are called autosomal recessive muscular dystrophies or congenital muscular 
dystrophies (CMD), and have variable brain and ocular abnormalities (Martin et al. 
2007;Yoshida et al. 2001).  
 
 
c) O- linked fucose. 
 
O-fucose (O-Fuc) is found on the EGF domains of different proteins and 
thrombospondin type 1 repeats (TSR). O-fucose is attached to the serine or threonine 
of the sequence -Cys-Xaa-Xaa-Gly-Gly-Thr/ Ser-Cys- on the EGF domain of human 
urokinase and in other clotting proteins, such as tissue plasminogen activator (t-PA) 
and clotting factor like factor VII (Bjoern et al.1991), factor XII (Harris et al.1993), and 
factor IX (Nishimura et al. 1992). The fucosyltransferase cDNA, responsible for the 
initiation of this modification, has been cloned and studied by Wang (Wang et al. 1996). 
In factor VII and IX, the O-fucose is extended with three additional sugars to form 
Neu5Acα2–6Galβ1–4GlcNAcβ1–3Fucα- and this particular tetrasaccharide is also 
present on many serum glycoproteins of N-glycans (Nishimura et al. 1992). The 
addition of the GlcNAc on the Fuc in β1-3 is catalized by a specific transferase. In 
contrast, the addition of sialic acid and galactose can be catalyzed by sialyltransferases 
and galactosyltransferases respectively, employed by other pathways.  
The function of these particular O-linked glycoproteins are not totally understood. In the 
case of t-PA, the O-linked fucose is essential for the binding and degradation of t-PA by 
HepG2 cells (a hepatoma cell line). The glycosylation confers a particular function to 
glycoproteins in hepatic clearance. However, it has been seen that, mutating the O-Fuc 
attachment site, had no effect on its binding to the mannose receptor. O-fucose on 
urinary-type plasminogen activator (uPA) is important to activate the uPA receptor 
(Rabbani et al. 1992). One important contribution of O-Fuc is on the protein receptor 
Notch, involved in cell-fate determination. 
Notch-1 has a series of 36 tandem EGF-like modules, and 12 of them have the 
consensus sequence for O-fucosylation. Addition of fucose residues to the hydroxyl 
group of serine and threonine occurs in the endoplasmic reticulum (ER) and is 
catalyzed by “protein O-fucosyltransferase” or Pofut1 (Stanley et al. 2007). The O-
linked fucose can be elongated by sequential addition of three other sugar residues: N-
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acetylglucosamine (GlcNAc), galactose (Gal) and sialic acid (SA). 
Fringe is a glycosyltransferase that modifies Notch (Moloney et al. 2000). This 
enzyme, called Fringe in Drosophila and Lunatic, Manic and Radical Fringe in 
mammals, transfers GlcNAc on the added O-linked fucose (see figure 1.8)  (Bruckner et 
al. 2000). Fringe mutations only alter some aspects of Notch signalling, in contrast the 
addition of O-fucose by POFUT1 is absolutely necessary for notch function (Yao et al. 
2011), so POFUT1 mutants can result in loss of Notch signaling (Okajima et al. 2002).  
O-fucosylation occurs also on TSP-1 (Thrombospondin-1) repeats. Specifically the O-
linked disaccharide Glc-Fuc-O-Ser/Thr is found in the motif CSX(S/T)CG of TSP-1 
(Hofsteenge et al. 2001). Apart from this protein the vast majority of fucosylation is 
found on EGF domains. 
 
                          
Figure 1.8 Canonical Notch signal transduction pathway and glycans of mammalian 
Notch1 on EGF repeats. The EGF repeats of both Notch receptors and ligands contain 
consensus sites for the addition of O-­‐fucose and O-­‐glucose glycans and AsnXSer/Thr 
consensus sequons for the addition of N-­‐glycans. The glycosylation of Notch determine the 
interaction between receptor and ligand. In the canonical Notch signaling pathway the Notch 
ligands Delta-like or Jagged (in mammals) bind to the extracellular domain of Notch receptors 
(NECD) on apposing cells and two sequential proteolytic cleavages ensue. When ligand binds, 
the dimeric Notch1 receptor is cleaved by an ADAM protease. The released ECD is 
endocytosed by the ligand-­‐expressing cell, and there it is cleaved by a complex with γ-­‐secretase 
activity. The released NICD forms a complex with the transcriptional repressor CSL/Rbp-­‐Jκ and 
activators (master-­‐mind like; MAML) and induces the expression of target genes such as Hes 
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d) O- linked glucose. 
 
Like the O-Fuc, the O-Glc pathway is an unusual form of posttranslational modification. 
While O-fucosylation occurs on TSP-1 repeats and EGF-like domains, O-glucosylation 
and O-fucosylation together occur only on EGF domains. Several serum proteins (factor 
VII, factor IX, protein Z) contain O-Glc on their epidermal growth factor-like repeats. The 
consensus sequence on the EGF domain by O-Fuc and O-Glc is different and the 
presence of both glycan types on a single EGF domain has been shown only for factor 
VII (Bjoern et al.1991) and δ-like protein 1 (Krogh et al.1997). A trisaccharide form of O-
glucose (Xyl-α1,3-Xyl-α1,3-Glc-β1-O-Ser) was found on bovine and human factor IX, 
human factor VII and protein Z (Nishimura et al.1989). Each of the xylose and the 
glucose residues is added sequentially by a separate glycosyltransferase: O-
glucosyltransferase (Poglut) for transferring the glucose on proteins such as Notch, 
coagulation factors VII and IX, protein Z, Delta-like protein, and thrombospondin (Shao 
et al. 2002), β-D-glucoside α-1,3-D-xylosyltransferase is responsible for adding the 
α1,3-Xyl onto O-glucose (Omichi et al. 1997), the α-D-xyloside α1,3 xylosyltransferase 
for adding the α1,3-Xyl onto Xyl (Minamida et al.1996). A consensus sequence for the 
addition of glucose has been recognized on these proteins: a C1-X-S-X-P-C2, where C1 
and C2 are the first and the second cystein of the EGF domain (Harris et al. 1993).  
The Notch-1 protein also has O-glucosylation sites in human and in Drosophila. In 
Drosophila eighteen of the 36 EGF repeats on the Notch receptor contain the 
consensus O-glucosylation motif. Leonardi et al. showed that all the glycosylated sites, 
not just a single one, contributes to maintain robust signalling of Notch, especially at 
higher temperatures (Leonardi et al. 2011). The O-glucosyltransferase that regulates 
Notch signaling is called Rumi (Lee et al. 2010). Rumi enzymes can have also a 
significant protein O-xylosyltransferase activity and the donor substrate (UDP-glucose 
or UDP-Xyl) used depends on the amino acid sequences of the recipient EGF repeat 
(Leonardi et al. 2011). 
In humoral defence the first step is the binding of C1q to the antibody IgG. 
Immunoglobulin G (IgG) antibodies are composed of two heavy chains (HC) and two 
light chains (LC) that form the Fab (fragment antigen binding) and Fc regions of the 
antibody. Within the Fc portion of the antibody, C1q binds to the CH2 domain (Yasmeen 
et al. 1976). Duncan and Winter localized the binding sites of C1q to three side chains, 
Glu 318, Lys 320 and Lys 322 in the mouse IgG2b isotype (Duncan & Winter, 1998).  
IgG is glycosylated in the Fc region at asparagine (Asn) residue 297 and the N- glycan 
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occuring has a biantennary complex structure with the following glycan sequence of 
GlcNAc2-Man3-GlcNAc2-Gal2 (Dwek et al. 1995). Significant reduction in Clq and Fc 
receptor binding was observed, when the quantity of galactose was decreased 
(Tsuchiya et al. 1989). Mimura, Church et al. reported that glycosylation in the Fc region 
gives CH2 domain stability, while stepwise truncation of the N-glycan sugar moieties 




e) O-linked galactose. 
 
O-galactosylation is a special type of O-linked glycosylation and consists of a galactose 
on hydroxylysines of few proteins like collagen, surfactant proteins (Larsen et al. 1999), 
complement factor I (Clq) and mannan-binding proteins (Iobst and Drickamer 1994) in 
the sequence -Gly-Xaa-Hyl-Gly- (Michaelsson et al. 1994).  
Selected hydroxylysines of the collagen can be modified by adding galactose in the 
endoplasmic reticulum and the reaction is mediated by two β(1-O) 
galactosyltransferases: GLT25D1 and GLT25D2 proteins. The GLT25D1 gene is 
constitutively expressed in all human tissues, whereas the GLT25D2 gene is expressed 
only at low levels in the human nervous system. Aberrant modification of O-linked 
galactose on collagen can be involved in the etiology of connective tissue disorders 
(Schegg et al. 2009) 
Complement Factor I (fI) is a protein of the complement system, part of the immune 
system. Galactose depleted IgG reduced Clq binding and Fc receptor binding, which 




1.4 Mucin type O-glycosylation. 
 
Mucin type O-glycosylation is the main subject of this study and it will be described 
more extensively in the next paragraphs."Mucin-type" O-glycosylation is characterized 
by a GalNAc attached to the hydroxyl group of serine/threonine(Ser/Thr) (Hang et al. 
2005). Mucin type O-linked glycosylation is the most common O-linked glycosylation 
and its name derives from the fact that this glycosylation is commonly found in many 
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secreted and membrane-bound mucins (Julenius et al. 2005). Mucin O-glycosylation 
involves the transfer of single sugars or monosaccarides from their nucleotide donors in 
an individual and sequential manner and can be characterized by the following steps: 
 
a. Initiation by peptidylGalNActransferase (ppGalNAcT). 
b. Elongation reactions to form core structures. 
c.  Termination reactions by the addition of sialic acid (SA), fucose (Fuc), galactose 
(Gal) or sulphate groups (Hanisch, 2001).  
The cellular repertoir of glycosyltransferases with their distinct donor and acceptor 
sugar specificities, their sequential action and their localisation in subcompartments of 
the Golgi, all determine the cell specific O-glycosylation profile. 
 
1.4.1 Initiation of mucin type O-glycosylation by peptidyl-GalNAc 
transferases. 
 
Mucin-type O-glycosylation is initiated by a family of enzymes called peptidyl N-
acetylgalactosaminyltransferases (ppGalNAcTs), that transfer GalNAc (derived from the 
donor substrate UDP-GalNAc) to serine and threonine residues on polypeptides 
(Clausen et al. 1996). 
The first ppGalNAcT gene, to be cloned and characterised, was from bovine tissue 
(Hagen et al. 1993). This enzyme was found to have a human equivalent with a highly 
homologous nucleotide sequence that had 79 nucleotide substitutions, encoding only 6 
amino acid differences (Clausen et al. 1996), and is a type II transmembrane protein 
with a small cytoplasmatic-oriented segment (Hennet et al. 1995).  
Subsequent studies have revealed that 24 unique homologous polypeptide GalNAcT 
genes are present in humans (Hogenesch et al. 2001). In isozyme comparisons among 
human sequences, the catalytic domain of ppGalNacT2 and ppGalNacT3 exhibits 60% 
and 67% amino acid identity to the catalytic domain of ppGalNAcT1 (Paulson et 
al.1989). 
Physicochemical parameters like volume, charge, hydrophobicity of the protein 
backbone around the glycosylation site can be crucial for the protein conformation and 
for the recognition by ppGalNAcTs (Kinarsky et al. 2003). This suggests that there are 
unique active site conformations for different ppGalNAcTs. ppGalNAcT1 and -T3 utilize 
only UDP-GalNAc, while GalNAc-T2 also utilizes UDP-Gal with one peptide acceptor 
substrate (Wandall et al. 1997). ppGalNAcT4, ppGalNAcT7 and ppGalNAcT10 seem to 
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require the prior addition of GalNAc to a synthetic peptide before they can catalyze 
sugar transfer to their substrate (Ten Hagen et al. 2003). Expression of ppGalNAcT1 
RNA is ubiquitous in mammalian cells, whereas others are expressed in a cell and 
tissue specific manner (see table 1.3).  This may reflect individual roles in cell type 
specific glycosylation of one or more glycoproteins (Ten Hagen et al. 2003). 
 
 

















1.4.2 Core structures. 
 
Following the addition of GalNAc to Ser or Thr, eight possible core structures can be 
formed by adding Gal, GlcNAc or GalNAc (Figure 1.9). In humans, core 1 - 4 are the 
most common structures produced in vivo. The core 1 subtype structure is formed by 
the addition of Gal in a β1-3  linkage to the GalNAc. Core 1 is also called T antigen 
(from Thomsen-Friedenreich antigen). The glycosyltransferase responsible for the 
formation of Core 1 (T) is known as the Core 1 β1-3 galactosyltransferase (Core 1 
GalT).  
C2GnT can generate core2 from core1 by the addition of GlcNAc to the GalNAc in a 
β1-6 linkage. Core 2 O-glycan may become elongated into a mono- or biantennary form 
with the presence of multiple lactosamine structures (Galβ1-4GlcNAc) that can be 
terminated with fucose and sialic acid. There are three functional forms of C2GnT that 
have been characterized (Stone et al. 2009). 
ppGaNTase isoforma Strongest signal for transcript 
expression in adult tissuesb 
ppGaNTase-T1 ubiquitous 
ppGaNTase-T2 Liver; skeletal muscle 
ppGaNTase-T3 Pancreas, testis 
ppGaNTase-T4 sm. intestine; stomach 
ppGaNTase-T6 Placenta; trachea 
ppGaNTase-T7 Spinal cord; trachea 
ppGaNTase-T9 Brain 
ppGaNTase-T11 Kidney 
ppGaNTase-T12 Stomach; sm. intestinef 
ppGaNTase-T13 Brain 
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Figure 1.9: Core O-glycan structures and biosynthetic pathways for the core structures. 
Cancer-associated antigens are shown in parentheses (Ten Hagen et al. 2003). 
 
 
C2GnT1 is the main functional form found in breast epithelial cells. Mucin O-linked 
glycosylation in the epithelial cells of resting, pregnant and lactating breast is Core 2 
based (Dalziel et al. 2001). The C2GnT-3 enzyme is expressed in the thymus and is 
found in the breast but at very low levels (Schwientek et al. 2000). The C2GnT-2 
enzyme can also synthesize the Core 4 structure from core 3 (see figure 1.10) but the 
presence of core 3 is restricted to GI tract tissues. The core 3 (GlcNAcβ1-3GalNAcα1-
Ser/Thr) structure of the O-glycan, is synthesized by core 3 β3-N-acetylglucosamine 
(GlcNAc)-transferase (core 3 GlcNAcT) and coded for the β3GNT6 gene. B3GNT6 
gene expression is restricted to mucus-secretory tissues. The core 3 structure is 
expressed on mucins by the stomach, small intestine, and colon, but downregulated in 
colon cancer. Core 3GlcNAcT is not expressed in the breast where only core 1 and 2 
structures have been observed (Brockhausen et al. 2006, Iwai et al. 2002). However, 
Blixt et al. found a high level of autoantibodies reactive with core 3 MUC1 (MUC1 is a 
glycoprotein overexpressed in 90% of breast and other type of cancers- see section 
1.7) in some sera from a cohort of 395 breast cancer patients compared to the healthy 
controls. In the same patients, it was also found a significant correlation with reduced 
incidence and increased time to metastasis. However, as the RT-qPCR performed in 
this study confirmed the lack of expression of B3GnT6 gene, the epitope recognized by 
these autoantibodies needs to be elucidated (Blixt et al. 2011). The above mentioned 
reactions and enzymes are summarized in the figure 1.10.    














Figure 1.10 Biosynthesis of the Core structure. GalNAc (Tn antigen) can be converted to 
core 1 (T antigen) by core 1 GalT or to core 3 structures by core 3 GlcNAcT, which can be 
branched by C2GnT2 to form core 4. Core 1 can also be elongated by a β3-GlcNAcT or can be 
branched by C2GnT to form core 2. All core structures can be further extended to form complex 
O-glycans (Brockhausen 2006). 
 
 
1.4.3 Elongation of the glycan chain. 
 
Addition of Gal in a β1,4 or β1,3 linkage to the GlcNAc of core 2 results in the formation 
of a type 2 chain. Addition of Gal in a β1,4 linkage determine the formation of a 
precursor of Lewisx and SialylLewisx (Lex and SLex) and addition of Gal in a β1,3 linkage 
determine Lewisa and SialylLewisa (Lea and SLea) formation.  
The Galβ1,4 GlcNAc disaccharide is known as lactosamine and is catalysed by β4-
galactosyltransferase (β4GalT), as seen in figure 1.11. Six β4-galactosyltransferase 
genes (B4GALT is the gene name) have been cloned from mammalian sources. Each 
encodes a galactosyltransferase that utilizes the donor substrate UDP-Gal and 
transfers Gal in α 1,4-linkage to GlcNAc or Glc (Lo et al. 1998). It was reported that 
β4GalT-4 is more efficient in galactosylating mucin-type, core 2 branch 
oligosaccharides. It was also suggested that β4GalT-5 may function best in transferring 
Gal to O-glycans (Ujita et al.1998, Ujita et al.1999). Glycoproteins often bear glycans 
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Figure 1.11 Elongation and assembly of Lewis antigens. In the first case, SialylLewisx 
structure is synthesized by the addition of a β4Gal to GlcNAc (type 2 chain) by a β4-Gal-
transferase (β4-GalT), an α3-Fuc to GlcNAc by an α3-Fuc-transferase (α3-FucT), followed by 
the addition of an α3-sialic acid to Gal by an α3-sialyltransferase (ST3Gal) to form sLex. 
SialylLewisa antigen chains are synthesized by β3-Gal-transferase (β3-GalT), α4-Fuc-
transferase (α4-FucT) and ST3Gal. 
 
 
Addition of GlcNAc to the inner galactose of the backbone is mediated by several 
transferases, for example those encoded by the B3GNT1, -2, -3 and -5 genes. GlcNAc 
residues constitute the basis for the attachment of Lewis antigens as seen in paragraph 
1.4.4 (see figure 1.13) (Potapenko et al. 2010). 
In the case of Lea and SLea, the GlcNAc sugar is modified by Gal in a β1,3 linkage by 
the action of β3GalT resulting in a type 1 chain. Furthermore, branching of the 





The addition of sialic acid, Gal, sulfate and GalNAc in an α linkage can all result in the 
termination of chain extension.  One of the most common termination reactions is the 
addition of the sialic acid N-acetyl-Neuraminic acid (Neu5Ac) to Gal by the action of 
sialyltransferases ST3Gal-I (figure 1.14). ST3Gal-I is a transferase that catalyzes the 
addition of sialic acid in an α2,3 linkage to Gal β1–3 GalNAc, and thus terminates chain 
extension by inhibiting core 2 formation. The only additional sugar that can be added is 
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sialic acid in the α2,6 position to GalNAc catalyzed by ST6GalNAcII, generating 
disialylT (Burchell et al. 1999). As ST3Gal-I uses the same substrate (core 1) as 
C2GnT1 there is competition between the two enzymes for their common substrate 
(Gal β1-3 GalNAc) (Dalziel et al. 2001). ST3Gal-I and its product SialylT (ST) are very 
important in the immune system. T cell maturation is accompanied by regulation of the 
sialyltransferase ST3Gal-I (Priatel et al. 2000). This subject will be discussed more in 










Figure 1.12 General pathways of O-linked glycosylation in normal mammary gland. In the 
normal mammary gland  Core1 is converted to Core2.  
 
 
Terminal GlcNAc residues, and especially those of core 2 structures, can be used as 
the basis for the attachment of Lewis antigens. These are antigens expressed on the 
surface of erythrocytes and a variety of cell types, including some epithelia (Narita et al. 
1993). These antigens are common to many types of glycans, including N- and O-
linked glycans as well as glycosphingolipids. Structurally these epitopes are composed 
of fucosylated three lactosamine units (Gal-GlcNAc) that can be either linked in a β1-3 
or β1-4 (Figure 1.11).   
β-1,3-Galactosyltransferases (B3GALT1, -2 and -5 genes) catalize the formation of the 
structure to be a type 1 Lewis epitope (Lea, SLea and Leb structures) as shown in figure 
1.11. On the other hand, β-1,4-galactosyltransferases 1, 2, 3 and 4 (B4GALT1, -2, -3, -
4) will synthesize type 2 Lewis antigens (for example Lex and Ley) by transferring a 
galactose to the GlcNAc saccharide in a β-1,4-linkage. This galactose may be 
fucosylated or sialylated. Fucosyltransferase 3 (FUT3) transfers a fucose in an α1,4 
residue on the GlcNAc to give Lea or Leb structures. Fucosyltransferase 3, 7 and 9 
(FUT3, FUT-7 and FUT9) transfer a fucose in an α1,3 linkage on type 2 antigens to 
give Lex and Ley. FUT3, 5 and 6 can also add a fucose on the Gal of short glycolipids. 
ST3GAL3 and -4 yield SLea by a transfer of a sialic acid in α1,3, `and ST3GAL6 activity 
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synthesized by fucosyltransferases 1 and 2 (FUT1 and FUT2) (Julien, Ivetic , 
Grigoriadis , QiZe , Burford , Sproviero  et al. 2011;Potapenko et al. 2010). The 
enzymes involved in the synthesis of sLex on glycoproteins are in figure 1.13.  
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1.5 Change of mucin type O-glycosylation in breast cancer. 
 
The epitopes found in cancer includes 1) β6GlcNAc branching in N-linked structure; 2) 
GM2, GD3 in lipid-linked structure, 3) sialyl-Tn, Tn in O-linked structure; 4) sialyl-Lex, 
sialyl-Lea, and Ley in either N-linked, O-linked, or lipid-linked structure and 5) T and ST 
in O-linked structure that are tumour associated structures. 
As described in section 1.3.2, β1,6 GlcNAc branching in N-linked structure added by 
MGAT5 are abundant in breast cancer tissues and other types of cancer (colon, 
leukemia etc. ) with high metastatic potential (Yoshimura et al. 1995, Fernandes et al. 
1991). 
Gangliosides have a role in cancer progression since 1) they act as 
immunosuppressors, 2) GM3 and GD2 are important in angiogenesis, 3) they regulate 
adhesion/motility fundamental in metastasis 4) they are modulators of signal 
transduction (Birklé et al. 2003). Gangliosides are expressed in breast, prostate, brain, 
lung and other type of cancer (Steenackers et al.2012, Hatano et al. 2011, Basu et al. 
2012, Segatori et al. 2012). 
STn is over-expressed in many epithelial cancers with the highest frequencies in 
pancreas, colorectal and ovarian cancers (Julien et al. 2012). Hence STn over-
expression occurs in carcinogenesis in tissues that normally don’t express the antigen 
(Ogata et al. 1998). It can be considered a good tumor marker of carcinogenesis and 
potentially useful for diagnosis (Julien et al. 2012). 
Sialyl Lewis antigens, sialyl Lewis a and Sialyl Lewis x, are used as tumor markers, 
since they are overexpressed in the majority of cancers (colon, prostate, breast, 
melanoma, lung, liver etc.) and they are associated with tumor progression and 
metastasis (by enhancement of cancer cell adhesion to endothelial E-selectin).  
In a screening of 28 mucinous adenocarcinomas from different locations (stomach, 
ampulla of Vater, colon, lung, breast and ovary), the O-linked glycoforms in 50% of the 
cases detected were Tn/STn/SLea/SLex-MUC1 and STn/SLea/SLex-MUC2 glycoforms 
and T/SLea-MUC2, STn/T/SLea/SLex-MUC5AC and STn/T/SLea/SLex-MUC6-were 
identified in a variable percentage of cases from different organs (Pinto et al. 2012).  
In the following section we will concentrate on the last three classes of glycans with a 
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1.5.1 Premature O-linked glycan chains observed in breast cancer. 
 
Differences of cellular glycosylation are observed between normal mammary epithelial 
cells and breast cancers. As discussed above, in normal resting, pregnant and lactating 
breast, mucin O-glycans are largely extended (core 2 type) structures. The addition of 
GalNAc is followed by the addition of Gal to form core 1 (T epitope) and core1 (T) acts 
as a substrate for the C2GnT1 enzyme, leading to the formation of branched, complex, 
core 2 glycans.  
In contrast, mucin O-glycans found in breast carcinomas is often truncated core 1 
based structures. Tn and T are expressed on breast cancer cells and are associated 
with a poor prognosis (Imai et al. 2001, Varki et al. 2009). 
The activity of Core1 GalT, the enzyme responsible for the formation of core1 (T), 
requires the expression of Cosmc (core 1 β1,3Gal-T-specific molecular chaperone). It 
was demonstrated that mutation of this chaperone results in a loss of core 1 structures 
(Ju et al. 2002, Wang et al. 2010) and can explain the expression of the tumour-
associated structure Tn and sialylated Tn (Neu5Acα2,6GalNAc) (see figure 1.14). 
However, in our lab it was found that Cosmic mutations are not the mechanism 
responsible for the expression of Tn and STn in breast cancer (paper in preparation).  
In contrast, one mechanism that is responsible for the increase in core 1 structures is a 
change in the expression of glycosyltransferases, particularly an increase in the 
expression of the sialyltransferase, ST3Gal-I, and a decrease or a loss of C2GnT1 
(Burchell et al. 2001).  ST3Gal-I, (Burchell et al. 1999) is not found in normal breast 
(see figure 1.12 and 1.14) and a high expression of this enzyme is associated with 
aggressive disease and may be immunosuppressive (Mungul et al. 2004). Furthermore, 
in around 25-30% of breast cancer the transcription of the sialyltransferase 
ST6GalNAc-I is turned on. This enzyme adds sialic acid, Neu5Ac, in α2,6 linkage to 
GalNAc linked to Ser or Thr, thus creating the STn epitope (Sewell et al. 2006). 
ST6GalNAc-I competes with Core1 glycosyltransferase and it has been shown to be 
located throughout the Golgi (Sewell et al. 2006). Of the short O-glycan expressed in 
carcinoma, the disaccharide, STn, is the most tumour specific (Julien et al. 2003).  
In summary the glycans on breast cancer cells can consist of Tn, T, STn, ST. However 
carbohydrate antigens, such as sLex and sLey, that are normally found on the periphery 
of long side chains, have also been demonstrated to be present in breast carcinomas 
(Nakagoe et al. 2000; Julien, Ivetic , Grigoriadis , QiZe , Burford , Sproviero  et al. 
2011). These epitopes will be dealt with in detail in the next sections. 
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1.5.2 Abnormal glycosylation on peripheral antigens. 
 
Although the Lewis and SialylLewis (Le and sLe) antigens can normally be found on 
lymphocytes that migrate from the blood stream to the tissues, they are not extensively 
found on mucin-like proteins expressed by epithelial cells. Sialyl Lewisa (SLea) and 
sialyl Lewisx (SLex) are abnormally found on glycoproteins in lung, colon, stomach and 
breast cancers and they are considered to be tumor-associated markers (Soejima & 
Koda, 2005). Fukushi et al. and Fukushima et al. reported decades ago that Lewis 
antigens were functionally important terminal glycan epitopes implicated in breast 


















Figure 1.14 Pathways of O-glycosylation in normal breast tissue and carcinoma. In breast 
carcinoma shorter O-glycans are formed by the increased expression of ST6GalNAc-I or 
ST3Gal-I. On the other hand, in normal epithelial breast O-Glycan structures are mainly core 2-
based resulting from the action of C2GnT-I on core 1 O-glycans (Sewell et al. 2006). 
 
 
Among the group of several type 2 antigens, SLex has been reported to have the 
prevalence in breast cancer cells (Matsuura et al.1998). Potapenko et al. reported an 
upregulation of enzymes like B4GALT1, -2, -3, FUT5 and ST3GAL4 in breast cancer. 
However down-regulation of FUT4, FUT9, FUT10, ST3GAL3 and ST3GAL6 genes was 
also observed (Potapenko et al. 2010). According to Recchi et al. ST3Gal III is the most 
expressed sialyltransferase involved in sialylation of Lewis antigen (Recchi et al. 1998) 
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(see section 1.6.2). In this lab it was demonstrated that sLex expression is associated 
with ER-negative status, lymph node involvement, and high grade of breast tumors, but 
not with the survival of patients. Moreover, in ER-negative breast tumors there was a 
higher expression of glycosyltransferases FUT3, FUT4, and ST3GAL6 (Julien, Ivetic , 
Grigoriadis , QiZe , Burford ,Sproviero  et al. 2011). Interestengly, FUT3 was one of the 
16 genes signature predicting distant metastasis in lymph node negative, ER-negative 
breast cancer (Wang et al. 2005).  However high levels of sLex in ER-positive cancers 
is correlated with bone metastasis, a metastatic site prevalent with ER positive tumours 
(Julien, Sproviero et al. 2011). Adhesion of cells to the endothelium can be mediated by 
E-selectin via sLex. E-selectin (also known as CD62A, ELAM-1) is a sialic acid-binding 
lectin (sugar binding protein-see section 1.8.2), expressed by endothelial cells, when 
they are activated by cytokines (Lowe et al. 1990). Importantly, E-selectin is 
constitutively expressed on the endothelial cells in bone marrow and in small vessels 
adjacent to tumor nests in primary breast cancer (Kobayashi et al. 1998).  
There are therapies that inhibit sLex binding to selectins, like glycosyltransferase 
inhibitors and receptor inhibitors for the treatment of cancer.  
A disaccharide precursor of sLex, GlcNAcβ1,3Galβ-O-napthalenemethanol, reduced 
levels of sLex on the surface of colon adenocarcinoma cells and decreased the 
interactions with selectins sufficiently to reduce lung metastasis in a murine tumour 
model (Foster et al. 2003). Shirota et al. showed that co-administration of GSC-150, an 
analogue of sLex, with the colon carcinoma cell line KM12-HX to mice reduced 
metastasis to the liver, compared with mice treated with the cells alone (Shirota et al. 
2001). Recently, Rillahan et al. showed the development of inhibitors of some 
fucosyltransferases and sialyltransferases that reduced the expression of sialyl Lewis  x 
on myeloid cells, resulting in loss of selectin binding and impaired leukocyte rolling. 
Other inhibitors of SLex, like GlycoDesign (GD39), Oxford Glycoscience (OGT719), 
GlycoGenesys (GCS-100), are currently under development in pharmaceutical 
companies. These data suggest that the sLex–selectin interactions contribute to 





ST3Gal-I is a sialyltransferase that catalyzes the addition of sialic acid in an α2,3 
linkage to Galβ1–3GalNAc, and, thus, terminates chain extension by inhibiting core 2 
formation (Burchell et al. 1999).. ST3Gal-I is the main subject of this thesis, so this 
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section will explain the class of sialyltransferases in general with an emphasis on the 
ST3Gal family. Specifically, ST3Gal-I (gene and protein) structure will be described and 
its role in the immune system, in diseases and in breast cancer will be dealt.  
 
 
1.6.1 Sialic acids and sialyltransferases. 
 
Sialic Acids (SA) form a large family of 9 carbon sugars. The most common sialic acid 
added to O-glycans is N-acetyl-Neuraminic acid (Neu5Ac or Neu-5-amido-3,5-dideoxy-
D-glycero-D-galacto-nonulosonic acid) (Varki et al.1997). Sialic acids derivatives are at 
the terminal positions of many oligosaccharides of glycoproteins, which determine the 
half-lives of many circulating glycoproteins and affect cell behavior (Zeng & 
Gabius,1992). In fact, these molecules are involved in cell-cell and cell-matrix 
interactions and, thus, in molecular recognition during tumor development, 
differentiation and progression (Wang et al. 2005). Sialyl residues are linked to 
galactose (Gal) residue via α2,6 or α2,3-linkage or linked to N-
acetylgalactosamine(GalNAc) via α2,6-linkage. Sialic acid can also be linked to another 
sialic acid on the C8.  
The transfer of Neu5Ac from CMP donors to glycoconjugates in the Golgi is catalyzed 
by a large family of sialyltransferases (Harduin-Lepers  et al. 2001), which differ in their 
substrate specificity, tissue distribution and various biochemical parameters.  Each 
sialyltransferase is linkage specific and has its own substrate specificities. There are 
four subgroups of these enzymes: the ST3Gal (α2,3-ST), ST6Gal (α2,6-ST), 
ST6GalNAc, and ST8Sia (α2,8-ST) families (Takashima et al.1999) (shown in table 
1.4). Every family is further classified into other subfamilies. All ST3Gal enzymes 
transfer Neu5Ac residues in 〈2,3-linkage to terminal Gal in glycoproteins or glycolipids. 
ST3Gal-I and -II transfer Neu5Ac on the structure Galβ1,3GalNAc-R, whereas the 
ST3Gal-III, -IV, -V, and -VI use the oligosaccharide isomers Galβ1,3/4GlcNAc-R and 
the ST3Gal-V subfamily transfers the sialic acid only on the lactosylceramide (i.e. 
Galβ1,4GlcNAc-Cer), giving rise to the synthesis of the ganglioside GM3 (Harduin et al. 
2005). There are only two sialyltransferases in ST6Gal family, ST6Gal-I and –II. They 
both have Galβ1,4GlcNAc-R as the acceptor substrate. The enzymes of the 
ST6GalNAc family transfer Neu5Ac residues in α2,6 linkage to the GalNAc residues, 
found in O- glycosylproteins (ST6GalNAc-I, -II and -IV) or found in glycolipids 
(ST6GalNAc-III, -V and -VI). Enzymes of the ST8Sia family catalyze the transfer of 
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Neu5Ac residues in α2,8-linkage to other Neu5Ac residues found in glycoproteins and 
glycolipids (Wang et al. 2005).  
 
 











Like all glycosyltransferases, sialyltransferases are type II transmembrane 
glycoproteins with a short amino (NH2) cytoplasmic tail, a 16-20 amino acid 
transmembrane domain, a highly variable stem region, and a large carboxyl (COOH)-
catalytic domain, which resides in the lumen of the Golgi (Datta et al. 1995). One 
conserved Cys residue is found in each of the L- and S-sialylmotifs, which are involved 
in disulphide bond formation and are essential for correct conformation and activity 
(Geremia et al.1997).  
 
 
1.6.2 ST3Gal enzymes. 
 
There are six ST3Gal gene sub-families that have been identified in various vertebrate 
genomes. Recombinant enzymes of the ST3Gal family catalyze the transfer of sialic 
acid in 〈2,3-linkage to the terminal Gal residues found on glycoproteins or glycolipids. 
There are two main subfamilies: 1) ST3Gal-I and ST3Gal-II subfamilies 2) ST3Gal III, 
ST3Gal IV, ST3Gal V and ST3Gal VI sub-families (Hashimoto et al. 2009). ST3Gal III, 
ST3Gal IV and ST3Gal VI catalyze the transfer of sialic acid on the Gal residue of the 
disaccharide Galβ1,3(4)GlcNAc of glycoprotein or glycolipids.  
In breast cancer, ST3Gal III, involved in sialylation of Lewis antigen formation, is the 
most expressed sialyltransferase and correlates to tumour size and the number of 
axilary nodes. ST3Gal III expression was positively correlated to the expression of 
ST6Gal I and ST3Gal IV, to tumor size, and to the number of involved axillary nodes. 
Patients with high ST3Gal III expression had a shorter overall survival, although the 
Sialyltransferase	  subgroups	   Linkage	  
ST3Gal	   Neu5Acα2,3	  to	  Gal 
ST6Gal	   Neu5Acα2,6	  to	  Gal	  
ST6GalNAc	   Neu5Acα2,6	  to	  GalNAc	  
ST8sia	   Neu5Acα2,8	  to	  Neu5Ac	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cohort size (n=49) was relatively small (Recchi et al.1998). ST3Gal IV and VI catalyze 
the transfer of sialic acid on Galβ1,3GlcNAc and preferentially on Galβ1,4GlcNAc 
sequence, found in the carbohydrate moieties of glycoproteins and glycolipids. ST3Gal 
VI is more specific in the synthesis of sLex on ceramide (see figure 1.13) (Okajima et 
al.1999). Human and mouse ST3Gal V leads to the biosynthesis of GM3 because it 
adds a sialic acid on lactosylceramide (LacCer, Galβ1,4GlcCer). This enzyme is also 
known as the GM3-synthase and it can be released in serum in a soluble form after 
cleavage of the N-terminus (Richardson et al.1995). ST3Gal V in placenta can use also 
GalCer, GA1 and GA2.50 as substrates. 
In the second subfamily, ST3Gal-I and ST3Gal-II use as substrate only the disaccharide 
Galβ1-3 GalNAc found on glycoproteins (core1 of O-glycosylproteins) and glycolipids 
(asialo-GM1 and GM1a) (Hatano et al. 2011). The members of these two gene sub-
families show the same number of exons and intron positions and the nucleotide and 
amino acid sequences of hST3Gal II show 56.3% similarity to hST3Gal-I (Kitagawa & 
Paulson,1994a, Kitagawa & Paulson,1994b ). The human ST3Gal-II was cloned from a 
T-cell cDNA library and showed activity on both glycolipids and glycoproteins 
(Giordanenco et al.1997). hST3Gal II mRNA is highly expressed in heart, liver, skeletal 




1.6.3 ST3Gal-I gene and peptide structure. 
 
ST3Gal-I is a sialyltransferase that transfers Neu5Ac to the Galβ1,3GalNAc 
disaccharide found on O-glycosyl proteins and gangliosides (Varki et al. 2009; 
Potapenko et al. 2010; Hatano et al. 2011). ST3Gal-I also has limited activity towards 
type I disaccharide (Galβ1,3 GlcNAc). However, human ST3Gal-I exhibits high transfer 
efficiency and high affinity (Km of 51 µM) towards the core 1 mucin type disaccharide 
Galβ1,3GalNAcα- (Kono et al.1997). In addition, the mouse ST3Gal-I has a preference 
for glycolipid acceptors leading to the biosynthesis of GM1b, GD1a and GT1b at least in 
in vitro (Lee et al.1993). However, a very recent study from Sturgill et al. showed that in 
the mouse, St3gal2 and St3gal3 are responsible for nearly all the terminal sialylation of 
brain gangliosides (Sturgill et al.2012). 
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Figure 1.15 ST3GAL-I Gene in genomic location (red band pointed out by the arrow). 
Bands locations are according to GeneLoc, Entrez Gene, Ensembl. 
 
 
The human ST3Gal-I is located on chromosomes 8 (8q24.2) (see figure 1.15) and the 
complete cDNA of the human ST3Gal-I gene was cloned from human placenta. 
Comparison with the porcine ST3Gal-I sequence showed a homology of 84% at the 
nucleotide level, with differences of a single amino acid deletion in the cytoplasmic tail 
and a two amino acid deletion in the stem region. 
There are two isoforms of ST3Gal-I distinguished as 48kDa and 45kDa proteins as 
shown in figure 1.16. The 48 kDa isoform has an additional 16 hydrophobic amino acids 
near the NH2 terminus than the 45-kDa (figure 1.16) (Reference Sequences: 
NM_003033.2 and NM_173344.2 for the longer and shorter form, respectively) 
(Gillespie et al.1992). The longer form is the active enzyme, while the shorter isoform, 
which is soluble, is not active (Gillespie et al.1992). Videira et al. analyzed the 
distribution of these two isoforms in bladder cancer cell lines and patients’ specimens. 
Although the intensities of the PCR products differed among the analyzed cell lines and 
patients’ samples, all samples expressed both transcripts (Videira et al. 2009).   
The primary structure of this enzyme consists of a short NH2-terminal cytoplasmic 
domain, a signal-membrane anchor domain, a proteolytically sensitive stem region, and 
a large COOH-terminal active domain (Lee et al. 1993). As described above, all 
eukaryotic sialyltransferases have three conserved peptide regions in the catalytic 
domain (sialylmotifs L, S, and VS). Sialylmotifs L and S are involved in the binding of 
donor and acceptor substrates, while the region between S and VS contains a stretch 
of four highly conserved residues. In this motif, ST3Gal-I has His299 and Tyr300, that 
together with His316 of the VS motif, are essential for activity of the enzyme. Also a Tyr 
residue (Tyr300) plays an important conformational role of ST3Gal-I. The human 
ST3Gal-I contains four potential N-glycan attachment sites in its catalytic domain, 
however, the glycosylation of these sites are not necessary for enzyme activity, but are 
important for the proper folding and trafficking of the enzyme (Jeanneau et al. 2004).        
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Figure 1.16 NH2-terminal amino acid sequences of the 48- and 45-kDa α2,3 sialyl-
transferase peptides (Gillespie et al.1992). 
 
 
1.6.4 Promoter studies of ST3Gal-I. 
 
The promoter of ST3Gal-I has not been widely studied. Taniguchi et al. cloned and 
sequenced the promoter of ST3Gal-I. The luciferase assay on leukaemia and colon 
adenocarcinoma cells showed that only the region between -304 and -145 is important 
for the transcriptional activity of ST3Gal-I. Transcription factor binding sites for Sp1 and 
USF1 are present in this region and are involved in the transcription of ST3Gal-I. 
Inserting base substitutions in the binding sites of both transcription factors resulted in a 
reduction of activity by 40-50% of ST3Gal-I (Taniguchi et al. 2001). In porcine kidney 
cells, transcriptional activation of this sialyltransferase can be induced by TGF-β1 (Son 
et al. 2011). Moreover Son et al. and Higai et al. found that NF-κb is involved in the 
transcription of ST3Gal-I (Son et al. 2011, Higai et al.2006). The expression of ST3Gal-I 
was investigated in two human colon adenocarcinoma cell lines HT-29, Colo205 and in 
one leukaemia cell line HL-60. NF-κb knockdown could inhibit the increase of 
expression of ST3Gal-I after TNF-α treatment (Higai et al. 2006).  
 
 
1.6.5 ST3Gal-I and SialylT antigen in the immune system. 
 
ST3Gal-I and its product SialylT (ST) are very important for the immune system. T cell 
maturation from the DP (double positive-immature T cells) to SP (single positive-mature 
T cells) stages is accompanied by regulation of the sialyltransferase ST3Gal-I. Analysis 
of ST3Gal-I knockout mice revealed that loss of this enzyme leads to disregulation of 
mature CD8 T cell homeostasis and to the extended survival of CD8 T (Priatel et al. 
2000). A consequence of this difference in glycosylation is that immature CD4/CD8ჼDP 
21006 Gal@l,3GalNAc  a2,3-Sialyltramferase 
4% kDa oeotide  seauence 
NH2-Ser-Thr-Leu-Lys-Leu-His-Thr-l eu-l eu-VaJ- 10 
11 1 eu-Phe-lle-Phe-l Pu-Thr-Ser-Phe-Phe-I AU- 20 
21  Asn-Tyr-COOH 
45 kDa peptide  sequence 
NH2-Lys-Tyr-Pro-Tyr-Arg-Pro-Thr-Thr-Thr-Thr- 10 
11 Arg-He-lle-Glu-Glu-Gln-Lys-Val-Ser-Ala- 20 
21 Phe-Phe-COOH 
FIG. 3. NHz-terminal amino acid sequences of the 48- and 
45 kDa (~2,3-si lyltransferase peptides. The 16 hydrophobic 
amino acids near the NHz terminus of the 48-kDa peptide,  comprising 
the putative  signal-anchor  domain, are underlined. 
(Shleicher and Schuell) as described. Nitrocellulose filters were hy- 
bridized with 32P-labeled cDNA probes and washed as described 
earlier  (13). 
Expression-A secretable  chimeric protein was made between the 
putative catalytic domain of the a2,3-sialyltransferase and insulin 
signal sequence by fusing the COOH-terminal 890 bp of clone AST2 
to the NH2-terminal portion of the vector pGIR-199 (gift of K. 
Drickamer) (27) at  a Sac1 site contained in  the reading  frame of both 
vectors. This chimera, sp-ST, was digested with the restriction en- 
zymes NheI and SmaI, the 1.0-kb fragment was isolated and sub- 
cloned into pSVL (Pharmacia) digest d with XbaI and SmaI, which 
cleave sites  contained in  the polylinker. The resulting  consruct was 
called pSVL-spST and was used as a vector for the  transient expres- 
sion of a soluble form of the a2,3-sialyltransferase in COS-1 cells. 
The supercoiled DNA, pSVL sp-ST, was transfected into COS-1 cells 
using lipofectin according to the procedure recommended by th  
supplier (60-mm culture dish containing 50% confluent cells was 
transfected with 5 pg. DNA, 20  ml  of lipofectin reagent). The COS-1 
cell media was collected 48 h  post-transfection and concentrated  15- 
fold on Centricon 30 filters  (Amicon)  for  assay of a2,3-sialyltransfer- 
as  ac iv ty.  a2,3-sialyltransferase  activity was determined  using an- 
tifreeze glycoprotein acceptor as described previously (20). 
Pulse-Chase Labeling of Transfected Cos-1 Cells-Forty eight  hours 
post-transfection with pSVL-spST the COS cells (60-mm culture 
dish) were washed with Met-free media (Dulbecco’s modified Eagle’s 
medium, 5% fetal calf serum) (GIBCO) and cultured in the same 
media for 1 h. The cells were pulse-labeled with 150 mCi/l50 pmol 
of [”SIMet Express label (Du Pont-New England  Nuclear) in 1.5 ml 
of  Met-free media for 2 h. These cells were then washed with PBS 
and chased for 5 h in media without Express label. The media, 
containing secreted proteins, were then harvested, concentrated 15 
times,  and subjected to  SDS-PAGE  and analyzed by fluorography. 
Polymerase Chain Reaction Experiments-Poly(A)+ RNA was used 
as a  template for construction of single-stranded cDNA using  a  kit 
supplied by Invitrogen. The cDNA served as template in the polym- 
erase chain  reaction (PCR) using reagents and protocols supplied by 
Perkin-Elmer Cetus. The specific conditions used were 92 ‘C for 1 
min; 50 “C for 2 min; and 72 “C for 2 min for denaturation, annealing, 
nd polymerization, respectively. PCR reactions were primed with 
30-bp oligonucleotides corresponding to sequences flanking the 120- 
bp deletion at  the 3’ end of ST1. The products of the amplification 
reaction were separated on a 2% agarose gel; two specific bands 
differing by 120 bp, corresponding to  the  ST1  and  ST2 clones, were 
identified by ethidium bromide staining. These bands were eluted 
from the gel (Qiaex kit, Qiagen), subcloned into the TA vector 
(Invitrogen), and sequenced, as above, for unambiguous identifica- 
tion. 
RESULTS 
Purification of Two Forms of the a2,3-Sialyltransferase- 
The (r2,3-sialyltransferase was purified using a  combination 
of two procedures described previously (20, 21). Briefly, the 
enzyme was purified from a porcine liver Triton X-100 extract 
by affinity chromatography on three successive columns of 
CDP-hexanolamine-agarose. The elution profiles from the 
first  and  third purification steps  are shown in Figs. 1 and 2, 
respectively. Fig. 1 shows that two peaks of sialyltransferase 
activity were observed in  the lution profile of the first  affinity 
column. These two peaks were separated by combining the 
indicated  fractions into pools A and B; these two pools  were 
subsequently found to be enriched  in two different molecular 
weight forms of the a2,3-sialyltransferase. 
The second round of affinity purification on each pool 
(profile not  shown) resulted in removal of most of the contam- 
inating a2,6-sialyltransferase, which is also present in porcine 
liver (20). After the  third round of affinity chromatography, 
column fractions were analyzed (see “Experimental Proce- 
dures”),  and individual fractions were found to be enriched in 
the 48  (Fig. 2 A ,  fractions 4-6)- or 45-kDa (Fig.  2B, fractions 
2-6) forms of the a2,3-sialyltransferase. These two protein 
species were designated Form A and Form B, respectively. 
The specific activity for peak fractions from both columns 
was 8-10 units/mg of protein. The strong band (-44 kDa) 
visible in  fraction  6 of Fig. 2, panel A, is not  a2,3-sialyltrans- 
ferase, since it represented one of the major contaminants in 
both pool A and pool B after the previous column but did not 
copurify with the enzymatic activity on the final affinity 
chromatography step. 
Sequence Analysis of the Two Molecular  Weight F o r m  of 
the a2,3-Sialyltransferase-Fractions enriched in the 48-kDa 
(form A) and 45-kDa (form B) forms of the sialyltransferase 
were subjected to PAGE, bl tted to  polyvinylidine difluoride 
membrane, and analyzed by NHz-terminal sequencing (see 
“Experimental  Procedures”).  Twenty-two  amino acid residues 
of sequence were obtained from each of the peptides (Fig. 3). 
The  NHz-terminal sequence of Form A contained a hydro- 
phobic stretch of amino acids consistent with the prediction 
of Sadler et al. (20) and Wescott et al. (22,23)  that  the smaller 
form was derived from the larger form by proteolytic cleavage 
of a hydrophobic peptide. This region was presumed to ac- 
count for the detergent and membrane binding properties 
unique to Form A. 
Cloning of the a2,3-Siulyltransferase-Several cloning strat- 
egies  were attempted in order to clone the cDNA for the a2,3- 
sialyltransferase, based on the amino acid sequence informa- 
tion  presented  in Fig.  3. In our first approach we prepared the 
polymerase chain reaction primers  in an  attempt  to generate 
a probe spanning  the  NHz-terminal sequences of the 48- and 
45-kDa protein species assuming that they were contiguous 
in  the  intact enzyme. In retrospect, this approach failed due 
to inaccuracies in  the amino acid sequence obtained for the 
45-kDa species (see Figs. 3 and 5) .  Other failed attempts  to 
obtain  a positive clone utilized short (16-20 bp) degenerate 
oligonucleotides as probes to screen a porcine submaxillary 
gland cDNA library. The approach that ultimately proved 
successful was to use a ondegen rate 53-bp oligonucleotide 
probe designed from an 18-amino acid region of the NH2 
terminus of the A form (see “Experimental Procedures”). The 
53-bp probe was used to screen 500,000 plaques of a X g t l O  
porcine submaxillary salivary gland cDNA library. A single 
1.6-kb clone was obtained, XST1, which had  a consensus ATG 
start codon (30, 31), an open reading frame encoding NHZ- 
terminal amino acid sequences of both Form A and Form B 
of the a2,3-sialyltransferase, and no  in-frame stop codon. The 
fact that  the  NH2-terminal amino acid sequences from both 
forms of the a2,3-sialyltransferase were present  in the  trans- 
lated open reading frame of XSTl indicated that  the XSTl 
clone encoded a  portion of the  a2,34alyltransferase. 
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thymocytes bind MHC class I tetramers more avidly than mature CD8 SP thymocytes. 
Moody et al. showed that sialic acid addition to core1 of mature CD8 single-positive 
thymocytes decreases CD8 binding to MHCI (Moody et al. 2001).  
Neuraminidase treatment of mature CD8 SPs enhanced CD8 noncognate binding 
(Starr et al. 2003) and ST3Gal-I up-regulation has shown to be responsible for the loss 
in noncognate CD8-class I binding that accompanies thymocyte maturation (Kao et al. 
2006). 
MUC1 carrying the sialylT (ST-MUC1) glycoform was shown to inhibit the differentiation 
and function of monocyte derived DCs. Human monocyte-derived DCs cultured in the 
presence of ST-MUC1, showed a modified phenotype with decreased expression of 
costimulatory molecules (CD86, CD40), antigen-presenting molecules (DR and CD1d), 
and differentiation markers. In this way DCs were defective in their ability to induce 
immune responses and may represent a mechanism by which epithelial tumors can 
escape immunosurveillance (Rughetti et al. 2005). However, these results should be 
interpreted with caution as subsequently we showed that ST-MUC1 purified from CHO 
cells contain small quantity of TGFβ (Beatson, Sproviero et al. 2011). 
 
 
1.6.6 ST3Gal-I in different diseases. 
 
Lebreve et al. showed a hyposialylation of O-glycans on CD43 and CD45 lymphocytes 
surface in HIV-1 (human-immunodeficiency-virus-l) infected T-cell lines. It was thought 
that a possible variation in mRNA transcription of hST3Gal-I could occur in this case 
(Lefebvre et al.1994). However, comparable levels of hST3Gal-I and hST3Gal II mRNA 
and enzymatic activity were observed in parental and HIV-1-infected T-cell lysates, so 
the variation of sialylation in this case is probably due to a different mechanism from an 
alteration of transcription and catalytic activity of ST3Gal-I (Giordanengo et al.1997).  
Influenza infection starts with the recognition of the sialic acids on the host cell surface 
by the hemagglutinin (HA) of the virus. All avian influenza viruses recognize α2,3 sialic 
acid linkage on the host cell (Gambaryan et al. 2004).  
Alterations of ST3Gal-I level of expression were found also in Grave’s disease (Kiljański 
et al. 2005) and SNPs (single-nucleotide polymorphism) in ST3GAL-I gene were 
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1.6.7 ST3Gal-I in breast cancer. 
 
Increased expression, relative to normal tissue, of ST3Gal-I is observed in many 
carcinomas, especially colon (Kudo et al. 1998), bladder (Videira et al. 2009), ovarian 
(Wang et al. 2005) and breast cancer (Burchell et al. 1999). In primary breast cancers, 
ST3Gal-I is overexpressed and its level is correlated with tumour grade (Burchell et al. 
1999). In contrast C2GnT1 is found to be low or absent in around 50% of carcinomas 
and breast cancer cell lines. ST3Gal-I activity was also found to be increased 8–10 fold 
in three breast cancer cells lines relative to the normal cell line (MTSV1–7), while the 
C2GnT enzyme activity was absent in two of the breast cancer cell lines (T47D & BT20) 
and reduced by 50% in MCF-7 (Brockhausen et al.1995). ST3Gal-I competes with 
C2GnT1 for the core 1 substrates and there is an overlap of the localization of two 
enzymes in the Golgi (Whitehouse et al. 1997). Although ST3Gal-I is localised mainly in 
the medial/trans Golgi, there are detectable levels in the cis Golgi. C2GnT1 has been 
located mainly in the cis Golgi, but with some expression in the medial cisternae and 
low levels in the trans Golgi. However, this overlap appears to be sufficient in allowing 
competition between the two enzymes (Dalziel et al. 2001). Since ST3Gal-I competes 
with C2GnT1, when ST3Gal-I is over-expressed, core1 will become sialylated and 
termination of the chain will occur (Dalziel et al. 2001). Importantly, over-expressing 
ST3Gal-I in the mammary gland can promote the early development of spontaneous 
mammary tumours in a murine model. Transgenic mice, expressing human ST3Gal-I 
from the MUC1 promoter (used to allow upregulation in the mammary gland and in 
mammary tumours), were crossed with Polyoma middle T mice (a model of 
spontaneous breast cancer). These mice showed a significant increase in the speed of 
mammary tumour development compared to the controls (Picco et al. 2010) (see figure 
1.17). 
 
                                           
Figure 1.17: Mammary tumours develop faster in the ST3Gal-I/PyMT mice compared to the 
controls. Kinetics of tumour formation in ST3Gal-I/PyMT and Control/PyMT mice. The 
difference between ST3Gal-I/PyMT and control mice was highly significant (P < 0.001), 
evaluated by the Breslow test (Picco et al. 2010). 
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1.7 One O-linked glycosylation mucin, MUC1, and antibodies to its 
glycosylated form.  
 
Mucin type O-glycosylation is dominant on mucin-type molecules like MUC1. MUC1 is a 
transmembrane glycoprotein overexpressed in many types of cancer, with a differential 
expression pattern of O-glycans in malignant compared to normal epithelial cells. O-
glycosylation occurs on five potential sites (Ser or Thr), found within each tandem 
repeat (TR) of 20 amino acids (Tarp et al. 2008). The extracellular domain of MUC1 can 
contain 20 to 150 of these tandem repeats. Many monoclonal antibodies, that target 
MUC1, recognize epitopes within the tandem repeat domain and show differential 
reactivity with this mucin, expressed by normal mammary epithelium compared to that 
on malignant breast epithelium (Taylor-Papadimitriou et al. 1999). SM3 is a monoclonal 
antibody that recognizes MUC1 produced by cancer cells but not by normal cells. SM3 
does not react with normal breast epithelium because its epitope is masked by the core 
2 glycans (Burchell et al. 1989, Dalziel et al. 2001, Mungul et al. 2004) (see figure 
1.18A). However, overexpressing ST3Gal-I in a cell line expressing C2GnT1, results in 
SM3 binding (Dalziel et al. 2001), demonstrating the competition that occurs between 
these two enzymes. Another two antibodies HMFG1 and HMFG2, also recognize a 
peptide epitope in MUC1 but their binding is influenced by its glycosylation. HMFG1 
reacts well with the mucin expressed by normal cells but the presence of sialic acid can 
decrease its binding to its epitope. In contrast, HMFG2 can react with shorter 
glycosylated chain and can be masked by longer carbohydrate side chain on normal 





Plant lectins are sugar-binding receptors, that bind glycans in an oligosaccharide and 
linkage specific manner. Lectins were first described in 1888 by Stillmark working with 
castor bean extracts. Some lectins were discovered by their ability to agglutinate red 
blood cells in vitro and other lectins by investigating various cell-cell interaction 
phenomena (Sharon et al. 2004). Sugar binding proteins are present in animals and in 
humans and to date 79 lectin-like binding receptors have been described and they are 
divided in three subfamilies: C-type lectins, I-type lectin and galectins.  
 
 



















Figure 1.18: A) Reactivity of SM3 with O-glycoforms in malignancy. SM3 does not react 
with normal breast epithelium because the epitope is masked by the Core 2 glycans. B) T47D 
transfected with C2GnT1 loses SM3 reactivity on MUC1. a) the breast cancer cell line T47D 
does not express C2GnT1 and therefore the MUC1 expressed by these cells bind SM3; b) T47D 




C-type lectin receptors (CLRs) are calcium-dependent carbohydrate-binding proteins 
and consist of a large family of receptors (60–80). C-type lectins can be divided into two 
categories (which are further divided into other subfamilies): 1) the mannose-specific C-
type lectins (which contain an EPN (Glu-Pro-Asn) amino acid motif) have a specificity 
for mannose- and/or fucose-terminated glycans; 2) the galactose-specific C-type lectins 
(which contain the QPD (Gln-Pro-Asp) sequence in the CRD- carbohydrate-recognition 
domains) and recognize galactose-terminated or GalNAc terminated glycan structures 
(Zelensky & Gready, 2005). The C-type lectins have mainly been identifed on antigen 
presenting cells (APCs), such as macrophages and dendritic cells (DCs). For instance 
dendritic cells express DC-SIGN (dendritic cell-specific ICAM grabbing non-integrin), 
MGL (macrophage galactose-type C-type lectin) and dectin-1, which are involved in 
glycan-mediated pathogen recognition and internalization of antigen for loading on 
major histocompatibility complex (MHC) class I and II molecules (Figdor et al. 2002). In 
general, C-type lectins can be expressed by mammalian cells or by pathogens, so they 
have dual function in host-pathogen recognition and immune cell responses (Weis et al. 
1998).   
I-type lectins are glycan-binding proteins with variable numbers of immunoglobulin 








enzymes. There are other two antibodies, HMFG1 and HMFG2, that recognizes MUC1 depending on 
its glycosylation. HMFG1 reacts well with the mucin of normal cells and the presence of sialic acid 
can decrease its binding to the epitope whereas HMFG2 can react with shorter glycosylated chain and 









Figure 2.  Reactivity of  SM3 with O-glycoforms in malignancy. SM3 is  a monoclonal antibody that recognizes 
MUC1 produced by cancer cells but not by normal cells. SM3 does not react with normal breast epithelium 
because the epitope is  masked by the Core 2 glycans. 
 
 
O-Glycosylation in breast cancer cell lines. 
 
The glycosylation patterns in cancer cells depend on tissue origin [21]. In this study, we focus our 
attention on six breast cancer cell lines and  each cell line has an individual well documented specific 
O-glycosylation pattern. The epithelial breast carcinoma cell lines used were MCF7, T47D, ZR-75-1  
(estrogen receptor positive), MDA-MB-231, SK-BR-3, BT-20 (estrogen receptor negative). They are 
all derived from metastatic cancer cells, apart from BT-20, which was derived from a primary tumour.  
The MCF7 cell line expresses MUC1 carrying Core 1 and Core 2 glycans and shows increase activity 
of ST3Gal I but also expression of C2GnT1 [14]. In the BT-20 and T47D breast cancer cell lines there 
is no Core 2 formation and this is due to the lack of expression of C2GnT 1 [17]. On the other hand 
there is an increase of the expression of the ST3Gal I activity. From mass spectra analysis, T47D 
exclusively expresses Core 1 based glycans [21].  
ZR-75–1 and MDA-MB-231 have Core 1 and Core 2 based structures. The Core 1 structures are 
mostly sialylated suggesting competition between C2GnT1 and ST3Gal I [17,21]. 
Mass spectrometry of the O-linked glycans on glycoproteins of different cell lines,  showed that the 
main O-glycan in SK-BR-3 was the TF antigen and the TF antigen is mostly sialylated [22]. Core 1 
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are sialic acid-binding immunoglobulin-like lectins and can selectively recognize 
sialylated structures of specific linkages (α(2-3), α(2-6) or α(2-8)) (Crocker et al. 2007).  
There are 13 members in the siglec family and it can be divided into two types: CD33-
related siglecs (Siglecs 3, 5, 6, 7, 8, 9, 10, 11 and 14) and a group consisting of 
sialoadhesin (Siglec-1 or CD169), MAG (Siglec-4) and Siglec-2 (CD22). Siglecs are 
widely expressed on immune cells like neutrophils, monocytes, B cells, DCs, NK cells, 
eosinophils and basophils. Siglecs have a role in recognizing sialic acids on pathogens 
and, on the other hand, have a role in intercellular communication of immune cells 
(Crocker et al. 2007). 
Galectins are a family of soluble lectins characterized by a common structural fold and 
a conserved CRD of about 130 AA, that recognize glycans containing the disaccharide 
N-acetyllactosamine (Gal-β(1-4)-GlcNAc) (Leffler et al. 2004). They (about 15 galectins 
have been identified in mammals) are classified in two main classes: 1) 'prototype' 
galectins’ (galectins 1, 2, 5, 7, 10, 11, 13, 14 and 15) which have one CRD that can 
dimerize, 2) 'tandem-repeat galectins' (galectins 4, 6, 8, 9 and 12) which contain two 
homologous CRDs in a single polypeptide chain (Liu & Rabinovich, 2005).  Galectin-3 
is an exception to these two classes, since it contains a CRD connected to a non-lectin 
N-terminal region (about 120 amino acids) that is responsible for oligomerization of the 
lectin and ligand cross-linking (Nieminen et al. 2007). In the immune system galectins 
are expressed by activated macrophages, regulatory T cells and activated T and B cells 
(Liu & Rabinovich, 2005). 
In this thesis lectins have been used to study the glycans found on the surface of breast 
cancer cell lines. The following two paragraphs will be dealing with some sialic-acid-
binding lectins, plant lectins specific for Core1 and sialylated-Core1 and selectins, a c-
type lectin subclass. 
 
 
1.8.1 Lectins binding Core1/sialylated-Core1 and Neuraminidase. 
 
There are two different lectins that bind with different affinities to α2,3 sialylated glycans 
including Core1:  
1) Maackia Amurensis agglutinin (MAA) derives from a leguminous seed and binds to 
α2,3 linked sialic acid (Loris et al. 2002). There are two types of MAA: a) Maakia 
amurensis leukoagglutinin (MAL), which binds Neu5Acα2,3Galβ1,4GlcNAc with the 
best affinity and b) Maakia amuresis haemagglutinating (MAH), which is more specific 
for Neu5Ac2,3Galβ1,3(Neu5Acα2,6) GlcNAc (Boyd et al. 1961);  
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2) Peanut agglutinin (PNA) from Arachis hypogaea, which binds specifically the Gal β-
1-3-N-acetylgalactosamine (T antigen) structures and this binding is inhibited by the 
presence of sialic acid (Novogrodsky et al. 1975).   
These lectins are used in combination with neuraminidase, glycoside hydrolase 
enzymes, responsible for the cleavage of sialic acid (Klenk & Uhlenbruck, 1957). The 
crystal structure for influenza neuraminidase was obtained in 1983 (von Itzstein et al. 
1993), and since then, many other sialidases have been characterized from other 
sources like Arthrobacter ureafaciens (which hydrolizes NeuAc bound in α2→3,6,8,9), 
Streptococcus pneumoniae (which hydrolize NeuAc bound in α 2→3), Vibrio cholerae 
(which hydrolize NeuAc in α2→3,6,8), Clostridium perfringens (which hydrolize NeuAc 
in α2→3,6) (Taylor et al. 1996). 
 
 
1.8.2 Selectins  
 
This work focused on the control of glycosyltransferase by COX-2, an enzyme mainly 
involved in inflammation, on O-linked glycosylation. The selectins are sugar binding 
proteins involved in inflammation. The C-type lectins (Ca2+dependant lectins) involved 
in inflammation comprise of three members, E(ndothelial), L(eukocytes), and P(latelet)-
selectin (Lowe et al. 2002). E-selectin is expressed on endothelial cells during 
inflammation but it is constitutively expressed on the endothelial cells of the 
microvasculature of bone marrow and skin (Sackstein, 2004). P-selectin is displayed on 
activated endothelial surfaces and on platelets. L-selectin is expressed constitutively by 
lymphocytes and neutrophils, with the highest expression being by active cells, that 
facilitate trafficking into tissues (Ley et al. 2004). Sialyl-Lewisx (sLex) and Sialyl-Lewisa 
(sLea) on scaffold proteins such as PSGL-1, MadCAM and CD34 are recognized by 
these selectins. Binding to selectins is used by malignant cells, especially colonic, 
during the metastatic process (Ono & Hakomori, 2004), and sialyl-Lewisx was shown to 
be expressed by breast cancers, where in the ER positive tumours high expression is 




1.9 Principles of inflammation and role in cancer. 
 
Inflammation is the body’s immediate response to infection or injury and its main 
function is to eliminate pathogens and toxins and to repair damaged tissue. These 
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responses must be ordered and controlled.  Inflammation is characterized by redness, 
swelling, heat and pain. These characteristics are due to increased blood flow and 
permeability across blood capillaries. The increased permeability of the blood 
capillaries allows leukocytes, antibodies and cytokines to migrate from the bloodstream 
into the surrounding tissue. The movement of leukocytes depends on the upregulation 
of adhesion molecules such as intercellular adhesion molecule-1 (ICAM-1), vascular 
cell adhesion molecule-1 (VCAM-1) and E, (P and L)-selectin (Kansas,1996) on the 
surface of endothelial cells, allowing leukocyte binding and subsequent diapedesis. 
After the leukocytes reach the tissue interstitium, they bind to extracellular matrix 
proteins via expressed integrins and CD44 (Hidalgo et al. 2007). The first cells that 
appear at the inflammation site are granulocytes, monocytes/macrophages, all involved 
in pathogen killing and in tissue repair. Inflammation is initiated by several factors like 
bacteria, chemical injury etc. that induce the release of inflammatory mediators from 
leukocytes, monocytes and macrophages including cytokines such as TNF-α and IL-1, 
eicosanoids, such as PGE2; nitric oxide; matrix metalloproteinases; and other 
mediators (Calderჼet al. 2006; Paterson et al. 2003).  
Chronic irritation and inflammation can give rise to tumorigenesis and induce apoptosis, 
migration of tumour cells and other neoplastic processes (Coussens et al. 2002). In the 
IX century Virchow hypothesized inflammation could enhance cell proliferation and that 
chronic inflammation could trigger cancer (Balkwill et al. 2001). In 1941 Rous 
recognized that cancer could initiate from viral and chemical carcinogens (Rous et al. 
1941). This initiation is irreversible (since it causes irreversible DNA alterations) or can 
last in normal tissue until a second exposure to a carcinogen, that can be also a 
chemical irritant (eg.phorbol esters), hormones, chronic irritation and inflammation, 
occurs (Coussens et al. 2002).  
It is estimated that more than 15% of malignancies is caused by infections (Kuper et al. 
2000). In chronic inflammation leukocytes and other immune cells induce release of 
free radicals of oxygen and nitrogen species, which can induce DNA damage in 
proliferating cells. When this process of inflammation repeats there is a risk of 
permanent genomic alterations such as point mutations, deletions, or rearrangements 
(Maeda et al. 1998).  
There are various examples of chronic inflammation that cause cancer. There is a 
strong association of inflammatory bowel diseases like chronic ulcerative colitis and 
Crohn’s disease with the development of colon cancer (Coussens et al. 2002). Patients 
with hepatitis C have higher risk of liver carcinoma; schistosomiasis is associated with 
bladder and colon carcinoma (Coussens et al. 2002) and Helicobacter pylori infection is 
the principle cause of stomach cancer (Ernst et al. 2000).  
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Additional evidence that inflammation is important during tumour development and 
progression is given by the study that aspirin and nonsteroidal anti- inflammatory drugs 
(NSAID) are associated with reduced risk of cancer (Garcia-Rodríguez et al. 2001; 
Agrawal et al. 2008;Takkouche et al. 2008), and are prophylactic for lung, oesophagus 
and stomach cancer (Baron et al. 2000;Garcia-Rodriguez et al. 2001). NSAIDs target 
and inhibit cyclooxygenases (COX-1 and -2). COX-2, in particular, is involved in 
inflammatory reactions  and is overexpressed in cancer.  
 
 
1.9.1 Cyclooxygenase and inflammation. 
  
Cyclooxygenase (COX) or prostaglandin endoperoxidase synthase converts 
arachidonic acid into the unstable intermediate prostaglandin G2. Cyclooxygenase has 
two actions: 1) an endoperoxide synthase action, which converts the arachidonic acid 
(released from membrane phospholipids by phospholipase A2) into prostaglandin G2; 
2) a peroxidase action that converts PGG2 to PGH2 (Wang & Dubois, 2006). 
Prostaglandin H2 is the precursor for several structurally related prostaglandins, like 
prostaglandin E2 (PGE2), prostaglandin D2 (PGD2), prostaglandin F2a (PGF2a), 
prostaglandin I2 (prostacyclin) and thromboxane-A2, which are formed by the action of 
specialized prostaglandin synthases (as shown in figure 1.19).  
COX enzymes are the targets of non-steroidal anti-inflammatory drugs (NSAIDs) and in 
1971 Vane and collaborators demonstrated that NSAIDs could inhibit prostaglandin 
formation and has in vivo anti-inflammatory activity (Vane, 1971). At present, three 
COX isoenzymes are known: COX-1, COX-2 and COX-3. COX-1 protein was 
discovered over 30 years ago and cloned in 1988. Daniel Simmons and collaborators 
discovered COX-2 in 1991 at Brigham Young University (Simmons et al. 1989, Xie et 
al. 1991).  
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Figure 1.19: Arachidonic acid cascade. (Botting 2004, Frontiers in Bioscience 9, 956-966) 
 
Simmons’s group discovered COX-3 in 2002. COX-3 is a splice variant of COX-1, 
which, in humans and rodents, has a frameshift mutation. For this reason, COX-3 
encodes a protein with a completely different amino acid structure from COX-1 or COX-
2 and does not have COX activity (Kis et al. 2005).    
 
 
1.9.2 COX-1 and COX-2: similarities and differences. 
 
COX-1 and COX-2 are encoded by two different genes (Reference Sequence: 
NM_080591.1 and NM_000963.2) on different chromosomes 9q32-q33.3 and 1q25.2-
q25.3. The sequence and the protein tertiary structure of the two isoforms are very 
similar. Numerous studies have shown that both COX-1 and COX-2 are located inside 
the lumen of the endoplasmic reticulum and the nuclear envelope (Morita et al.1995). 
The proteins are of similar molecular weight (approximately 70 and 72 kDa 
respectively), highly homologous in sequence (60% identity at the amino acids level) 
and have nearly identical three-dimensional structure.  
COX-1 and COX-2 are homodimers (Kurumbail et al. 2001) and have four common 
domains (identified by X-ray crystallography): amino-terminal signal, an epidermal 
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growth factor domain or dimerization domain, a membrane-binding motif, a catalytic 
domain. 
1. N-Amino Terminal Signal Peptide. COX-2 amino-terminal signal peptide region is 
17 amino acids long in all species and is less hydrophobic than the COX-1 peptide, 
which contains 4 or more leucines and isoleucines. The amino-terminal signal peptides 
are important in directioning COX-1 and COX-2 into the lumen of the endoplasmic 
reticulum (HLa et al. 2002).  
2. Dimerization Domain. COX-1 and COX-2 are dimers and each monomer has a 
dimerization domain, held together by hydrogen bonds and salt bridges. The 
dimerization domain consists of about 50 amino acids near the amino terminus. This 
domain has 3 disulphide bonds, resulting in a similar structure to epidermal growth 
factor structure. 
3. Membrane Binding Domain. This region consists of 50 amino acids found just after 
the dimerization domain. It is composed of a tandem series of four amphipathic helices, 
which form a hydrophobic channel.  
4. C-terminal Catalytic Domain. The carboxy-terminal is formed by 480 amino acid 
and it represents 80% of the protein (Simmons et al. 2004). The catalytic domain has 
two distinct lobes that are linked together: Cyclooxygenase Active Site and Peroxidase 
Active Site. The Cyclooxygenase Active Site catalizes the conversion of arachidonic 
acid to prostaglandin G2. This region is a hydrophobic dead-end channel and the 
entrance is surrounded by the four amphipathic helices of the membrane binding 
domain (Picot et al. 1994). Tyrosine 385 of the catalytic pocket activates arachidonyl 
radical that undergoes the cyclization/oxygenation reaction (Schneider et al. 2002). The 
Peroxidase Active Site reduces prostaglandin G2 to prostaglandin H2. This site 
contains a heme cofactor, which is linked via an iron-histidine bond (Malkowski et al. 
2000). Arg-120, Glu-524 and Tyr-355 are part of the hydrogen-bonding network, which 
stabilizes substrate/inhibitor interactions. NSAIDs generally bind at the mouth of the 
COX channel between Tyr385 and Arg120 (Picot et al. 1994). The synthesized PGH2 is 
converted to prostaglandins (PGD2, PGE2, PGF2α), prostacyclin (PGI2), or 
thromboxane A2 by different synthases (Hamberg et al. 1974). Although, COX-1 and 
COX-2 have a very similar structure, there are some important differences between 
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COX-1 and COX-2 are N-linked  glycosylated. COX-1 is glycosylated  at three 
asparagines, whereas COX-2 may be glycosylated at up to four asparagines. (Nemeth 
et al., 2001). Glycosyl moieties are of the high mannose type. The glycosylation on 
COX-1 promotes the right protein folding and it  is essential for COX-1 catalitic activity 
(Otto et al., 1993).  
COX-2 is frequently observed in two or three glycosylated states according to Western 
Blot and  mass spectrometry results analysis (Nemeth et al., 2001). The  most common 
form of COX-2 is the glycosylated form at Asn580 (74 kDa) and the unglycosylated (72 
kDa). Sevigny et al. demonstrated that COS cells expressing COX-2 glycosylated form 
at Asn580 have five times less COX-2 activity than cells expressing the not glycosylated 
COX-2. Thus, COX-2 turnover appears to depend upon glycosylation of the 72kDa 
glycoform (Sevigny et al. 2006). 
COX-1 is the constitutive isoform and its expression does not change under 
physiological and pathological conditions. The prostaglandins, produced by COX-1, 
play a central role in many physiological processes, like cytoprotection of the stomach, 
vasodilatation in the kidney, and production of a proaggregatory prostanoid, 
thromboxane, by the platelets (Fitzpatrick et al. 2001). It was shown that COX-1 is the 
dominant isoform, regulating the relatively alkaline pH at the gastric luminal surface in 
mouse stomach (Baumgartner et al. 2004). Table 1.6 shows how COX-1 is involved in 
stomach cytoprotection and how COX-2 is involved in ulcer healing and resistance in 
ischemia induced gastric damage. 
Effect	  (Species)	   COX	  Isoform	  
Inhibition	  of	  gastric	  acid	  secretion	  (rat)	   COX-­‐1	  
Inhibition	  of	  gastric	  acid	  secretion	  (mouse)	   COX-­‐1	  
Bicarbonate	  secretion/juxtamucosal	  pH	  gradient	  in	  stomach	  (mouse)	   COX-­‐1	  
Maintenance	  of	  mucosal	  surface	  hydrophobicity	  (mouse)	   COX-­‐1	  
Decreased	  epithelial	  permeability	  to	  acid	  (rat)	   COX-­‐1	  
Mucosal	  blood	  flow	  (rat)	   COX-­‐1	  
Ulcer	  healing	  (rat)	   COX-­‐2	  
Ulcer	  healing	  (mouse)	   COX-­‐2	  
Resistance	  to	  ischemia/reperfusion-­‐induced	  gastric	  damage	  (mouse)	   COX-­‐2	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COX-2 is normally not expressed in most cells and tissues (apart from some parts of 
the brain, kidneys, ovaries) and its expression, induced by cytokines and growth 
factors, is responsible for the high production of prostaglandins during inflammation 
(Wang, 2006). In fact, according to the ‘COX-2 hypothesis’—the “inflammatory 
prostaglandins” derive principally from COX-2, while prostaglandins important in 
homeostatic roles, like the protection of the gastrointestinal mucosa, are derived from 
COX-1 (Fries et al. 2005). So, the inhibition of all prostaglandins and of thromboxanes 
by COX-1 and COX-2 inhibitors, (like aspirin, ibuprofen, diclofenac etc) explains the 




















Figure 1.20: Actions of the two known isoforms of COX (PGHS). The hypothesis stemming 
from this scheme is that the therapeutic effects of drugs, such as aspirin, are due to inhibition of 
COX-2 whereas the unwanted side effects (and the action on platelets) stem from inhibition of 
COX-1. (Vane 1994) 
 
 
Secondly, COX-2 has a hydrophobic “side pocket”, created by Valine -523, hydrogen 
bonds to Arginin-513 and the peptide bond of Phenylalanine-518. This pocket is not 
present in COX-1, since the Val-523 is substituted by an isoleucine at position 523, that 
creates steric hindrance (Kurumbail et al.1996). The presence of the “side pocket”, 
created by Val-523, allows the design of inhibitors selective for COX-2. These selective 
inhibitors block COX-2 with high affinity, but are too big to fit into the COX-1 catalytic 
domain (see figure 1.21). This overcomes the major side effects of the non-selective 
inhibitors of COX-2, which block the production of the good prostanoids from COX-1. 
This class of NSAIDs is called “second generation COXIBs” and comprises etoricoxib, 
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1.9.3 Prostaglandins and Cyclooxygenase  
 
A prostaglandin is a lipid compound containing 20 carbon atoms including a 5 carbon 
ring and are derived enzymatically from fatty acids and, in particular, from arachidonic 
acid.
 
Goldblatt and von Euler were the first to extract prostaglandins from semen, 
prostate, and seminal vesicles in the 1930s. Between 1950s and 1960s Bergström and 
collaborators purified the first prostaglandin isomers and identified that arachidonic acid 
is the precursor of prostaglandins. Samuelsson and colleagues identified the 
cyclooxygenase reaction that catalyzes the production of PGG2 from arachidonic acid 
(Hamberg & Samuelsson, 1973). 
Prostaglandins are classified into types A to I, however type A, B, C are not found in 
nature and are only produced artificially. PGH2 and PGG2 have the same structure but 
PGG2 has a hydroperoxy instead of a hydroxy group on the C15. As said above, the 
most important products of cyclooxygenase pathway are PGI2, PGD2, TXA2, PGE2 
and PGF2α (Narumiya et al. 1999).  
                 
Figure 1.21: COX-1 and COX-2 substrate-binding channels. A, Nonselective inhibitors have 
access to the binding channels of both isoforms. B, The more voluminous residues in COX-1, 




PGI2 is a mediator of oedema and pain and is found after tissue injury or inflammation. 
It causes vasodilatation, inhibition of platelets aggregation, rennin natriuresis. 
PGD2 causes vasodilatation, inhibition of platelet aggregation, uterine and 
gastrointestinal relaxation. PGF2α is a mediator of myometral contraction in humans. 
02/07/2012 18.57BIOCHEMISTRY, BIOLOGY, AND STRUCTURE OF CYCLOOXYGENASE-1 AND …m Firestein: Kelley's Textbook of Rheumatology on MD Consult
Page 7 of 8http://mulla.pri.ee/Kelley's%20Textbook%20of%20Rheumatology,%208th%20ed./HTML/379.htm
Figure 54-4  Cyclooxygenase (COX)-1 and COX-2 substrate-binding channels. Schematic depiction of the structural differences between
the substrate-binding channels of COX-1 and COX-2 that allowed the design of selective inhibitors. The amino acid residues, Val434,
Arg513, and Val523, form a side pocket in COX-2 that is absent in COX-1. A, Nonselective inhibitors have access to the binding channels
of both isoforms. B, The more voluminous residues in COX-1, Ile434, His513, and Ile532, obstruct access of the bulky side chains of the
coxibs.  (From Grosser T, Fries S, FitzGerald GA: Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic
challenges and opportunities. J Clin Invest 116:4-15, 2006.)
The upper part of the channel, the catalytic pocket, contains tyrosine 385, which is essential for the
cyclization/oxygenation reaction. Ser530, the residue transacetylated by ASA, along with valine 349,
seems to govern the stereochemistry of the pocket such that AA is sterically blocked from a functional
interaction with the catalytic domain. [60]  A crucial structural difference between COX-1 and COX-2 is a
substitution of isoleucine523 of COX-1 for a valine in COX-2 that opens a hydrophobic area in COX-2
that can be accesse  by some coxibs. [15]  COX-2 seems to have a wider and more fl xible
hydrophobic substrate-binding channel, a structural feature that has been exploited with respect to the
development of coxibs, as shown in Figure 54-4 . [61]
	   60 
TXA2 has vasoconstriction, bronchoconstriction, platelets aggregation effect and it is 
mainly produced by COX-1 (Mukherjee et al. 2001). PGE2 can have different effects 
depending on the receptor it binds. There are four PGE2 receptors (EP receptors) that 
can be expressed in different tissues.  If PGE2 binds to EP1 there is contraction of 
bronchial and gastrointestinal smooth muscle; if it binds to EP2 or EP4 it causes 
bronchodilatation, vasodilatation, relaxation of GI smooth muscle; binding EP3 causes 
inhibition of gastric acid secretion, contraction of intestinal muscle and stimulation of 
contraction of the uterus in pregnant women (Rang & Dale 2003).  
In summary, prostaglandins are important pathological mediators, since they are 
implicated in inflammation, pain, pyrexia, cancer, glaucoma, male sexual dysfunction, 
osteoporosis, cardiovascular disease and asthma (Abramovitz et al.1998). They are 
also important in physiological functions such as homeostatis of the gastrointestinal 
tract, renal function, blood clotting, embryonic implantation and parturition (Simmons et 
al. 2004).  
Considering that they are lipids, prostanoids are transported through a prostaglandin 
transporter across biological membranes. Bao et al. only ten years ago found the first 
known PG transporter in rats (Bao et al. 2002). The half-life of most prostaglandin is 
very short (between 30 seconds and 1 minute). Once prostanoids are uptaken by the 
carrier, there is a rapid inactivation by several intracellular enzymes, like 15-
hydroprostaglandin dehydrogenase (15-PGDH). The best substrate for 15-PGDH is 
PGE2 and PGF2α. There are two isoforms of 15-PGDH: one is found in most organs of 
the body (including lung, GI tract, kidney, heart) and it needs NAD+ as a cofactor, while 
the second isoform is mainly in the kidney, brain and erythrocytes and the cofactor is 
NADP+. The metabolites are secreted in the urine (Rang & Dale 2003). 
 
 
1.9.4 Prostanoid receptors 
 
There are two DP receptors (DP1 and DP2) for PGD2, two IP receptors (IP1 and IP2) for 
PGI2, one TP for TXA2, one FP for PGF2α and four EP receptors for PGE2. The 
prostanoid receptors are all G-protein-coupled receptors (GPCRs) and have seven-
transmembrane regions, an extracellular N terminus, an intracellular C terminus, and 
three interhelical loops on each side of the membrane.  
G proteins are composed by three subunits: α, β, γ. The α subunit, with its enzyma-
tic activity, converts GTP (Guanine nucleotide) to GDP. The β and γ subunits  are very 
hydrophobic and so they remain associated with each other within the cytoplamic mem-
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brane. When an agonist binds a G coupled receptor protein, the cytoplasmic domain of 
the receptor acquires high affinity with the α, β, γ subunits, which, at this stage, bind a 
molecule of GDP. When the receptor is activated, GTP replaces GDP and the α-GTP 
complex dissociates from the βγ subunits. α-GTP complex is the active G protein, which 
in turn, activates or inactivates other ion channels or enzymes (eg.like adenylate 
cyclase). The complex gets inactivated, when GTP is hydrolysed to GDP by the 
GTPase activity of the α unit, and this allows the α subunit to reassociate with βγ and 
start a new cycle (Lodish et al. 2000, Rang & Dale 2003).  
There are different G-proteins that interact with specific receptors and effectors: 
adenylate cyclase, phospholipase C, Rho family GTPase. There are four types of G-
proteins: Gs, Gi/0, Gq/11, G12/13. The Gs activates plasma membrane adenylyl cyclases, 
increasing cellular cyclic AMP (cAMP). Gi/0 inhibits adenylyl cyclases, decreasing 
cellular cAMP. The level of cytosolic cAMP may then determine the activity of various 
ion channels as well as members of the Ser/Thr specific Protein Kinase A (PKA) family. 
Gq/11 activates phospholipase Cβ (PLCβ), which cleaves phosphatidylinositol 4,5-
biphosphate (PIP2) at the plasma membrane, and generates inositol (1,4,5) 
trisphosphate (IP3) and diacylglycerol (DAG) that releases Ca2+ from intracellular stores 
and activates phosphorylation by protein kinase C. IP3 acts on IP3 receptors on the 
membrane of the endoplasmic reticulum (ER) to elicit Ca2+ release from the ER, while 
DAG diffuses along the plasma membrane where it may activate Protein Kinase C 
(PKC). Since many isoforms of PKC are also activated by increases in intracellular 
Ca2+, these pathways can converge on each other to signal through the same 
secondary effector. The effectors of the G12/13 pathway are three RhoGEFs (p115-
RhoGEF, PDZ-RhoGEF, and LARG), which, when bound to G12/13 allosterically, activate 
the cytosolic small GTPase, Rho.                                    
Prostaglandin E2 (PGE2) is the most abundant prostanoid in the human body and it 
has various functions in reproduction, neuronal, metabolic, and immune systems. PGE2 
action is mediated via four receptors (EP1, EP2, EP3, EP4) with different signalling 
pathways. EP1 is mainly a Gq coupled receptor with phospholipase C signalling through 
Ca2+; EP2 and EP4 are Gs coupled receptors signalling through adenylyl cyclases; EP3 
instead is mainly a Gi coupled protein and inhibits adenylyl cyclases, decreasing cellular 
cAMP. The EP2 and EP4 receptors stimulates of cyclic AMP (cAMP) and protein kinase 
A (PKA) (Ichikawa et al. 2010). However EP2 is more efficient than EP4 in inducing 
cAMP probably because EP4, unlike EP2, can also activate Phosphoinositide-3-kinase 
(PI3K) through Gi (Fujino & Regan. 2006). EP2 and EP4 differ also in their sensitivity to 
PGE2 and EP4 is desensitized after short-term exposure (Nishigaki et al. 1996).  
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The EP3 and EP4 receptors are found throughout the body, (Honda et al.1993), while 
EP1 is expressed only in the kidney, lung, and stomach(Rang & Dale 2003). EP2 is the 
least expressed of the EP receptors, but it is induced by different stimuli, like LPS in a 
macrophage cell line and gonadotropins in the uterus (Katsuyama et al. 1997, 
Katsuyama et al. 1998). EP1 and EP3 have alternative mRNA splice variants while EP3 
has eight different isoforms in humans and it can associate with Gi, Gs, Gq, and G12/13 
(Israel & Regan et al. 2009).  
This is summarized in table 1.7 (Narumiya et al. 1999). The EPs are G-protein-coupled 
receptors (GPCRs), so they have seven-transmembrane α helices, an extracellular N 
terminus and intracellular C terminus.  
 
 




















The principal mechanism of action of NSAIDs (Nonsteroidal anti-inflammatory drugs) is 
to target cyclooxygenase. This class includes nonsteroidal anti-inflammatory, 
nonsteroidal analgesics and antipyretic (fever-reducing) drugs. The first NSAID 
discovered was aspirin. The active ingredient is a compound called salicilin, which is 
present in the willow tree. Although the salicilin was discovered in the XIX century by 
Leroux and it was introduced on the market by Bayer with the name Aspirin, bark and 
leaves of the willow tree were used by Hippocrates (460-377 B.C.) to heal pain and 
fevers. At the end of the 19th century other drugs with the same anti-inflammatory 
properties of the aspirin were discovered. In 1963 indomethacin was introduced as a 







	   63 
been introduced in the last few years, including the latest COX-2 selective inhibitors 
(COXIBs) (Rao & Knaus, 2008).  
NSAIDs differ in how quickly they bind the COX active site and how they are released 
from the COX channel. Traditional NSAIDs (tNSAIDs), ie. nonselective inhibitors for 
COX-1 and COX-2, have three different modes of binding: 1) reversible binding (eg: 
ibuprofen), 2) slowly reversible binding-time-dependent, (eg: fluorbiprofen, 
indomethacin), 3) irreversible binding caused by a covalent modification of the enzyme 
(eg: aspirin) (Marnett et al. 1998). Furthermore, NSAIDs can be classified based on 
their chemical structure: a) Salicylates (aspirin, diflunisal), b) Propionic acid derivatives 
(Naproxen, Ibuprofen, Ketoprofen etc.), c) Acetic acid derivatives (indomethacin, 
diclofenac etc), d) Enolic acid (Oxicam) derivatives (Piroxicam, Meloxicam), e) Fenamic 
acid derivatives (Mefenamic acid, Meclofenamic acid etc.), f) Sulphonanilides 
(Nimesulide), g) selective COX-2 inhibitors (COXIBs) (Celecoxib, Parecoxib, Rofecoxib, 
Valdecoxib etc.).  
As reported in the previous section, selective inhibitors of COX-2, the COXIBs, were 
developed to avoid or at least decrease the risk of gastrointestinal complications. 
Selective COX-2 inhibitors bind tightly to the COX-2 active site (Rao et al. 2008) and 
valdecoxib and rofecoxib are about 300 times more potent at inhibiting COX-2 than 
COX-1, while, Celecoxib is approximately 30 times more potent at inhibiting COX-2 
than COX-1. Table 1.8 shows IC50 for COX-1 and COX-2 for selective and non-selctive 
COX-2 inhibitors. 
Some patients using COXIBs reported superior pain relief compared to that 
experienced on traditional nonsteroidal anti-inflammatory drugs (tNSAIDs). This was not 
true for all patients and the clinical response to a particular NSAID vary from patient to 
patient (Fries et al. 2005). Even if gastrointestinal side effects decreased, COXIBs 
(rofecoxib, valdecoxib, and celecoxib) are associated with increased incidence of 
cardiovascular complications like stroke, myocardial infarction (Cannon et al. 2006; 
FitzGerald et al. 2004). Since COX-2 is the predominant source of vascular prostacyclin 
(PGI2) (important for vasodilatation and inhibition of platelets) and TXA2 (cause of 
vasoconstriction, bronchoconstriction, platelets aggregation) is mainly produced by 
COX-1,	   selective inhibition of COX-2 alters the balance of PGI2 and TXA2 synthesis 
more than tNSAIDs. This is the most frequently proposed mechanism to explain the 
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Table 1.8: Comparison of nonsteroid anti-inflammatory drugs for their selectivity towards 
COX-1 and COX-2 (Vane et al. 1998) 
                            
 
 
Celecoxib Long-term Arthritis Safety Study (CLASS; 8059 patients) confirmed that 
COXIB drugs are associated with an increased risk of thrombotic cardiovascular events 
(myocardial infarction, unstable angina, cardiac thrombus, resuscitated cardiac arrest, 
sudden or unexplained death, ischemic stroke, and transient ischemic attacks) 
(Mukherjee et al. 2001).  
COXIBs represent a cardiovascular hazard, so, on FDA recommendation, Rofecoxib 
and Valdecoxib were withdrawn from the market by Merck and Pfizer (the 
pharmaceutical companies that first marketed these drugs) (FDA, Center for Drug 
Evaluation and Research, 2008). Celecoxib is the only and the best selling COXIB on 
the market (Fries et al. 2005). Epidemiological and experimental studies have reported 
that COXIBs can reduce the risk of colonic tumors (Steinbach et al. 2000).  
The FDA (Food and Drug Administration) approved the use of Celebrex (Celecoxib) in 
patients with familial adenomatous polyposis (FAP). Because of the increased risk of 
cardiovascular (CV) diseases, COXIBs may be best suited for use by young patients 
(with a reduced risk of CV diseases) with familial adenomatous polyposis (FAP) (Garcia 
Rodriguez et al. 2012).  
However in a meta-analysis of randomised trials in patients receiving celecoxib, there 
was no increased cardiovascular risk with celecoxib relative to placebo. Furthermore, it 
was demonstrated that there was a comparable rate of cardiovascular risk both with the 
use of celecoxib and nonselective NSAIDS (White, 2007). So the association of 
       
P1: ARS/ary P2: ARK/plb QC: ARK/bs T1: ARK
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Table 1 Comparison of nonsteroid anti-inflammatory drugs for their selectivity towards COX-1
or COX-2
IC50 COX-1 IC50 COX-2 Ratio IC50
Drug (µM) (µM) COX-2/COX-1 System
Nonselective for COX-2
Piroxicam 0.0005 0.3 600 Cultured animal cells (110)
Aspirin 1.67 278 166 Cultured animal cells (110)
Indomethacin 0.028 1.68 60 Cultured animal cells (110)
Diclofenac 1.57 1.1 0.7 Cultured animal cells (110)
6-MNAa 278 187 0.67 Human whole blood (111)
Selective for COX-2
Etodolac 34 3.4 0.1 Human whole blood (111)
Meloxicam 4.8 0.43 0.09 Human whole blood (111)
Nimesulide 9.2 0.52 0.06 Human whole blood (111)
SC58125 38.7 0.27 0.007 Human whole blood (111)
NS398 16.8 0.10 0.006 Human whole blood (111)
L-745, 337 369 1.5 0.004 Human whole blood (111)
Celecoxib 15 0.04 0.003 Human enzymes (80)
DFU >50 0.04 <0.001 Human enzymes (81)
a6-MNA, 6-methoxy-2-naphthyl acetic acid, the active metabolite of nabumetone.
with several 100-fold selectivity for COX-2 (Table 1). The constant molecular
motifs in this range of compounds are the absence of a carboxylic group and the
presence of a sulphonamide or sulphonemoiety (Figure 2). Extensive structure-
activity analyses of selective COX-2 inhibitors have been undertaken by the
pharmaceutical industry, and some of these have already been reviewed (15).
Table 2 Inhibition of COX-1 and COX-2 by NSAIDs in different systems
COX-2/COX-1 Ratio
System Indomethacin Nimesulide Etodolac Meloxicam
Cultured 22 (112) 0.05 (122) 0.33 (113)




enzymes 1.3 (115) 0.2 (118) ⇠0.001 (81) 0.003 (81)
>75 (116) 0.02 (124) 0.09 (127) 0.01 (118)
2.3 (14) 0.16 (125) 0.8 (116)
9 (117) 0.01 (81)
3.5 (118) 0.02 (120)
Human whole
blood cells 0.51 (119) 0.19 (120) 0.1 (127) 0.09 (111)
12.5 (120) 0.06 (111)
2.9 (121) 0.07 (126)
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increased cardiovascular risk with COXIBs is still controversial and there are various 
clinical trials using Celecoxib for different diseases (see section 1.10.1). 
 
 
1.9.6 Inducers of COX-2 expression. 
 
The human COX-2 gene is on chromosome 1 q25.2–q25.38 (Khuri et al 2001). It is 
approximately 8.3 kb long and comprises 10 exons (Appleby et al. 1994). The promoter 
region of the COX-2 gene was well characterized. Xie and Herschman (1995) showed 
that the cAMP response element (CRE) on the promoter was critical for transcription 
(Xie & Herschman, 1995). Sequence analysis of the 5′-flanking region revealed several 
potential transcription regulator elements like the cAMP response element (CRE), the 
C/EBP-NF-IL6 (“CAAT/enhancer binding protein”), NFAT (“nuclear factor of activated T 
cells”) and NFκB (“nuclear factor kappa B cells”) sites (see figure 1.22), the E-box, SP1 
(Crofford et al.1997; Herschman et al.1997; Sirois & Richards, 1993; Diaz-Munoz et al. 
2012). CRE and AP-1 binding regions are located at –60 to –40 from the transcription 
start site and overlap with CRE binding protein (CREB), ATF, C/EBP, C-Jun, C-Fos, 
and USF binding sites (Schroer et al. 2002) (shown in figure 1.22).  
There are several inducers of COX-2 expression. Bacterial lipopolysaccharide (LPS) 
was the first to be identified (Lee et al. 1992). This factor can activate COX-2 through 
several pathways like MEK/ERK and the TRAF6/NIK/Tpl2/IKK/NFkB pathway (Chen et 
al. 2005). Several cytokines such as IL-1 or IFN-γ (Caivano et al. 2000) and several 
growth factors including IGF (by PI3Kinase and Src/ERK), TGFα and EGF (through 
p38MAPK, ERK1/2 and PI3K pathways) can induce COX-2 expression (Chun et al. 
2004). Moreover, UVB was shown to induce COX-2 mRNA using cancer cells signalling 
through CREB, ATF1, p38MAPK and PI3K (Bachelor et al. 2005). Glycogen synthase 
kinase 3 (GSK3) phosphorylates/inactivates β-catenin, leading to inhibition of the 
transcription factor TCF4, which regulates COX-2 transcription (Dihlmann et al. 2003). 
Cyclooxygenase 2 (COX-2) is also induced by p53 and DNA damage through 
Ras/Raf/MAPK cascade (Han et al. 2002). 
 
                                    
Figure 1.22: Structure of the human COX-2 promoter region. Transcription factor binding 
sites in the 5′-flanking sequences (promoter) of the human Cox-2 gene (Diaz-Munoz et al. 2012). 
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1.9.7 TPA induction of COX-2. 
 
The phorbol ester TPA is another COX-2 inducer. TPA (12-O-Tetradecanoylphorbol-13-
acetate) a tetracyclic diterpenoid, is a tumor promoter. TPA mimics the action of diacyl 
glycerol (DAG), an activator of protein kinase C, which regulates different signal 
transduction pathways and other cellular metabolic activities. TPA can influence the cell 
cycle. In a study on HeLa cell lines, it was seen that TPA blocked G2 phase of cell cycle 
(Kinzel et al. 1984). Using guinea pigs, TPA was shown to cause inflammation and 
epidermal hyperproliferation, by inducing DNA synthesis through prostaglandin 
activation, especially prostaglandin E (Bourin et al. 1982). However, TPA in high 
concentrations can be toxic and results in death of animals, reduced milk yield and 
reproduction (Forsyth et al.1968). TPA increases binding of CREB-2, C-Jun, and C-Fos 
to the CRE/AP-1 region and C/EBPβ to the C/EBP element at –124 to –132 of human 
COX-2 (Schroer et al. 2002; Saunders et al. 2001). In breast cancer cell lines, 
turmerone, a natural remedy with anti-inflammatory property, suppressed the TPA-
induced up-regulation of COX-2 expression, by blocking NF-κB, PI3K/Akt and ERK1/2 
signalling (Park et al. 2012).  
Another mechanism of TPA induction of COX-2 involves PKC pathway. In glioblastoma 
cells, activation of protein kinase C (PKC) and extracellular signal-regulated kinases 
(ERKs) are involved in TPA-induced migration/invasion, COX-2 protein expression, and 
MMP-9 activation (see figure 1.23) (Chiu et al. 2010). The epidermis of TPA-treated 
mice, overexpressing PKCα, displayed increased expression of cyclooxygenase-2 
(COX-2) compared to TPA treated wild type mice (Wang & Smart 1999). TNF-α induces 
COX-2 expression via activation of ERK1/2 and NFκB (Nakao et al. 2002), but can also 
induce its expression through the PKC pathway. In pulmonary carcinoma cells, a 
protein kinase C (PKC) inhibitor, staurosporine, attenuated TNF-α or TPA induced 
COX-2 promoter activity, whereas overexpression of PKCα induced COX-2 promoter 























Figure 1.23: TPA induction of COX-2 expression.TPA binds to PKC and activates MEK1/2, 
PI3K/AKT, p38 MAPK, JNK, all of which can activate COX-2. 
 
 
1.10 COX-2 in breast cancer. 
 
Increased levels of COX-2 were reported in carcinomas of the colon (Eberhart  et al. 
1994), stomach (Ristimaki et al. 1997), esophagus (Zimmermann et al. 1999), lung 
(Hida et al. 1999),  liver (Koga et al. 1999) and pancreas (Tucker et al. 1999). 
Moreover, COX-2 was found to be overexpressed in about 40% of cases of invasive 
breast carcinoma (associated with unfavorable distant disease-free survival) (Ristimaki 
et al. 2002) and at a higher frequency in preinvasive ductal carcinoma in situ (Boland et 
al. 2004). COX-1 is ubiquitously expressed in mammary tissues, while COX-2 
expression was observed confined to the tumor epithelium (Simmons et al. 2004). 
COX-2 mediates its deleterious effects via prostaglandin synthesis. In particular, PGE2 
was observed in high levels in breast tumor cells and it is synthesized by several 
human breast cancer cell lines (Schrey et al. 1995). PGE2 is an immunosuppressive 
agent and can, therefore, contribute to the evasion of tumour-specific immune 
responses. It was demonstrated that PGE2 shifts the tumour immune response from 
Th1 to Th2 (Luft et al. 2002), by downregulating Th1 cytokines (TNF-α, interferon-γ and 
IL-2) and increasing the secretion by dendritic cells of Th2 cytokines (IL-4, IL-10 and IL-
6).  
COX-2 overexpression in human breast cancers is associated with factors causing poor 
prognosis, such as overexpression of HER2 and overexpression of aromatase (Ranger 
et al. 2004; Brueggemeier et al. 1999). Overexpression of HER2 can induce COX-2 
transcription in different breast cancer cell lines (Subbaramaiah et al. 2002; Half et al. 
2002). Both HER2 and COX-2 are expressed at high frequencies in DCIS and so the 
combined targeting of COX-2 and HER-2 was suggested as a potential strategy to 
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prostaglandin E2 (PGE2) can stimulate aromatase activity and estrogen biosynthesis in 
the surrounding adipose tissue (Purohit et al. 2002 a; Purohit et al. 2002 b) and EP1 
and EP2 selective antagonists decreased aromatase activity (Richards et al. 2003). 
Local estrogen production by breast tumors is considered to be an important 
mechanism by which tumors develop, evolve, and possibly metastasize (Purohit et al. 
2002a). 
Ristimaki et al. observed that elevated expression of COX-2 in ER-positive tumors is 
also associated with poor survival (Ristimaki et al. 2002), and Díaz-Cruz that COX-2 
inhibitors decreased aromatase mRNA and activity in breast cancer cells (Díaz-Cruz et 
al. 2005). The use of combined COX-2 and aromatase inhibitor was more effective than 
the single agent used alone in decreasing aromatase activity and, consequently, 
estradiol production (Prosperi and Robertson, 2006). So, it is possible that elevated 
COX-2 expression in ER-positive cancers could enhance estrogen production via the 
aromatase pathway in the stromal cells and cause tumorigenesis and poor survival. 
However, there are conflicting reports as Ristimaki et al. found that elevated levels of 
COX-2 are associated with negative and positive hormone receptor status (Ristimaki et 
al. 2002), Zerkowski et al. found a correlation with negative ER status (Zerkowski et al. 
2007), while Ranger did not find any correlation (Ranger et al. 2004). 
In breast cancer cells, COX-2 may contribute to the enhancement of lymph node 
metastasis and distant metastasis. Lymph node metastasis is associated with high 
expression of VEGF-C (vascular endothelial growth factor) and the prostaglandin EP1 
and EP4 receptors are involved in COX-2 mediated VEGF-C up-regulation (Su et al. 
2004). COX-2 up-regulates, via EP2 and EP4 receptors, CCR7 (a chemokine receptor 
associated with breast cancer metastasis) expression in breast cancer cells. It regulates 
matrix metalloproteinase expression, which can digest the extracellular matrix and the 
basement membrane (Pan et al. 2008). Gene expression analyses and mouse model 
systems revealed correlations between COX-2 overexpression and breast cancer 
metastasis to the lung, bone, and brain (Singh et al. 2007; Minn et al. 2005; Bos et al. 
2009). Moreover, COX-2 overexpression, in MDA-MB-231 breast cancer cell line, 
increases their motility and invasion (Singh et al. 2005), while silencing of COX-2 
inhibits migration of this line in vitro and metastasis in vivo (Stasinopoulos et al. 2007).  
COX-2 is also involved in angiogenesis and in migration of endothelial cells. 
Angiogenesis is the formation of new blood vessels from preexisting ones and it is 
important in tumorigenesis for cell growth and metastasis (Costa et al. 2002). In COX-2 
knockout mice, the expression level of angiogenesis-related genes (VEGF, Ang1, and 
Flt1) in the mammary glands was found significantly reduced compared to that found in 
COX-2 wild-type (Howe et al. 2005). PGE2 stimulates VEGF secretion through the 
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stimulation of ERK2/JNK1 signalling pathways in endothelial cells (Pai et al. 2001) and 
in ovarian cancer cells the EP2/EP4 receptors have been shown to be involved (Spinella 
et al. 2004). Moreover, Timoshenko et al. demonstrated that VEGF production could be 
blocked by EP1 and EP4 inhibition in several human breast cancer cell lines 
(Timoshenko et al. 2003). However, other studies suggested that EP3 receptor could 
play a role in angiogenesis. In a model that can mimic tumor-stromal angiogenesis, an 
EP3 agonist, ONO-AEI-248, increased angiogenesis in a dose dependent manner and, 
in EP3 knockout mice, angiogenesis was significantly reduced compared to wild-type 
mice (Amano et al. 2003). Celecoxib was shown to decrease tumor angiogenesis 
(reducing functional vessel density) and to reduce the growth of a variety of 
experimental primary tumors, including colorectal, prostate, and breast tumors (Klenke 
et al. 2006).  
COX-2 can suppress apoptosis and inhibit the apoptosis mechanism, caused by some 
anti cancer drugs (Chang et al. 2001). Apoptosis (programmed cell death) is essential 
to mantain tissue homeostasis and any failure in this mechanism can cause excessive 
cell survival, essential for tumorigenesis (Hanahan and Weinberg, 2011). There are 
many mechanisms by which cancer cells can evade apoptosis and one of them is the 
overexpression of Bcl-2 protein, that can inactivate the apoptotic caspase cascade 
upstream of the mitochondria (Danial & Korsmeyer, 2004). It was shown that in 
transgenic mice overexpressing the human COX-2 gene in the mammary gland, there 
were reduced levels of the proapoptotic proteins Bax and Bcl-xL and an increase of Bcl-
2, suggesting that enhanced COX-2 expression is sufficient to inhibit apoptosis and 
induce mammary gland tumorigenesis. Therefore, inhibition of COX-2 may represent a 
mechanism-based chemopreventive approach for carcinogenesis (Liu et al. 2001). 
Indeed, the cell apoptosis induced by celecoxib in a mouse mammary tumour was 
associated with an activation of antiapoptotic/prosurvival kinase (Akt) and increased 
expression of proapoptotic protein Bax (Basu et al. 2004). 
 
 
1.10.1 NSAIDs and breast cancer. 
COX-2 expression associated with cancer is considered a possible target for breast 
cancer chemoprevention and therapy. Studies that examined the correlation between 
risk of breast cancer and use of NSAIDs, like aspirin and ibuprofen, published between 
1966 and 2008, were analyzed by meta-analysis. Among 38 identified studies 
(including about 3 million people), it was found that NSAIDs are associated with 
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reduced risk of breast cancer (Takkouche et al. 2008; Agrawal et al. 2008). These 
meta-analyses included the study of Harris et al. that showed a reduced risk of breast 
cancer in 66% of women using ibuprofen and aspirin for more than one year (Harris et 
al. 1996). A reduction in incidence of breast cancer was shown in patients taking aspirin 
and other NSAIDs in two studies from Schreinemachers and Everson and Sharpe et al. 
(Schreinemachers & Everson, 1994; Sharpe et al. 2000). For its cardiovascular benefit 
and efficacy data, aspirin is the most likely NSAID for chemoprevention in cancer 
(Cuzick et al. 2009). 
 
             
Figure 1.24 Design of phase III clinical trial REACT (Randomised European Celecoxib 




A multicentre phase III clinical trial, the Randomised European Celecoxib Trial 
(REACT), is now underway for women with breast cancers that are either node positive 
or high-risk node negative. Patients are randomized and either receive two years of 
Celecoxib or placebo. Women with tumours that are estrogen or progesterone receptor 
positive receive tamoxifen, followed by exemestane for a total of 5 years. Coombes et 
al. showed that there is a reduction in the death rate in women ER positive, who 
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1.11 Glycosylation and inflammation. 
 
Functions of glycans in inflammation are well defined. As said above, L-selectin is 
expressed by most leukocytes, whereas E-selectin and P-selectin are expressed by 
inflamed endothelial cells and they are adhesion molecules for granulocytes, 
monocytes and T lymphocytes (Carlos et al. 1991). L-selectin, P-selectin and E-selectin 
recruit lymphocytes to sites of inflammation, and mediate the initial interaction of the 
leukocytes with the endothelial surface. The selectins bind to SLex, carried on specific 
protein or lipid backbones, and binding slows down the flow of lymphocytes allowing 
them to roll along the endothelial surface and bind to adhesion molecules, such as 
integrins. This allows their movement into the tissues, which is induced by chemokines 
(Ley et al. 1995). L-selectin, P-selectin and E-selectin interact with P-selectin 
glycoprotein ligand 1 (PSGL1) (McEver et al. 1997) and other glycosylated ligands 
(CD44 and E-selectin ligand 1 (ESL1) (Hidalgo et al. 2007).  
The Sialyl Lewis x (sLex)-like glycans are expressed in relatively high numbers by 
circulating leukocytes and endothelial cells in the lymph nodes and in the endothelium 
of inflamed tissues (Varki et al. 1997). Munro et al. performed an analysis of sLex 
expression on leukocytes, monocytes and other cells in the context of inflammatory and 
immune processes. They analysed tissues from inflammatory disease (like appendicitis, 
sinovium rheumatoid, chronic dermatitis, psoriasis) and from secondary lymphoid 
tissues. A substantial number of monocytes/macrophages in inflamed appendiceal 
synovial and dermal tissues reacted with a SLex antibody (CSLEXI) compared to the 
uninflamed sites (Munro et al. 1992). Furthermore, other monoclonal antibodies to 
SLex, such as MECA-79 (which share similar specificity to L-selectin) or PNAd, which 
reacted with the endothelium of chronically inflamed tissues, were used (Kannagi et al. 
2002; Rosen et al. 1999).  Inhibitors for leukocyte migration into inflamed tissues 
(inhibitors for selectins and for the biosynthesis of their ligands) constitute an attractive 
target for anti-inflammatory therapy. Therapeutics that block selectins like selectin 
inhibitor PSGL-1 (Khor et al. 2000) or inhibitors of the glycosyltransferases (Chen et al. 
2011; Lee et al. 2003) are presently under development. However, selectins and some 
glycosyltransferase are present in various part of the body, so an inhibitor would face 
multivalent and low-affinity interactions in vivo. 
Very importantly, Kaneko et al demonstrated that IgG (immunoglobulins G) acquires 
anti-inflammatory properties with the sialylation of the constant domain (Fc) of 
immunoglobulins. Sialylation is reduced upon the induction of an antigen-specific 
immune response (Kaneko et al. 2006).  
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Some non-invasive diagnostics for sites of chronic inflammation (like inflammatory 
diabetes), prior to the presentation of clinical symptoms, are in the process of 
development. Denis et al. have reported a diagnostic for inflammatory diabetes that 
targets leaky vasculature, an early event in this kind of disease (Denis et al. 2004). This 
method consists of imaging the expression of L-selectin ligands, which probably 
precedes inflammatory tissue damage. Sibson et al. reported a strategy for the early 
detection of inflammation in the brain: an MRI-contrast reagent coupled to an sLex 
mimetic that binds E-selectin (Sibson et al. 2004). Understanding the early changes in 
glycosylation can actually improve strategies for early detection and cure of 
inflammatory diseases.  
 
 
1.12 PGE2 changes the expression of C2GnT1 and ST3Gal-I. 
 
The idea for this study arose from the findings of Julien et al., which reported that PGE2 
changes the expression of glycosyltransferases expressed by dendritic cells: C2GnT1 
was rapidly down regulated and the ST3Gal-I was up-regulated (Julien et al. 2007). 
Prostaglandin E2 is fundamental during monocytes derived dendritic cells (MoDC) 
maturation and triggers the migration of these cells from the tissue to the lymph node-
derived induced by chemokines (Kalinski et al. 1998). PGE2 signals in human MoDCs 
through EP2 or EP4 either alone or in combination (Legler et al. 2006). It is reported that 
dendritic cells express all EP receptors (Harizi et al. 2003).  
There are a few studies on the interaction between glycosyltransferases and COX-
2/PGE2 pathway in colorectal and prostate cancer that associate PGE2/COX-2 
pathway with ST3Gal-I expression (Hatano et al. 2011; Kakiuchi et al. 2002). Kakiuchi 
et al. showed that, in epithelial colorectal adenocarcinoma cells, COX-2 overexpression 
or PGE2 treatment  reduced  ST3Gal-I expression, while Celecoxib (COX-2 selective 
inhibitor) increased its expression (Kakiuchi et al. 2002). In contrast, Hatano et al. 
showed that in castration-resistant prostate cancer cell lines, PC3 and DU145 cells, the 
expression of ST3Gal-I could be mildly induced by phorbol-12-myristate-13-acetate 
(TPA), and TPA-induced expression of ST3Gal-I could be inhibited by NF-κB decoy 
oligodeoxynucleotides (ODN) (Hatano et al. 2011). 
As PGE2 is the main metabolite of COX-2, an enzyme overexpressed in invasive 
breast cancer, and PGE2 can influence the expression of the glycosyltransferases 
C2GnT1, and ST3Gal-I in DCs, this study aims to investigate the role of PGE2/COX-2 
pathway in the regulation of glycosyltransferases (GT) in breast cancer. To our 
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knowledge this is the first study investigating the interaction between COX-2 and the 
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a) Cell culture.  
 
T47D, MDA-MB-231, SKBr3 and ZR75-1 (human breast cancer cell lines) were cultured 
in Dulbecco’s modified Eagle’s medium containing 10% fetal calf serum (FCS) and P/S 
(pen/strep) and glutamine. MCF7(human) was cultured in the same medium with the 
addition of 10% insulin. Cell cultures were grown at 37° C in a humidified atmosphere of 
5% CO2. Cells were mainly plated in either T-80 flasks or 6 well plates and grown to 
subconfluency. Before treatment, the media was changed every two days.  
 
b) Tissue samples. 
 
  All tissue samples used were from the Guy's and St. Thomas' Breast Tissue & Data 
Bank and had been approved for use in this study in accordance with their NHS REC 
approval (REC No: 07/H0874/131). These tumours are available from the Breast Tissue 
Bank (thanks to the Tissue Bank Manager, Dr Cheryl Gillett).  
 
c) Antibodies  
 
-HMFG1, HMFG2, SM-3 were produced in this lab;  
-Polyclonal rabbit anti-human prostaglandin receptor 1,2,3,4 antibodies (Cayman 
Chemicals, Ann Arbor, MI, USA);  
-Rabbit monoclonal antibody to EpCam (Abcam) ; 
-Rabbit COX-2 polyclonal antibody (Oxford Biomedical Research) and Mouse COX-2 
monoclonal antibody (Cayman); 
-Mouse Anti-beta-Actin Monoclonal Antibody (Sigma Alrich);  
-Rabbit p44/42 MAPK (Erk1/2) Monoclonal Antibody (mAb), Rabbit Phospho-p44/42 
MAPK (Erk1/2) (Thr202/Tyr204) mAb, Rabbit FAK mAb, Rabbit Phospho-FAK mAb, 
Rabbit CREB, Phospho-CREB (Ser133) mAb (Cell Signalling Technology). All the 
antibodies are HRP Conjugate. 
- PNA (Vector laboratories); 
- HRP-conjugated goat anti-mouse IgG (Dako). 
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d) Reagents. 
 
Prostaglandin E2 (Sigma),  




Celecoxib (Sigma Aldrich). 
NS398 (Sigma Aldrich). 
Gö 6976 and Gö 6983 (kind gift from Prof. Peter Parker’s lab) 
 
 
2.2 Incubation of chemicals on cell lines culture. 
 
Previous to incubation with either PGE2, TPA, COX-2 inhibitors, PKC inhibitors, cells 
were starved in serum free medium from 2 to 6 hours. All compounds were incubated in 
serum free medium. 
 
 
2.3 Molecular Biology techniques: RNA 
 
2.3.1 Extraction of total RNA from cell lines. 
 
Cells were counted using the CASY counter. 25 µL of “RNA Later” was used for each 
million cell. Cells were either snapped frozen or directly used for extraction. RNA was 
isolated using the Nucleospin RNAII kit (Macherey-Nagel). Unfortunately, the company 
does not release the composition of any of the buffers contained within the kit. It is 
known, however, that both buffer RA1 and RA2 contain the guanidine isothiocyanate 
that removes the hydration shell surrounding RNA molecules, allowing them to bind the 
silica membranes within the columns. The presence of the guanidine isothiocyanate 
and the addition of β-mercaptoethanol to the lysis buffer ensures complete denaturation 
of RNases, preventing RNA degradation. Contaminated DNA, bound to the silica 
membrane, is removed by a rDNase solution, which is directly applied onto the silica 
membrane during the preparation. Optimal conditions for the rDNase are achieved by 
washing the silica membrane with a specific desalting buffer before treatment. Salts, 
metabolites and macromolecular cellular components are removed by simple washing 
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steps with two different buffers. Total RNA is finally eluted with RNase-free water 




The pellet of cells was diluted in 350 µL Buffer RA1 containing 3.5 µL β-
mercaptoethanol. Insoluble materials from the lysate were removed by filtration through 
a Nucleospin filter by centrifugation at 11,000g for 1 minute. The eluate was mixed with 
350 µL 70% ethanol and loaded onto a Nucleo-spin RNA II column before being 
centrifuged at 11,000 g for 30 seconds. The eluate was discarded and the column 
desalted by addition of 350 µL membrane desalting buffer. The column was centrifuged 
at 11,000 g for 1 minute. The column was treated with 95 µL reconstituted DNase and 
incubated at room temperature for 15 minutes. The column was washed by the addition 
of 200 µL buffer RA2 prior to centrifugation at 11,000 g for 30 seconds. Following an 
additional wash using 600µL buffer RA3 and centrifugation at 11,000 g for 30 seconds, 
250 µL buffer RA3 was added and the column subsequently centrifuged at 11,000 g for 
two minutes. The RNA was eluted from the column into an RNase-free 1.5mL 
eppendorf by the addition of 60µL RNase-free water and centrifugation at 11,000 g for 
one minute. The RNA was stored at -20 OC until required. 
 
 
2.3.2 Extraction of total RNA from human tissue samples. 
 
Samples were crushed using mikrodismembrator II and then homogenised in RNA1 
lysis buffer or qiazol. RNA extraction was carried out using Macherey-Nagel RNA Spin 
L (1-10) or Qiagen Rneasy lipid tissue mini kit (Macherey-Nagel up to 200mg of tissue, 




2.3.3 Quality of RNA and measurement of nucleic acid concentration. 
 
The quality of the RNA extracted was checked by running an aliquot on an agarose gel 
stained with ethidium bromide (described in paragraph 2.5.3), and by measuring the 
optical density 260/280 ratio of each sample. Intact total RNA shows two sharp bands 
on agarose gel; these two bands represent 28S and 18S ribosomal RNA. For 
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quantification of DNA or RNA concentration, OD readings were taken at 260nm and 
280nm of a diluted sample. Estimates of purity were obtained from the ratio 
OD260/OD280. This is because nucleic acid is detected at 260 nm, whereas protein, salt 
and solvents are detected at 280 nm. The ratio is typically 1.8 for DNA and 2.1 for RNA. 
 
 
2.3.4 Reverse Transcription of RNA in cDNA.  
 
The production of cDNA was performed by reverse transcriptase. This enzyme is 
capable of using its polymerase activity to synthesize a complementary DNA strand 
from RNA. 
 Reaction mixture A and B were produced. 
1) Reaction Mixture A: 
    1µL Random Primers, 1µL dNTPs; 
2) Reaction Mixture B 
    1µL Superscript II reverse transcriptase, 4 µL 5x FS Buffer, 1µL DTT, 1µL RNase 
Out. 
All the reaction reagents were purchased from Invitrogen. RNA concentration was 
measured by Nanodrop and the same amount of RNA (1-2µg) was used and diluted in 
dH2O. RNA was mixed with 2 µL of Reaction Mixture A and incubated at 65°C for 5 
minutes. This was mixed with reaction mixture B and incubated at 50°C for 1 hour. The 
reaction was stopped at 94°C for 5 minutes. The samples were incubated on ice for at 
least 1 minute. Each sample was treated with 1µL RNase H and incubated at 370C for 
20 minutes. The samples were diluted with 80µL of nuclease free distilled water or less 
water, in order to give a concentration of 10-100ng/µL. 
 
 
2.3.5 Amplification of ST3Gal-I, C2GnT1 and COX-2 sequence by 
Real Time quantitative Polymerase Chain Reaction. 
 
Once the cDNA had been obtained, it was probed with primers specific for the 
sequence of interest. The RT-qPCR was performed with the primers described in table 
2.2, using the Opticon RT-qPCR Analysis System (MJ Research). 10-20 ng of cDNA 
was used for each reaction. For independent biological experiments the same amount 
of cDNA for reaction was used. In quantitative RT-qPCR a measurable fluorescent 
signal is associated to the amount of amplification product present. The dye used in this 
work is SYBR® Green, a fluorescent dye that binds to the minor groove of the DNA 
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double helix. As the copies of the DNA template are exponentially produced with 
increased cycles, the amount of fluorescence detected increases exponentially. Melting 
curve analysis is a simple way to check qPCR reactions for contamination and to 
ensure reaction specificity and accurate quantification. As the temperature increases 
through the dissociation temperature, the double stranded DNA product separates into 
complementary strands and SYBR® Green molecules are released and they decrease 
in fluorescence. The Tm is calculated to be the point at which maximum fluorescence is 
lost. The amount of target is normalized to an endogenous reference gene.  
The relative amount of expression is performed by the “comparative CT Method,” given 
by the mathematical expression 2 –∆CT (see appendix of materials and meethods). The 
CT is the threshold cycle number and it indicates the fractional cycle number at which 
the amount of amplified target reaches a fixed threshold. The exponent ∆CT is given by 
the difference between the CT of the target gene and CT of the reference gene (Applied 
Biosystems User Bulletin). 
The protocol used was according to Julien et al. 2007: 
Denature      5 minutes at 95°C 
Denature      15 sec at 94°C 
Anneal       30 sec at 60°CTm         35-45 cycles 
Extend       30 sec at 72°C 
Fluorescence detection  30 sec at 78°C 
 
Final extension    10 minutes at 72°C 
Hold       4°C 
 
A melting curve fluorescence analysis was performed on each sample, once the 
amplification cycles were completed, to verify that a single product had been amplified. 
Each sample was normalized to the housekeeping gene β-actin or PUM1 (Pumilio 
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 Table 2.2. Pairs of primers used in qPCR.2.4 Protein techniques. 
 
 
2.4.1 Western blotting 
 
a) Preparation of lysate from cell culture  
 
Cells were washed with ice-cold PBS. PBS was drained, and then lysis buffer (RIPA or 
Laemmli SDS PAGE buffer 1x) was added. The two protocols are described below: 
 
1.Lysis in RIPA buffer. 
The RIPA buffer (Radio Immuno Precipitation Assay buffer) is composed of 150 mM 
sodium chloride, 1.0% NP-40 or Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS 
(sodium dodecyl sulphate) 50 mM Tris, pH 8.0. 
The lysate was incubated for 30 minutes at 4°C and then centrifuged in a 
microcentrifuge at 4°C. A BCA assay was performed (ThermoFisher). Bovine serum 
albumin (BSA) was used for the protein standard. The same amount of protein and 
volume was used for all the samples. They were diluted with 6x Laemmli buffer, boiled 
at 95oC, and loaded on the gel with 5 µL of Prosieve protein Ladder (Amersham). 
 
2. Lysis in Laemmli 2X SDS PAGE sample buffer  
The Laemmli 2X buffer is composed by 4% SDS, 10% 2-β-mercaptoehtanol, 20% 
glycerol, 0.004% bromophenol blue, 0.125 M Tris HCl pH 6.8. 
In this case Laemmli buffer 1x (1 µL/10000 cells determined by counting a parallel well) 
was used directly on the cell layer. The lysate was passed through a needle, boiled at 
Protein Forward Primer (5’–3’) 
 
Reverse Primer (5’–3’) 





PUM1 GATTATTCAGGCACGCAGGT AGCAGCGCTGATGATGTATG 






ST3Gal I ATGAGAGGTTCAACCAGACC ATGGTGTCATTCAAGTTATTGG 
C2GnT1 AGAAGGATACACAAAACGTACC ACCTTTCTAGCTAACTGTGCTC 
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94oC and loaded on a gel with 5 µL of Prosieve protein Ladder (Amersham) in a parallel 
lane. 
 
b) Casting the gel. 
 
The gel is formed by a resolving and stacking gel. The resolving gel contained 7.5% 
acrylamide, 1M Tris-HCl pH 8.8 and 0.1% SDS and was polymerised by the addition of 
0.6% TEMED and 0.03% ammonium persulphate. A stacking gel was prepared and 
once the resolving gel was set, it was poured on top and left to polymerize around a 
comb. The stacking gel was composed of 5% acrylamide, 1M Tris pH 6.8, 0.1% SDS 




The protein samples were loaded in an equal volume of sample buffer and loaded onto 
the gel. Rainbow molecular weight markers (Amersham International) were used for 
size comparison. Electrophoresis was performed in 1x SDS-PAGE running buffer at 
150V. The proteins were run until fully separated and then Western blotted. 
 
d) Western blotting 
 
Following electrophoresis, the gel was equilibrated in transfer buffer (25 mM Tris, 192 
mM glycine, 10% methanol). Hybond-C nitrocellulose membrane and 4 sheets of 
Whatmann 3mm paper were cut to the size of the gel and soaked in 1x transfer buffer.  
The transfer sandwich was built in this order on the anode side of the transfer tank: 
- Sponge  
- Whatmann 3M paper sheet 
- Nitrocellulose sheet (Pall Corporation) 
- Gel (gently moved taking it by the more concentrated side = bottom) 
- Whatmann 3M paper Sheet 
- Sponge  
The air bubbles were rolled out between the membrane and the gel. The gels were 
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e) Probing of Western blot membranes. 
 
The membrane was washed briefly with deionised water and stained with a Ponceau 
solution for not more than 5 minutes to confirm efficient transfer. The Ponceau solution 
was removed and the membrane washed with clear water until a satisfying staining 
contrast was obtained. Non-specific binding of nitrocellulose membranes were blocked 
in wash buffer (PBSA, 0.1% Tween-20, 5% milk or 5% BSA.) for 1 hour at room 
temperature or overnight at 4°C. All antibodies were diluted in blocking buffer. The 
membrane was incubated in primary antibody at room temperature with gentle agitation 
at the appropriate concentration for 1 hour. The membrane was then washed 3 times 
for 10 minutes in wash buffer, before the HRP conjugated secondary antibody was 
added at a determined dilution. The membrane was incubated for 1 hour at room 
temperature with gentle agitation and then was washed as describe previously. The 




2.4.2 Stripping for reprobing protocol. 
 
The buffer used was made of 20 ml SDS 10%,12.5 mL Tris HCl pH 6.8 0.5 M, 67.5 mL 
ultra pure water and 0.8 mL β-mercaptoethanol. The buffer was warmed to 50°C and it 
was then added to the membrane. The membrane was incubated at 50°C for up to 20 
minutes with some agitation, it was rinsed for 1 hour in PBS/BSA, was again blocked 
and probed as described above. 
 
 
2.4.3 Mouse Kidney Sample Preparation (as Positive Control for EP 
Receptor Antibodies). 
 
Two mouse kidneys were weighed and 1 mL buffer (20 mM Tris ph 7.5, 5mM EDTA, 
with protease inhibitor-Roche) per 0.3 g tissue was added. The kidneys were ground 
with dry ice in a mortar and pestle and homogenized in Teflon/glass tube homogenizer. 
The product derived from homogenization was centrifuged at 10,000g for 15 minutes 
and the pellet was solubilized with ~2 mls of the buffer used to grind the tissues 
containing 1% TritonX-100. The derived solution was centrifuged for 10 minutes and 
the pellet discarded. The protein concentration was measured on supernatant by BCA-
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protein assay (Thermo Scientific). Equal volume of 2x Laemmli sample buffer was 
added to the protein sample and set in boiling water bath for 5 minutes. 10 µg was 
loaded per lane of a small gel. The protocol was provided by Cayman Chemicals. 
 
 
2.4.4 Human Phospho-Kinase Array Protocol. 
 
The kit used is called Human Phospho-Kinase Array Kit from R&D systems. It consists 
of 46 capture antibodies of different kinases and proteins and control antibodies that 
have been spotted in duplicate on nitrocellulose membranes. The Human Phospho-
Kinase Array is divided into two parts (A and B) to maximize sensitivity and minimize 
cross-reactivity. Membrane A has 28 and B 18 capture antibodies. One million cells 
were seeded in a six well plate and three wells were used for each condition. Cells were 
treated with TPA 10nM for 5 and then rinsed with cold PBS and lysis buffer (1 x 
107cells/mL), provided by the kit, was added to solubilize the cells. The extracts were 
resuspended and rocked gently in 1.5 ml eppendorfs at 2-8° C for 30 minutes and then 
microcentrifuged at 14,000 x g for 5 minutes. The supernatant was transferred into a 
clean tube and a BCA assay was performed to determine the protein concentration of 
the lysates. 100µg of protein in a volume up to 334µL was used and this volume was 
adjusted to a final of 2.0mL with Lysis Buffer 6. Membrane A and B were placed in the 
8-well multi dish provided and 1.0mL of Array Buffer 1, used as a block buffer, was 
pipetted into each well. After 1 hour of incubation, the Array Buffer 1 was removed and 
1.0 mL of lysate (with 50 µg of protein) was added to both the Part A and Part B 
membrane and incubated overnight at 2-8°C on a rocking platform. The membranes 
were washed three times with 1X Wash Buffer, by soaking for 10 minutes on a rocking 
platform. 1 mL of Antibody Cocktail A and mL Antibody Cocktail B were added 
respectively to membrane A and B into the 8-Well Multi-dish and incubated for 2 hours 
at room temperature on a rocking platform. Each membrane was washed three times 
with 1X Wash Buffer by soaking for 10 minutes with rocking. 1 mL of the Streptavidin-
HRP labelled second antibody was pipetted into each well of the 8-Well Multi-dish and 
incubated for 30 minutes at room temperature with rocking. The membranes were 
washed as described previously and the protein bands were visualized by the ECL Plus 
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2.4.5 Immunocytochemistry protocol. 
 
Cells (1x105) were plated the day prior to staining. Cells were fixed in 4% 
paraformaldehyde at 4°C for 10 min. Non-specific binding was blocked using 100% 
FCS serum. Slides were incubated with 1:100 polyclonal rabbit anti-COX-2 antibody 
(Oxford Biomedical) overnight at 4°C. Cells were then washed and incubated with 
Alexa Fluor® 546 Goat Anti-Rabbit IgG (H+L) *Highly Cross-Adsorbed* *2 mg⁄mL* 
secondary antibodies. The slides were then washed twice with PBSA and mounted in 




2.4.6 Flow Cytometric Analysis (FACs). 
 
Cells were gently removed from the culture with 5 mmol/L EDTA in PBS, counted, using 
a CASY, and the volume adjusted to have 0.5 x 106 cells/mL for each reaction. Cells 
were incubated for 1 hour on ice in PBS containing 0.05% BSA (human bovine serum 
albumin) with corresponding antibodies. Flow cytometry and analysis were performed, 
using a Coulter EPICS XL cytometer with Expo32 ADC software or a FACScalibur 
cytometer with Cellquest Pro software. Cell monolayers were detached, using 5 mmol/L 
EDTA in PBS. When necessary, cells were treated with 500mU of type V 
neuraminidase from Clostridium perfringens (Sigma-Aldrich) in serum-free medium for 1 
hour at 37o C, prior to first antibody staining. After 3 washes, samples were incubated 
with FITC streptavadin Ab (BD Pharmingen) (in the case of PNA staining), or FITC 
conjugated polyclonal rabbit anti-mouse IgG (Dako) (in the case of HMFG1, 2 and SM3) 
or with FITC-conjugated goat anti-rabbit IgG (Dako) (in the case of the EP receptors) for 
1 hour on ice in PBS containing 0.5% BSA. Cells were then fixed in 1% formaldehyde. 
After three washes with PBS/0.05% BSA, cells were incubated with the secondary 
antibody for another hour and then fixed in 0.5% PF (paraformaldehyde) (Sigma, 
Deisenhofen, Germany). Appropriate isotype controls were used. Cell lines were 
analyzed for MUC1 expression with HMFG1, HMFG2, SM3 or for Core1 with PNA. 
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2.4.7 Propidium iodide treatment in FACs analysis. 
 
Propidium iodide is a fluorescent vital dye that stains DNA and crosses the cell 
membrane of dead cells or cells in the late stages of apoptosis. PI is detected in the 
orange range between 562-588 nm band pass filter. Propidium iodide binds to DNA by 
intercalating between the bases with little or no sequence preference and it is used in 
flow cytometry to evaluate cell viability. Flow cytometry assay was run only on cells that 
could not be stained by PI. When necessary, 20 µL of PI were added to the solution 
and incubated for 15 min at RT (25°C) in the dark. Cells were analyzed by flow 
cytometry within 1 hr without using any paraformaldehyde. 
 
 
2.4.8 Intracellular FACS staining. 
 
Cells were fixed in 200 mL 4% paraformaldehyde, incubated for 3 minutes and spun.                                          
After 2 washes in PBSA and 1 wash in PBS/BSA/saponin/NaN3, cells were incubated 
for 15 minutes with PBS/BSA/sapanonin/FCS/NaN3. Cells were stained with EP 
Receptor Polyclonal Antibody diluted in PBS/BSA/sapanonin/FCS/NaN3 (1 mg/mL) for 
30 minutes. After two washes with PBS/BSA/saponin/NaN3, cells were incubated for 30 
minutes with FITC-conjugated goat anti-rabbit IgG. Pellets were then fixed with 1% 
formaldehyde in PBSA and PBS/BSA/sapanonin/FCS/NaN3. 
 
 
2.4.9 Enzyme-linked immunosorbent assay (ELISA) for PGE2 
measurement.  
 
The PGE2 Immunoassay is a competitive enzyme immunoassay designed to measure 
PGE2 in cell culture supernates, serum, plasma, and urine. It was provided by R&D. 
This assay is based on the competitive binding technique, in which PGE2 present in the 
samples competes with horseradish peroxidase (HRP)-labeled PGE2 for a limited 
number of binding sites on a mouse monoclonal antibody. Therefore there is an inverse 
relationship between the signal obtained and the concentration of the analyte in the 
sample, i.e. the more analyte the lower the signal. The standard curve was determined 
using PGE2 (provided by the R&D kit) in culture medium (DMEM). The range of 
concentration of the standard curve spans between 2,500 pg/ml and 39 pg/ml. To test 
the efficiency of the kit, an aliquot of PGE2 (Sigma-Aldrich) was diluted in the calibrant 
medium for a final concentration of 25 ng/ml and tested.  
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All the materials are furnished by the kit PGE2 Assay Catalog Number -R&D: 
-Goat Anti-mouse Microplate - 96 well polystyrene microplate (12 strips of 8 wells)    
coated with a goat anti-mouse polyclonal antibody. 
-PGE2 Conjugate - 6mL/vial of PGE2 conjugated to horseradish peroxidase with red 
dye and preservatives. 
-PGE2 Standard that is reconstituted in 1.0 mL of deionized or distilled water. The 
concentration is then 25,000pg/mL.  
-Primary Antibody Solution - 6mL/vial of a mouse monoclonal antibody to PGE2 in 
buffer with blue dye and preservatives.  
-Wash Buffer made of buffered protein base with preservatives.  
-Color Reagent A - 12.5mL/vial of stabilized hydrogen peroxide. 
-Color Reagent B - 12.5mL/vial of stabilized chromogen (tetramethylbenzidine). 
Color Reagent A should be mixed to Color reagent B in equal volumes within 15 
minutes of use and protected from light.  
-Stop Solution - 11 mL/vial of 2N sulfuric acid. 
-Calibrator Diluent RD5-56 - 21mL/vial of a buffered protein base with preservatives. 
Even if the kit provides this diluent, the standard was diluted in serum free medium like 
the samples analyzed. The instruction adviced to remove the serum in a serum 
separator tube. This is the reason why cells were treated in absence of serum. 
After the standard curve was set up, the samples were added in duplicates. First the 
primary antibody was added to each well and, after an incubation of 1 hour, HRP-
labeled PGE2 was allowed to bind to the antibody. Following a wash to remove 
unbound materials, a substrate solution was added to the wells to determine the bound 
enzyme activity. The color development was stopped, and the absorbance was read at 
450 nm. The intensity of the color was inversely proportional to the concentration of 
PGE2 in the sample. 
 
 
2.5 Molecular Biology techniques: DNA 
 
2.5.1 Transformation of competent bacteria. 
 
Competent cells were thawed on ice for 10 minutes. 50ng of plasmid, dissolved in 
water, were added to the cells, gently mixed and left on ice for 30 minutes with regular 
mixing to resuspend the cells. The cell and DNA mix was then heat-shocked at 42°C for 
90 seconds and then placed on ice for at least 2 minutes. 160ml of L-Broth was added 
and incubated with shaking at 37°C for 30 minutes. Using aseptic techniques, the 
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transformed cells were plated onto L-Agar plates containing the appropriate antibiotics, 
inverted and incubated overnight at 37°C. Ampicillin was used at a concentration of 
50µg/ml; and kanamycin was used at 25µg/ml. 
 
 
2.5.2 Large scale preparation of DNA-Maxiprep. 
 
Constructs, used for transfection, were produced using a large scale extraction of DNA. 
800 ⎧L of an overnight culture of transformed bacteria was grown in 200ml of L-Broth 
containing the appropriate antibiotic (ampicillin 50 µg/ml) at 37°C with shaking. 
The culture of transformed bacteria was centrifuged at 6000 rpm for 15 minutes at 4 °C 
and the pellet was resuspended in 10mL of Buffer P1. 10 mL of Buffer P2 was added 
and it was inverted 4-5 times. 10mL of Buffer P3 was added and it was inverted 4-5 
times. The sample was centrifuged at 12000 rpm in a Beckam jA rotor for 30 minutes at 
4 °C. QIAGEN-tip 500 was washed with 10ml of buffer QBT and the supernatant was 
allowed to enter the resin of the column by gravity flow. The column was washed twice 
with 30 ml of Buffer QC. The column was placed in new cylinders and 15 mL of buffer 
QF was applied to the resin. The DNA was precipitated by adding 10.5 mL room 
temperature isopropanol to the eluted DNA. It was centrifuged at 7000 rpm for an hour 
at 4° C. The pellet was washed with 70% ethanol and centrifuged for 20 minutes at 
7000 rpm. The pellet was left for 5-10 minutes to dry and then the DNA was redissolved 
in 200 µL of sterile water. 
 
 
2.5.3 Agarose gel electrophoresis. 
 
A 1% (w/v) agarose gel was prepared in TBE (Tris/Borate/EDTA) by boiling the solution 
in a microwave oven. The solution was cooled to 50°C and then ethidium bromide was 
added to a final concentration of 1 mg/mL. The agarose was poured into a gel tray with 
a gel comb and set at room temperature. One third of DNA loading buffer was added to 
each DNA sample and then 20 µL was loaded into the wells of the gel (submerged in 
TBE running buffer).  
A volume of 5 µL 1 kb ladder (Invitrogen) was used. Gels were run at 90-120 V in a 
horizontal gel tank at room temperature and then viewed under a UV transilluminator 
(Biorad) and photographed using a digital video. 
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2.5.4 Restriction digest of DNA. 
 
For screening of minipreps, 5 µL of eluted DNA was used. The COX-2 plasmid was 
cleaved with two endonucleases (EcoRI and NotI). EcoRI and NotI are active in EcoRI 
NEB buffer at the same temperature (37°C) and both are inactivated at 65°C. The 
concentration of the two enzymes was 20 units/mL each for EcoRI and NotI.  One unit 
is defined as the amount of enzyme required to digest 1µg of λ DNA (HindIII digest) in 1 
hour at 37°C in a total reaction volume of 50 µL. For a total volume of 30 µL a volume of 
1 µL of EcoRI and 1µL NotI were used. A color-coded 10X NEBuffer (New England 
Biolabs) was used to ensure optimal (100%) activity. Both of these restriction 
endonucleases require BSA at a final concentration of 100 µg/mL for optimal activity 
from a 10mg/mL (100X) stock. EcoRI NEB buffer (3 µL) and BSA 10x (3µL) were added 
to the samples. Digestions were performed for 1 hour at 37°C.  Analysis of fragments, 
generated by the digestion, was performed by agarose gel electrophoresis. 
 
 
2.5.5 Transfection of COX-2 in MDA-MB-231. 
 
MDA-MB-231 and COS cells were transfected with the COX-2 vector using 
Lipofectamine LTX (Invitrogen) and the protocol was provided by Invitrogen. 
Cells were plated the day prior to transfection in DMEM supplemented with 10% fetal 
bovine serum in either 6 well plates or T80s flasks. The day of transfection the medium 
was changed and the confluency was around 60-70%. For each well of cells to be 
transfected, 2.5 µg (18 µg for the T80) of DNA was diluted in 500 µL (3.750 mL for the 
T80) of Opti-MEM® I Reduced Serum Media without serum. PLUS Reagent was added 
to the same tube and it was incubated for 5 minutes at room temperature. The Plus 
reagent, according to the manufacturer’s instructions, improves the plasmid delivery 
and gives superior performance. Invitrogen does not explain the composition of the 
reagent. For each well of cells, 5 µL (37.5 µL for the T80 flask) of Lipofectamine LTX-
TM Reagent was added into the diluted OptiMEM-DNA-Plus Reagent solution. It was 
mixed gently and incubated for 30 minutes at room temperature to form DNA- 
Lipofectamine LTX-TM Reagent complexes. After 30 minutes incubation, the DNA-
Lipofectamine LTX-TM Reagent was added to the wells or flasks and mixed gently by 
rocking the plate back and forth. Complexes do not have to be removed following 
transfection, however, the medium was changed after 6 hours. The cells were 
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incubated at 37oC in a CO2 incubator for 48-72 hours post-transfection, before 
assaying for transgene expression.  
 
 
2.5.6 siRNA transfection protocol. 
 
MDA-MB-231 (1x 106) were seeded in six well plates 18 hours before treatment in 2 mL 
DMEM supplemented with FBS but without P/S (Pen/Strep). Cells at 60-80% 
confluency were incubated at 37°C in a CO2 incubator for 18-24 hours. For each 
transfection 6 µL of siRNA duplex (60 pmols siRNA) were diluted into 100 µL siRNA 
Transfection Medium Solution (Santa Cruz Biotechnology). siRNA Transfection reagent 
(Santa Cruz Biotechnology) (6 µL) were also diluted in 100 µL siRNA Transfection 
Medium Solution. No serum and antibiotics were added to the siRNA Transfection 
Medium. The siRNA duplex solution (Solution A) was directly added to the dilute 
Transfection Reagent (Solution B) using a pipette and the mixture was incubated for 30 
minutes at room temperature. The Control siRNAs (Santa Cruz Biotechnology) and 
other 2 controls siRNA from Dharmacon were used. After 30 minutes 800 µL of siRNA 
transfection medium was added to the mixture and 1mL of this reaction was added to 
each well of cells for 5 to 8 hours. 
The sequence of the three siRNA used are: 
1) siRNA COX-2 SC ( provided by Santa Cruz biotechnology) 
Sense: CUGCUCAACACCGGAAUUUTT; 
Antisense: AAAUUCCGGUGUUGAGCAGTT. 









In 2’ COX-2 siRNA mentioned in chapter 5, 1siRNA and 2siRNA were pooled.  
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2.6 ChIP Chromatin Immunoprecipitation. 
 
The EpiTect ChIP OneDay kit was used. Ten million cells were plated in T75 flasks and 
were left to grow overnight. One flask was treated with TPA and the other with the 
vehicle for 5 hours and then cells were treated with 10 mL of 1% Formaldehyde and 
incubated at 37o C for 10 minutes. Formaldehyde is used to cross-link the proteins to 
the DNA as illustrated in the figure below. Excessive cross-linking reduces antigen 
accessibility and sonication efficiency. The reaction of formaldehyde with proteins starts 
with the formation of methylol adducts on amino groups. The methylol adducts of 
primary amino groups are partially dehydrated, yielding labile Schiff-bases, which can 
form cross-links with several amino acid residues, e.g. with tyrosine (Metz et al. 2004). 
1.1 ml of Stop Buffer was added per plate for 5 minutes at room temperature. The stop 
buffer contains glycine that quenches the formaldehyde and terminates the cross-
linking reaction. 
  
                                           
Figure 2.1 Cross linking between protein and formaldehyde 
 
Cells were washed twice with PBS and 1.5 mL ice-cold cell harvesting buffer and 
collected to be sonicated. Cells were centrifuged at 800g for 10 minutes at 4o C, the 
supernatant was removed and the pellet was dissolved in IP Lysis Buffer and Protease 
Inhibitor Cocktail. The rest of the lysate was sonicated, centrifuged for 10 minutes at 4o 
C and the supernatant was stored at -80o C. Some of this supernatant was tested on a 
1.5% agarose gel to check the correct fragment size (between 100 and 600 bp). For 
each IP Fraction, 100 µL of this sheared ready Chromatin was dissolved in 900 µL IP 
Buffer A, containing protease inhibitor. Protein A beads (50µL) for each IP fraction were 
added and incubate for 50 minutes at 4oC. The beads removed by centrifugation at 
4000g for 1 minute at 4o C and the pre-Cleared Chromatin was transferred to a new 
tube. 10µL of the supernatant was stored in another eppendorf at 4o C (and used as 
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Input Fraction later when the elution buffer and proteinase K was added). The pre-
Cleared Chromatin was incubated with the appropriate antibody on rotator at 4oC 
overnight. Then, 60µl Protein A Beads were added to each IP and incubated at 4oC for 
1 hour. The solution was centrifuged at 4000xg for 1 min at 4oC and the supernatant 
discarded. The beads were washed in cold wash Buffers for three times for 4 minutes 
and each time the supernatant discarded after each centrifugation. Elution Buffer 
(30µL) and Proteinase K was added to each IP Fraction (including the Input Fraction) 
and they were incubated in a thermomixer at 500 rpm at 45oC for 30 minutes. DNA 
Extraction Beads (to remove the Proteinase K) were added to each IP Fraction 
incubated on thermomixer at 500rpm at 95o C for 10 minutes. Samples were then 
centrifuged at 14,000 g for 1 minute at room temperature. 200 µL of each supernatant 
was transferred to a new tube and 100 µL of elution Buffer was added to each sample. 
Column Binding Buffer was added to each 200 µL IP fraction sample, mixed and 
allowed to go through a DNA Spin Column. The column was washed, centrifuged and 
100 µL of elution Buffer was added to the center of the column in a new tube. The 
column was centrifuged at 11,000g for 1 minute at room temperature and the same 
step was repeated. So at the end a final volume of 200 µL of the purified ChIP DNA 
samples was stored at – 20o C.  
 
 
2.6.1 ChIP qPCR 
 
For each 25 µL PCR, 12.5 µL RT² qPCR Master Mix, 6.5 µL of ddH2O, 5 µL of either 
undiluted or diluted ChIP DNA template, 1 µL ChIP-qPCR Assay Primers (10 µM each).  
The protocol used was according to Qiagen EpiTect ChIP OneDay Handbook: 
• Denature     10 minutes at 95°C 
• Denature        15 sec at 95°C 
                                                                           40 cycle                                                               
• Anneal  and extend           1 min   at 60°C     
• Final extension        1 minutes at 95°C 
                                        30 seconds at 55°C 
                                        30 seconds  at 95°C 
 
 
The primers used were designed very close to the transcription start site and the 
sequence for ST3Gal-I was forward GCCCACTATGCCAGACAGTT and reverse 
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2.7 Statistical analysis. 
 
Statistical analysis was carried out using the t test calculator of Graphpad software. A 
value of p < 0.05 was considered significant. For the correlation of ST3Gal-I and COX-2 
expression in primary breast cancers, Spearson and Person’s T test was applied. The 
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Appendix 
The following appendix explains the equation used for the calculation of the amount of 
target in RT-qPCR. It was taken entirely from User Bulletin #2 ABI PRISM 7700 




User Bulletin #2: ABI PRISM 7700 Sequence Detection System Page 11 of 36
Comparative CT Method (Separate Tubes)
Similar to Standard
Curve Method
The comparative CT method is similar to the standard curve method, except it uses 
arithmetic formulas to achieve the same result for relative quantitation. 
Note It is possible to eliminate the use of standard curves for relative quantitation as long as 
a validation experiment is performed. See “Validation Experiment” on page 14.
Arithmetic Formulas The amount of target, normalized to an endogenous reference and relative to a 
calibrator, is given by:
2 –∆∆CT
Derivation of the Formula
The equation that describes the exponential amplification of PCR is:
where:
The threshold cycle (CT) indicates the fractional cycle number at which the amount of 
amplified target reaches a fixed threshold. Thus,
where: 
Xn = number of target molecules at cycle n
Xo = initial number of target molecules
EX = efficiency of target amplification
n = number of cycles
XT = threshold number of target molecules
CT,X = threshold cycle for target amplification
KX = constant
Xn Xo 1( EX )+× n=
XT Xo 1( EX )+× CT X, KX==
Page 12 of 36 User Bulletin #2: ABI PRISM 7700 Sequence Detection System
A similar equation for the endogenous reference reaction is:
where:  
Dividing XT by RT gives the following expression:
The exact values of XT and RT depend on a number of factors, including:
! Reporter dye used in the probe
! Sequence context effects on the fluorescence properties of the probe
! Efficiency of probe cleavage
! Purity of the probe
! Setting of the fluorescence threshold. 
Therefore, the constant K does not have to be equal to one.
Assuming efficiencies of the target and the reference are the same:
EX = ER = E,
or
where:
RT = threshold number of reference molecules
Ro = initial number of reference molecules
ER = efficiency of reference amplification
CT, R = threshold cycle for reference amplification
KR = constant
XN = Xo/Ro, the normalized amount of target
∆CT = CT,X - CT,R, the difference in threshold cycles for target and reference
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User Bulletin #2: ABI PRISM 7700 Sequence Detection System Page 13 of 36
Rearranging gives the following expression:
The final step is to divide the XN for any sample q by the XN for the calibrator (cb):
where:
For amplicons designed and optimized according to Applied Biosystems guidelines 
(amplicon size < 150 bp), the efficiency is close to one. Therefore, the amount of 





For the ∆∆CT calculation to be valid, the efficiency of the target amplification and the 
efficiency of the reference amplification must be approximately equal. A sensitive 
method for assessing if two amplicons have the same efficiency is to look at how ∆CT 
varies with template dilution. The standard curves for c-myc and GAPDH used in the 
previous section provide the necessary data. Table 2 shows the average CT value for 
c-myc and GAPDH at different input amounts.
Figure 6 on page 14 shows a plot of log input amount versus ∆CT. If the efficiencies of 
the two amplicons are approximately equal, the plot of log input amount versus ∆CT 
has a slope of approximately zero. 
∆∆CT = ∆CT,q – ∆CT,cb






K 1( E ) CT q,∆–+×
K 1( E ) CT cb,∆–+×
------------------------------------------- 1(= E ) CT∆∆–+= =









1.0 25.59±0.04 22.64±0.03 2.95±0.05
0.5 26.77±0.09 23.73±0.05 3.04±0.10
0.2 28.14±0.05 25.12±0.10 3.02±0.11
0.1 29.18±0.13 26.16±0.02 3.01±0.13
0.05 30.14±0.03 27.17±0.06 2.97±0.07
0.02 31.44±0.16 28.62±0.10 2.82±0.19
0.01 32.42±0.12 29.45±0.08 2.97±0.14
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Chapter 3. Breast cancer cell lines: Characterization for the 





Julien et al. (2007) showed that prostaglandin E2 (PGE2) influences the expression of 
the glycosyltransferases C2GnT1 and ST3Gal-I in dendritic cells (DCs). In order to 
investigate if PGE2 has any effect on glycosyltransferases in breast cancer, a panel of 
breast cancer cell lines available in the laboratory (MCF-7, T47D, SK-Br-3, BT-20, 
MDA-MB-231, ZR-75-1) were first characterized for COX-2 expression, prostaglandin 
receptors (EP) expression and PGE2 secretion. These cell lines show a range of 





1. Define the mucin O-glycosylation core types found in six breast cancer cell lines. 
2. Determine COX-2 expression by the six breast cancer cell lines by RT-qPCR.  
3. Measure the PGE2 concentration in the media of the six breast cancer cell lines 
by ELISA. 
4. Determine the EP1-4 expression at the mRNA and protein level by the six 
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3.3 Results 
 
3.3.1 Profile of mucin O-glycosylation core types on the six breast 
cancer cell lines.  
 
Initially the cell lines MCF7, T47D, MDA-MB-231, SK-BR-3, BT-20, ZR-75-1 were 
analyzed for their binding to the MUC1 specific monoclonal antibodies HMFG1, HMFG2 
and SM3 to obtain an indication of their Core 1 and Core 2 expression. As discussed in 
section 1.7, SM3 reacts with an epitope on MUC1, which is masked by the Core 2 
glycans on normal breast epithelium (Burchell et al. 1989; Girling et al 1989). HMFG1 
reacts well with MUC1 on normal cells but the presence of sialic acid can decrease its 
binding to its epitope, whereas the binding of HMFG2 is inhibited by longer 
carbohydrate side chain on normal mucins (Burchell et al.1993). Table 3.1 shows the 
presence of core1 and core2 structures as determined by mass spectrometry of the six 
















Table 3.1: Expression of core 1 and core 2 in the six breast cancer cell lines analyzed. 
Cells (3x105) were stained with SM3, HMFG1 and HMFG2, followed by FITC-conjugated 
polyclonal rabbit anti-mouse IgG. As can be seen from figure 3.1, breast cancer cell lines react 
differently with the three antibodies in line with their core 1/core 2 expression. 
 
 
All the lines reacted with SM3, but, as expected, T47D and BT-20 had the highest level 
of binding and MDA-MB-231 the lowest (Müller et al. 2002). MDA-MB-231 has in fact 
the lowest level of MUC1 among the cell lines analyzed, and this was confirmed by the 
low reactivity with HMFG1 and HMFG2. HMFG1 binding is greater on MCF7 and ZR-
75-1 cell lines and this reflects the fact that they express a higher level of core 2 than 
the others. In contrast, BT-20, SK-BR-3 and T47D react more strongly with HMFG2.  
 
 core1 core2 SM3 HMFG1 HMFG2 
MCF7 ++ ++ + ++ ++ 
T47D +++ - ++ + +++ 
MDA-MB-231                               
(very low MUC1 expressed) + + +/- +/- +/- 
SK-BR-3 ++ - ++ + +++ 
BT-20 ++ - ++ + +++ 
ZR-75-1 + + + +++ ++ 














Figure 3.1: Flow cytometric analysis of the core 1 and core 2 MUC1 glycoforms on the six 
breast cancer cell lines. Cells were stained using the SM3, HMFG1 and HMFG2 monoclonal 
antibodies, followed by FITC-conjugated polyclonal rabbit anti-mouse IgG. The shaded peak is 
the isotope control, the black, green, purple open peaks are, respectively, the SM3, HMFG1, 
and HMFG2 antibody staining.  
 
 
3.3.2 COX-2 expression by the six breast cancer cell lines.  
 
The level of expression of COX-2 in MCF7, T47D, SK-BR-3, MDA-MB-231, BT-20, ZR-
75-1 cell lines was analyzed by RT-qPCR. Two biological experiments were performed 
using the same conditions. Initially 4x105 cells of each cell line were cultured and the 








Figure 3.2: Quality control of RNA. a) An aliquot of 5 µL of RNA was run on 1% agarose gel. 
The ladder used is a 1 kb ladder (New England Biolabs). b) The Nanodrop measurements of the 
optical density ratio for two biological experiments are shown in the table. The values for each 
cell line are about two.  
 
 
The quality of the RNA extracted was checked by running an aliquot on an agarose gel, 
stained with ethidium bromide, and by measuring the optical density to obtain the 
260/280 ratio of each sample, as described in material and methods (section 2.3.3). 

















In order to select two or more cell lines to study PGE2 regulation of GTs, it is necessary to establish 
the expression of COX-2, receptors and production of endogenous PGE2. 
 
Profile of mucin-core protein on the six breast cancer cell lines. 
 
 
A panel of 6 epithelial breast cancer cell lines available in the lab were analyzed and characterized. 
Initially the cell lines, MCF7, T47D, MDA-MB-231, SK-BR-3, BT-20, ZR-75-1 were analyzed for 
their binding to the MUC1 specific monoclonal antibodies HMFG1, HMFG2 and SM3  to obtain an 




were stained with SM3, HMFG1 and 
HMFG2, followed by FITC- conjugated polyclonal rabbit anti-mouse IgG (Dako). 
As can be seen from figure 5 breast cancer cell lines react differently with the three antibodies in line 






















were stained using the SM3, HMFG1 and HMFG2 monoclonal antibodies followed by FITC- 
conjugated polyclonal rabbit anti-mouse IgG (Dako).The shaded peak is stained with the control antibody, the 
black, green, purple open peaks are respectively  the SM3, HMFG1, and HMFG2  antibody staining. 
 
All the lines reacted with SM3 but as expected T47D and BT-20 had the highest level of binding and 
MDA-MB-231 the lowest. MDA-MB-231 has in fact the lowest level of MUC1 among the cell lines 


































OD260/280 Cell lines 
I experiment II experiment III experiment 
MCF7 2.16 2.12 2.15 
T47D 2.12 2.19 2.16 
MDA-MB-
231 
2.15 2.18 2.16 
SK-Br3 2.15 2.2 2.12 
BT20 2.16 2.15 2.13 
ZR75-1 2.16 2.18 - 
b)#a)# b)#
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The agarose gel showed two bands for each cell line (figure 3.2 a), confirming that in all 
the samples the RNA was of good quality. This was confirmed by the ratio OD260/OD280 
of the RNA from the two biological experiments used in this experiment (table b figure 
3.2). (In the results of the other chapters the quality of RNA will not be shown, even 
though it was always analyzed).  1 µg per reaction of mRNA was used for the reverse 
transcription and the cDNA was then used for the qPCR.  
SYBR® Green, a fluorescent dye, that binds to the minor groove of the DNA double 
helix (as described in appendix of materials and methods), was used in quantitative RT-
qPCR and in these experiments the results were normalized to β-actin, a reference 
gene that does not vary in different cell lines. Figures 3.3 and 3.4 show the melting 














Figure 3.3: Melting curves analysis for all the cell lines cDNA with β-actin primers. 
The qRT-PCR reaction was performed with SYBR® Green, as described in materials and 
methods(section 2.3.5). Melting curve analysis was performed, after amplification, using a 































Figure 3.4: Melting curves analysis for all the cell lines cDNA with COX-2 primers. The RT-
qPCR reaction as described in figure 3.3. 
 
 
The relative amount of expression was performed by the “comparative CT method”, 
given by the mathematical expression 2-∆CT (see appendix of materials and methods). 
The values shown in figure 3.5 are the mean of 2-∆Ct of two biological experiments. 
MDA-MB-231 showed the highest level of COX-2 followed by SK-BR-3, BT-20 and ZR-
75-1; MCF7 and T47D the lowest level. This result agrees with published data showing 




              
Figure 3.5: MDA-MB-231 cell line 
expresses the highest level of COX-
2 mRNA. The dots represent the 
mean±SD of the 2-∆Ct of two 
biological experiments comparing 
COX-2  (the target gene) to β−actin 
(the reference gene) for six breast 
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3.3.3 Secretion of PGE2 by the breast cancer cell lines.  
 
The level of PGE2 was determined by ELISA (see materials and methods, section 
2.4.9). Two million cells, for each cell line, were cultured for 24 hours and the 
supernatant tested. The concentration of PGE2 in the medium, shown in table 3.6 
below, was calculated from the equation of the standard curve. Since it is a competitive 
ELISA, there is an inverse relationship between the signal obtained and the 




Table 3.6: Table of the concentrations of PGE2 found in the supernatant of the six breast 
cancer cell lines after 24 h of culture.  
PGE2 concentration was calculated from the equation of the ELISA assay. MDA-MB-231 and 
BT-20 are the only cell lines that have a greater PGE2 concentration than the negative control 














This assay demonstrated that only MDA-MB-231 and BT-20 supernatant showed a 
concentration of PGE2 higher than the negative control used, while the PGE2 
concentration of most of the cell lines was below the negative control value and 
therefore considered as zero. 
 
 
3.3.4 PGE2 receptor expression in breast cancer cells.  
 
PGE2 action is mediated via four receptors (EP1, EP2, EP3, EP4) with different signalling 
pathways. EP1 is mainly a Gq coupled receptor with phospholipase C signalling through 
 Mean OD  Concentration (pg/ml) 
Negative control  1.123 29.09±4.66 
MDA-MB-231 1.055 41.68±5.25 
BT20 1.044 44.26±4.63 
ZR75-1 1.169 22.65±4.25 
MCF7 1.179 21.54±3.92 
SK-Br-3 1.158 24.05±3.87 
T47D 1.25 14.88±4.41 
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Ca2+ and EP2 and EP4 are Gs coupled receptors to protein kinase A (PKA). On the other 
hand EP3 is mainly a coupled Gi protein and is linked to a decrease of cAMP (discussed 
in section 1.9.4) (Narumiya et al.1999). The expression of the EP receptors was 
determined at the protein level by FACS and Western Blotting. 
Rabbit polyclonal antibodies raised against the EP receptors antibodies, followed by 
FITC-conjugated goat anti-rabbit IgG were used for the flow cytometric analysis. The 
antibodies were against a synthetic peptide from the C-terminal intramembrane domain 
of the EP receptors, so the cells had to be permeabilized before staining. Results are 
shown in figure 3.7. To confirm the success of the intracellular staining, a positive 
control (a Rabbit monoclonal antibody to the cytoplasmic domain of EpCam-C-term) 


















Figure 3.7: Flow cytometric analysis of EP receptors in the six breast cancer cell line.  
Cells (4*105) were fixed, permeabilized by PBS/BSA/saponin/NaN3 and stained with EP 
Receptor Polyclonal Antibody (Cayman Chemicals) followed by FITC-conjugated goat anti-rabbit 
IgG (Dako) as described in Materials and Methods. Shaded peak, staining with control antibody, 
open clear peak, EP staining. a, b, c, d, e, f are MCF7, T47D, MDA-MB-231, SK-Br-3, BT-20, 
ZR-75-1 respectively.  
 
 
From figure 3.7 it is evident that the positive mean fluorescence to each EP receptor 
was more or less the same in each cell line, which raised some concerns. Therefore, in 
order to check the specificity of the antibodies to each receptor, Western Blot analysis 
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Figure 3.8: Westen Blots to determine EP2 and EP4 expression. 410.4, ZR-75-1, BT-20, SK-
Br-3, MDA-MB-231, T47D, MCF7 protein lysate (10 µg) were immunoblotted with Rabbit 
polyclonal antibodies (Cayman Chemicals) to EP2 (a) and EP4 (b) receptors followed by HRP-
conjugated swine anti-rabbit IgG (Dako). Both blots were stripped and reprobed with Mouse 
Anti- β−actin, followed by HRP-goat antimouse IgG (Dako), as loading control. Membranes were 
developed with the ECL system (Amersham), according to the manufacturer’s instructions. 
 
 
Cells were cultured in T80 flasks and after each cell line reached 80% of confluency, 
pellets were collected. Cell disruption was conducted as described in the materials and 
methods. Protein concentration was measured by BCA-protein assay and 10 ⎧g of 
protein of each sample was loaded onto a 7.5% SDS-PAGE gel. The murine mammary 
cell line, 410.4 was used as positive control for the EP receptors (Ma et al. 2006). In 
figure 3.8, it is evident that very little expression of EP2 is seen in MCF7 and MDA-MB-
231. In contrast the expression of EP4 is expressed by all the cell lines with an increase 
of expression in MDA-MB-231 and MCF7. Western Blots with EP receptor antibodies 
showed optimum and clear results for EP2 and EP4, which did not agree with the flow 
cytometric analysis, confirming the concerns about this assay. A repeat of a Western 
blot with different protein lysate gave identical results.  
For EP1 and EP3, an additional control of mouse kidney lysate was used together with 
410.4. The EP1 and EP3 antibodies did not appear to be specific as a number of bands 
of varying migration were observed. As shown in figure 3.9, there was no band of the 
expected size of EP1 receptor (42 kDa) in the cell lines. BT-20 and MCF7 lysates 
showed a band of about 30 kDa that came up in three different experiments. This band 
could be a breakdown product or a cross-reacting band. 
EP3 has a predicted molecular weight of 53 kDa. Figure 3.9b shows a common band of 
53 kDa in all the cell lines (apart from the mouse kidney control), but together with this 
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band there are many other unspecific bands. This lack of specificity of the antibodies 











Figure 3.9: Westen Blots to determine EP1 and EP3 expression.  
Mouse kidney, 410.4, ZR-75-1, BT-20, SK-Br-3, MDA-MB-231, T47D, MCF7 protein lysate (10 
µg) were immunoblotted with Rabbit polyclonal antibodies (Cayman Chemicals) to EP1(a) and 
EP3(b) receptors followed by HRP-conjugated swine anti-rabbit IgG (Dako). Both blots were 
stripped and reprobed with Mouse Anti-β−actin followed by HRP-goat antimouse IgG (Dako) and 
were used as loading control. Membrane were developed with the ECL system (Amersham) 
according to the manufacturer’s instructions.  
 
 
In conclusion all the breast cancer cell lines examined (MCF-7, BT20, MDA-MB-231, 
ZR-75-1, SK-Br-3, T47D) express the EP2 and EP4 receptors, but at different levels. 
However, no clear conclusion can be drawn on the expression of the EP1 and EP3 
receptor as non-specific binding of the antibodies were observed on the Western blots.	  
siRNA for EP1 and EP2 can be used to validate EP antibodies. Moreover, the presence 
of EP1 and EP3 proteins can be confirmed by mass spectrometry of some lysate from 
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3.4 Discussion. 
 
The glycosylation changes that occur during maturation of dendritic cells are similar to 
the changes in glycosylation observed in malignant breast epithelium. In dendritic cells 
at maturation, C2GnT1 is rapidly down regulated and the sialyltransferases ST3Gal-I is 
upregulated, resulting in the change from core 2 based glycans to sialylated core 1 
glycans. In our lab it has been demonstrated that prostaglandin E2 alone can induce 
the upregulation of ST3Gal-I and the downregulation of C2GnT1 in dendritic cells 
(Julien et al. 2007). Preliminary data showed the possible implication of the prostanoid 
receptors EP2 and EP4 in this process.  
To study how PGE2 regulates the expression of the glycosyltransferases (GT), C2GnT1 
and ST3Gal-I, in breast cancer, it was important to characterize the breast cancer cell 
lines available in the lab and investigate the expression of COX-2, PGE2 receptors and 
production of endogenous PGE2 by these lines. The six breast cancer cell lines have a 
different O-glycosylation profile: MCF7, ZR-75-1 have core 2 and core 1 based glycans, 
while T47D, BT-20 and SK-Br-3 only express core 1 (Müller et al. 2002). The O-
glycosylation pattern was confirmed by RT-q-PCR which showed a very low or lack of 
expression of C2GnT1 in BT-20, SK-Br-3 and T47D (data not shown).  
The expression of COX-2 detected by qPCR, is relatively low in all the cell lines with the 
highest expression being by the ER negative breast cancer cell line, MDA-MB-231. This 
is in agreement with Half et al., who showed that the COX-2 levels in SK-BR-3, MCF7, 
MDA-MB-231 is very low in comparison to a colon-cancer cell line like HCF-7; however 
they also showed that MDA-MB-231 expresses the highest amount of COX-2 compared 
to the other two breast cancer cell lines (Half et al. 2002). Moreover, Liu et al. published 
data showing that MDA-MB-231 expressed high levels of COX-2 compared to MCF7 
(Liu et al. 1996). Although MDA-MB-231 has the highest expression of COX-2 among 
the breast cancer cell lines studied, the level of the metabolite PGE2 secreted is low, as 
detected by the ELISA assay.  
Previous studies described dramatic differences in PGE2 production between cell lines 
and primary tumours from specific tissues, including those derived from human lung 
and colon tumours (Hubbard et al. 1988). Schrey and Patel showed how MCF7, T47D, 
BT-20, ZR-75-1 do not secrete PGE2 in the media, even when stimulated with the 
phorbol ester TPA or IL-1β, while MDA-MB-231 and other invasive breast cancer cell 
lines demonstrated a large increase of the metabolite in response to the two stimulating 
agents (Schrey & Patel, 1995). In the present study MDA-MB-231 and BT-20 are the 
only cell lines, among the panel of breast cancer cell lines considered, that showed any 
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secretion of PGE2. However, a concentration of about 40 pg/ml is very low, as the 
background detected in the medium was 29.09 pg/ml.  
There are various parameters to be considered for the PGE2 production. First of all, the 
half-life of PGE2 in the circulatory system is approximately 30 seconds and rapid 
metabolic inactivation of any PGE2, formed by the cancer cells, may also limit its 
detection (Fitzpatrick et al. 1980). The enzyme responsible for the metabolic 
inactivation of prostaglandins is 15-hydroxyprostaglandin dehydrogenase. According to 
Wolf et al. low levels of this enzyme were detected in MDA-MB-231 cells but high levels 
in MCF7 (Wolf et al. 2006).  
The absence of detectable accumulation of PGE2 in the cell culture medium does not 
necessarily mean that there is no PGE2 produced by the COX-2 enzyme. PGE2 could 
be bound to the four prostanoid receptors and trigger a downstream response. For this 
reason, the expression of all four EP isoforms was characterized in the six breast 
cancer cell lines. However, the western blots for EP1 and EP3 were unclear, as many 
non-specific bands were present. Different lysates were used, but they did not improve 
the blots. Therefore, no conclusion can be made on these two prostanoid receptors. In 
contrast, EP2 and EP4 receptors blots are very clear (Figure 3.8). The EP2 receptor is 
weakly expressed by MCF7 and MDA-MB-231, while it is expressed in the other cell 
lines and prevalently in ZR-75-1. The EP4 receptor is present in all the cell lines and 
has the highest intensity in MCF7 cell line.  
In the literature, it is evident that EP receptors play different roles during breast cancer 
progression and that EP2 and EP4 are the receptors likely to be involved in the 
regulation of mammary tumor progression and angiogenesis (Subbaramaiah et al. 
2008; Chang et al. 2004). Importantly, these are the receptors that we have established 
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The previous chapter described the characterization of six breast cancer cell lines 
(MCF-7, T47D, SK-Br-3, BT-20, MDA-MB-231, ZR-75-1) for their COX-2 expression, 
PGE2 secretion and EP receptors expression. The MDA-MB-231 cell line expressed 
the highest level of COX-2. Moreover, it was found that only media from the BT-20 and 
MDA-MB-231 cell lines contained PGE2 and this was at a very low concentration. 
Protein expression of the receptors was examined by Western blot analysis and all the 
breast cancer cell lines expressed EP2, EP4 receptors but by different degrees. No 
conclusion could be drawn for EP1 and EP3.  
Julien et al. had previously shown that stimulation of dendritic cells with PGE2 could 
change the expression of glycosyltransferases expressed by monocyte derived 
dendritic cells: C2GnT1 was rapidly down regulated and the ST3Gal-I upregulated 
(Julien et al. 2007). Although the breast cancer cell lines expressed EP receptors, the 
expression of COX-2 and PGE2 was low or below the level of detection. Therefore, to 
be able to investigate the influence of the COX-2 pathway on the expression of 
glycosyltransferases ST3Gal-I and C2GnT1 in breast cancer, exogenous PGE2 and 
TPA (inducer of COX-2 expression) were added to the breast cancer cell lines. The 
expression of the two enzymes and their product were determined by RT-qPCR and 





1. Treat six breast cancer cell lines with PGE2 and determine the change in 
glycosyltransferase expression. 
2. Determine eventual modification of PNA staining in cell lines that showed a change 
in expression of ST3Gal-I and/or C2GnT1 after PGE2 treatment.  
3. Treat six breast cancer cell line with TPA and determine change in 
glycosyltransferase expression. 
4. In the cell line that showed change of expression of a glycosyltransferase, measure 
by FACS the modification of PNA staining after TPA treatment. 
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4.3 Results. 
 
4.3.1 Choice of a gene for normalization of real-time RT-PCR data for 
the breast cancer cell lines. 
 
The fluorescent quantitative Real Time PCR (RT-qPCR) has become a very popular 
technique to quantify gene expression in basic and translational biomedical research 
(Bustin et al. 2009; Bustin et al. 2000). 
One of the disadvantages of this technique is the possible variation in the amount of 
starting material among samples, so it is necessary to normalize the gene expression to 
an internal reference (Wong & Medrano, 2005). It is important to choose reference 
genes that do not vary with the possible treatment. The most common housekeeping 
genes used are GAPDH or β-actin. GAPDH (Glyceraldehyde 3-phosphate 
dehydrogenase) is an enzyme that catalyzes the sixth step of glycolysis, while β-actin is 
a cytoskeleton protein involved in the motility and integrity of the cell and it is 
ubiquitously expressed in most cell types (Bustin et al. 2000). It was observed that 
GAPDH levels of expression vary in different developmental stages (Puissant et al. 
1994), during the cell cycle and with different treatments (TPA, dexamethasone, carbon 
tetrachloride etc.) (Bustin et al. 2000). On the other hand, β-actin levels of transcription 
can vary widely in human breast epithelial cells (Spanakis et al. 1993). 
Lyng et al. in their study established which reference gene could be more reliable for 
qPCR of breast cancer (ER positive and negative), normal breast and breast cancer cell 
lines data. The reference genes investigated were RPLP0, TBP, PUM1, ACTB, GUS-B, 
ABL1, GAPDH and B2M. The authors idendified PUM1 (homolog of Pumilio, 
Drosophila) as the best reference gene for all sample combinations (Lyng et al. 2008). 
Therefore, in this work, PUM1 was used as a reference for all experiments. For each 
experiment, it was confirmed that the Cts of the reference gene was the same before 
and after treatment. 
 
 
4.3.2 Prostaglandin E2 (PGE2) enhances ST3Gal-I expression and its 
product α2,3 sialyl-Core1 in T47D cell line. 
 
Most of the RT-qPCR results reported in this thesis will be plotted as fold-change. The 
fold change in mRNA expression is defined as the difference of the mean log treatment 
data and the mean log control and both values are normalized against the log value of 
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the house keeping gene for each sample (ΔΔCts). The values are then represented as 
2-ΔΔCts (see appendix of materials and methods).  
The breast cancer cell lines, MCF-7, T47D, MDA-MB-231, SK-BR-3, BT-20 and ZR-75-
1, were treated with PGE2 (0.1 µM) for 4 hours. Figure 4.1 shows the fold change of 
ST3Gal-I and C2GnT1 to PUM1 in two ER positive, MCF-7 and ZR75-1 and in one ER 
negative breast cancer cell line, MDA-MB-231. After treatment with PGE2, there was no 
significant change in the expression of ST3Gal-I and C2GnT1 in any of these cell lines 
(figure 4.1) and SK-Br-3 and BT-20 also showed no change in expression of the two 
























Figure 4.1: Exogenous PGE2 does not affect ST3Gal-I and C2GnT1 in MCF-7, ZR-75-1 and 
MDA-MB-231.Cells were treated for 4 hours in presence of 0.1 µM PGE2 or the vehicle 
(ethanol). RNA was extracted and the expression of ST3Gal-I and C2GnT1 determined by RT-
qPCR. The histograms show the average±SD of two independent experiments. n.s. =not 
statistically significant.  
 
Pan et al. showed that CCR7 has high RNA and protein expression in MDA-MB-231 
cells (COX-2 expressing breast cancer cell line), while it was low in MCF-7 cells that 
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express low levels of COX-2. When MCF-7 were treated with PGE2 (0.1 µM for 24 
hours), it was found that PGE2 increased CCR7 mRNA and protein expression (Pan et 
al. 2008). This positive control was used in the cell lines investigated, but no change in 
the expression of CCR7 was seen (data not shown).  
However, when the ER positive cell line T47D was treated with PGE2, a consistent and 
statistically significant increase in ST3Gal-I expression was observed as shown in figure 















Figure 4.2: PGE2 increases ST3Gal-I expression in T47D. Cells were starved for 2 hours in 
serum free medium and treated for 4 hours in presence of 0.1 uM PGE2 or the vehicle (ethanol). 
RNA was extracted and the expression of ST3Gal-I determined by RT-qPCR. The histogram 
shows the average ± SD of three independent experiments. **p<0.01. 
 
 
The time course of the induction of ST3Gal-I by PGE2 was investigated over 24 hours, 
by RT-qPCR. Figure 4.3 shows that the level of expression of ST3Gal-I increases by 
nearly 4 fold compared to the control between 2 and 4 hours (120 and 240 minutes) of 
PGE2 treatment. After 8 hours the level started to drop until it returned to the baseline 

























Figure 4.3: Time course of the induction of ST3Gal-I mRNA in T47D treated with PGE2. 
The cell line T47D was starved for 2 hours in serum free medium and treated for ½, 2, 4, 8, 24 
hours with 0.1 mM PGE2 or vehicle (ethanol). RNA was extracted and the expression of 
ST3Gal-I determined by RT-qPCR. Red line: T47D cells treated with PGE2; Blue line: T47D 
treated with the vehicle. 
 
 
It is not possible to quantify the change in protein expression of ST3Gal-I since there 
are no antibodies available to ST3Gal-I that work on Western blots. However, it is 
possible to quantify the change of the product of ST3Gal-I, sialylated Core1. Peanut 
agglutinin (PNA) is a lectin that binds to core 1 and it is inhibited by sialic acids linked in 
the α2,3 position to galactose. Because of the specificity of PNA, this lectin was chosen 
to determine ST3Gal-I activity. If the level of expression of ST3Gal-I increases, the 
sialyl-core 1 will increase and the PNA staining, therefore, will decrease (PNA is 
inhibited by sialyl-core 1). T47D cells were treated with PGE2 for 92 hours to allow turn-
over of surface proteins, and cells were analysed for PNA staining by flow cytometry 
(FACS). 
          
                                                    
Figure 4.4: Treatment with exogenous PGE2 of 
T47D increases sialylated core1, demonstrated 
by a decrease in PNA staining.  
T47D cells were treated for 92 hours with or without 
PGE2. The filled grey peak and blue line are the 
control for respectively PGE2 treated and untreated 
T47D (FITC streptavadin (BD Pharmingen). Green 
and and red lines are PNA stained T47D treated 
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The red line (PGE2 treated cells) of figure 4.4 is shifted to the left compared to the 
green line (untreated cells), so when the T47D cell line is treated with PGE2, PNA 
binding decreases, suggesting the presence of increased sialylation of core1, the 
product of ST3Gal-I. Taken together, these results show that in the breast cancer cell 




4.3.3 TPA enhances ST3Gal-I expression and its product α2,3 sialyl-
Core1 in MDA-MB-231 cell line. 
 
COX-2 is reported to be one of the early-response genes induced by the tumour 
promoter 12-O-tetradecanoylphorbol-13-acetate (TPA). The aim of this experiment was 
to see if inducing COX-2 over-expression could change the expression of ST3Gal-I and 
C2GnT1. The six breast cancer cell lines were treated with TPA (10 nM) for 18 hours 
following 4 hours of starvation according to Schrey et al. (1995).  
The expression of mRNA for COX-2 was measured in MCF-7 and T47D. Figure 4.5 
illustrates the average of three biological experiments. The expression of COX-2 after 
TPA treatment in MCF-7 and T47D did not change significantly, compared to the control 
(cells treated with the vehicle). COX-2 mRNA expression did not change in ZR-75-1, 
BT-20 and SK-Br-3 (data not shown). 
                                  
Figure 4.5: TPA treatment does not affect COX-2 levels in T47D and MCF-7. Cells were 
starved for 4 hours in serum free medium and treated for 18 hours with 10 nM TPA or the 
vehicle (ethanol). RNA was extracted and the expression of COX-2, determined by RT-qPCR.  
Each histogram shows the average±SD of three independent experiments for each cell line. 
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However, treatment of MDA-MB-231 with TPA gave a consistent and proportional 
increase (depending on the concentration) in the expression of COX-2 (Figure 4.6). 
Moreover ST3Gal-I mRNA increased and C2GnT1 decreased after TPA treatment 




   Figure 4.6: TPA induces COX-2 mRNA 
expression in MDA-MB-231. MDA-MB-231 
cells were treated as described in figure 4.5 
with 2 concentrations of TPA. RNA was 
extracted and the expression of COX-2 was 
determined by RT-qPCR. Data represent the 
average of three independent experiments.   










Figure 4.7: TPA induces ST3Gal-I and decreases C2GnT1 mRNA expression in MDA-MB-
231. MDA-MB-231 cells were treated as described in figure 4.5 with 2 concentrations of TPA. 
RNA was extracted and the expression of ST3Gal-I and C2GnT1 was determined by RT-qPCR. 
Data represent the average of three independent experiments. * p<0.05, **p<0.01, *** p< 0.001. 
 
 
TPA 10nM and 10µM could increase the basal level of COX-2 in MDA-MB-231 by up to 
7 fold and 42 fold respectively. At the same time 10nM and 10µM could increase 
ST3Gal-I by 4 and 8 fold and decrease C2GnT1 by 1.5 and 2 fold.  
A time course experiment was then carried out. 10 µM TPA was initially used and the 
expression of ST3Gal-I and COX-2 mRNA was determined at the times indicated in 
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Figure 4.8: TPA (10 µM) induces the expression of COX-2 and ST3Gal-I in MDA-MB-231 
cells in a range of 24 hours. MDA-MB-231 cells were starved for 4 hours and incubated with 
vehicle or 10 nM of TPA for the times indicated. RNA was extracted and the expression of COX-
2, ST3Gal-I and C2GnT1 was determined by RT-qPCR. The black and the grey lines represent 
TPA and vehicle treated cells respectively. 
 
However, incubating the cells with 10 µM TPA for 24 hours did induce some toxicity, as 
observed by Forsyth et al. (1968). Cells were detached from the flask and started to die 
already after 18 hours. In figure 4.8, it seems that the amount of vehicle affects the cells 
so much as to vary the control level of C2GnT1 after 18 hours. This effect can be 
attributed either to TPA or to the amount of vehicle used (60 µl of ethanol in 10 ml of 
medium). 
Therefore, the time course was repeated using 10 nM TPA. As can be seen from figure 
4.9, COX-2 mRNA expression started to rise between 50-100 minutes and kept on 
increasing till 5 hours, when the experiment was stopped. In contrast, ST3Gal-I mRNA 
did not start increasing until after 2 hours. This delay in ST3Gal-I expression relative to 
COX-2 is in agreement with the induction of ST3Gal-I being indirect through COX-2. 
 
Figure 4.9: Time course of TPA (10 nM) induction of COX-2 and ST3Gal-I expression in 
MDA-MB-231 treated cells. MDA-MB-231 cells were starved for 4 hours and incubated with 
vehicle or 10 nM of TPA for the times indicated. RNA was extracted and the expression of COX-
2, ST3Gal-I determined by RT-qPCR. The black and the grey lines represent TPA and vehicle 
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Looking at the time course in figure 4.9, MDA-MB-231, treated with 10 nM of TPA, 
expresses high levels of ST3Gal-I and COX-2 after 5 hours of treatment. Figure 4.10 
represents the mean of four independent experiments of MDA-MB-231, treated for 5 
hours with 10 nM TPA. The results show that, after 5 hours of treatment, ST3Gal-I and 
COX-2 expression increases nearly of 4 and 85 fold respectively. 
The protein level of expression after TPA treatment was evaluated by western blot. 
Unfortunately we couldn’t see any bands on the western blots using different antibodies 
(see section 5.3.3 A for western blot results). 
 
 
Figure 4.10: ST3Gal-I and COX-2 expression increase by 4 and 85 fold after 10 nM TPA 
treatement for 5 hours. MDA-MB-231 cells were starved for 4 hours and then treated for 5 
hours with 10 nM TPA. RNA was extracted and the expression of COX-2 and ST3Gal-I 
















Figure 4.11: A) TPA increases the ST3Gal-I product, sialyl-core1. MDA-MB-231 cells were 
treated for 72 hours with and without TPA. The solid grey peak and blue line are the control 
for respectively TPA treated and untreated MDA-MB-231 (FITC streptavadin Ab). Light green 
and red lines are PNA stained MDA-MB-231 treated without (green) and with TPA (red). 
B)Neuraminidase treatment restores PNA staining of TPA treated MDA-MB-231. TPA (red 
line) and vehicle (green line) incubated cells were treated for 30 minutes with neuraminidase 
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To determine if TPA had increased ST3Gal-I activity, MDA-MB-231 cells were 
incubated with TPA for 72 hours and then stained with PNA. Cells treated with TPA (red 
line in figure 4.11A) showed a shift to the left compared to the control, demonstrating 
that there is less unsubstituted core1 (T antigen) in the TPA treated cells compared to 
the control.  
To confirm that the decrease in PNA staining, after TPA treatment of MDA-MB-231, 
was dependent on the increase of sialylation of core1, the cells were treated with 
neuraminidase. The neuraminidase used was derived from Clostridium perfringens and 
it hydrolyzes α(2→3), α(2→6), and α(2→8)-glycosidic linkages of terminal sialic 
residues of various glycomolecules. Figure 4.11B shows PNA staining of TPA and 
vehicle treated MDA-MB-231 cells after treatment with Neuraminidase. The red line 
(TPA treated cells) overlaps with the green line (vehicle treated cells), indicating that the 
pool of core1 based structure was unchanged in the TPA treated cells and confirming 
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4.4 Discussion. 
 
This chapter describes the initial data that suggest that ST3Gal-I can be induced by 
COX-2. We showed that in T47D cells PGE2, a product of COX-2, induced expression 
of ST3Gal-I mRNA. We also showed that TPA, which among its many effects has been 
known to induce COX-2, can also induce the mRNA expression of ST3Gal-I. In both cell 
lines, induction of ST3Gal-I mRNA led to increased activity of this sialyltransferase.  
Different responses in two breast cancer cell lines, T47D and MDA-MB-231, to PGE2 
and TPA, were observed. In T47D, PGE2 induced the expression of ST3Gal-I, resulting 
in increased expression of Sialyl-core1. However T47D did not respond to TPA. In 
MDA-MB-231 TPA induced COX-2 and ST3Gal-I expression, but these enzymes were 
not induced by exogenous PGE2 in this cell line. 
MDA-MB-231 and T47D represent two different subtypes of breast cancer. MDA-MB-
231 is an adenocarcinoma breast cancer cell line, representative of triple negative 
breast cancer (ER, PR and HER-2 negative-see introduction). T47D is a ductal 
adenocarcinoma breast epithelial tumor cell line, which is estrogen receptor positive. 
Both were derived from metastatic pleural effusions. The glycosylation pattern is also 
different. In T47D breast cancer cell lines there is no core 2 formation and this is due to 
the lack of expression of C2GnT1. Dalziel et al. showed, by Northern analysis, that  
C2GnT1 was not expressed in T47D cells, while it was  expressed in a non-malignant 
breast cell line, MTSV1-7 (Dalziel et al. 2000). On the other hand, ST3Gal-I is very 
active (Lloyd et al. 1996, Whitehouse et al. 1997). MDA-MB-231 has core 1 and core 2 
based structures. The core 1 structures are mostly sialylated, suggesting competition 
between C2GnT1 and ST3Gal-I (Muller et al. 2002).  
However, the different responses to PGE2 and TPA may be due mainly to the different 
expression of EP receptors (PGE2 receptors) and expression of COX-2. As discussed 
in Chapter 3, MDA-MB-231 cells express low levels of the EP2 PGE2 receptor, but 
expresses EP4. EP2 and EP4 are receptors coupled to PKA/adenyl cyclase and mediate 
elevation in intracellular cAMP (Narumiya et al. 1999). However, in contrast to EP2, the 
signal, produced by the EP4 receptor, is lost within a few minutes because of agonist 
induced desensitization (Nishigaki et al. 1996). Thus, the lack of response of MDA-MB-
231 to PGE2 may be explained by this line requiring a continuous PGE2 stimulus that 
can be provided by TPA, but not by the exogenous PGE2 which has a very short half-
life (Fitzpatrick et al.1980). 
TPA only induced COX-2 overexpression in MDA-MB-231, which has the highest 
amount of COX-2 compared to the other breast cancer cell lines (as demonstrated in 
chapter 3). This agrees with Liu et al. who demonstrated that MDA-MB-231 cells 
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expressed constitutive levels of COX-2 that increased further in the presence of TPA 
(Liu et al.1996).  
Kakiuchi et al. (2002) found that COX-2 overexpression or PGE2 treatment reduced 
ST3Gal-I expression, while Celecoxib (COX-2 selective inhibitor) increased its 
expression in colonrectal cancer cell lines. This result is in opposition to what was found 
here. However, Hatano et al. (2011) showed that in castration-resistant prostate cancer 
cell lines, PC3 and DU145 cells, the expression of ST3Gal-I could be mildly induced by 
TPA, and TPA-induced expression of ST3Gal I could be inhibited by NF-κB decoy 
oligodeoxynucleotides (ODN).  
The results presented in this chapter suggest that ST3Gal-I can be induced by COX-2 
action, but more convincing data is required. Chapter 5 describes the series of 
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In the previous chapter it was demonstrated that TPA could induce the overexpression 
of COX-2 and of ST3Gal-I in MDA-MB-231. In the breast cancer cell line T47D, PGE2 
could increase the expression of ST3Gal-I at the mRNA level and at the protein level. 
This chapter will focus on the MDA-MB-231 model and the involvement of COX-2 in the 
induction of ST3Gal-I after TPA treatment. 
To confirm the involvement of COX-2, inhibitors of COX-2 were used together with TPA 
to see if the effect of the phorbol ester could be reversed. The enzyme was silenced or 
overexpressed in MDA-MB-231 and ST3Gal-I mRNA expression was determined by 
RT-qPCR. The expression of ST3Gal-I and COX-2 by 78 primary breast cancers was 





1. Treat cells with TPA and the COX-2 selective inhibitors NS398 or celecoxib and 
determine if there is any effect on the glycosyltransferases by qPCR. 
2. Determine the change of PNA staining of ST3Gal-I product after TPA and 
Celecoxib treatment by FACS analysis. 
3. Silence COX-2 with RNAi and check for COX-2 expression and ST3Gal-I RNA 
expression. 
4. Transfect COX-2 into MDA-MB-231 and determine the expression of ST3Gal-I. 
5. Determine the correlation between the expression of ST3Gal-I and COX-2 by 78 
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5.3 Results. 
 
5.3.1 Role of COX-2 inhibitors after TPA induction of ST3Gal-I in 
MDA-MB-231. 
 
The six epithelial breast cancer cell lines (MCF-7, T47D, MDA-MB-231, SKBr-3, BT20 
and ZR75-1) were treated with a selective COX-2 inhibitor, NS398. NS398 can block 
any possible release of PGE2 in the medium. No difference was seen in ST3Gal-I and 
C2GnT1 expression of two biological experiments after 24 hours of NS398 treatment 
(figure 5.1). 
 
Figure 5.1: NS398 treatment in six breast cancer cell lines cannot change ST3Gal-I and 
C2GnT1 expression. All the breast cancer cell lines were treated for 24 hours with NS398 or 
the vehicle in serum free condition and the mRNA of ST3Gal-I and C2GnT1 determined by RT-
q-PCR. The histograms show the mean of two biological experiments. 
 
 
The expression of COX-2 and of ST3Gal-I was therefore induced with TPA in MDA-MB-
231 and two selective inhibitors, NS398 and Celecoxib, were used to determine if the 
TPA effect could be reverted by blocking COX-2. Cells were starved for 4 hours, then 
treated with 10 nM TPA in the presence or absence of NS398 (20 µM) or Celecoxib (20 
µM) for 18 hours.   
Figure 5.2 shows that COX-2 expression increased after TPA treatment and could be 
decreased by NS398. Induction of ST3Gal-I expression could also be slightly 
decreased by NS398, but neither the reduction of COX-2 or ST3Gal-I was statistically 
significant. No effect of NS398 was seen on C2GnT1 mRNA. In a third biological 
experiment, COX-2 induction was very high (over 45 fold) but NS398 could still partially 






























































































































































































































Figure 5.2: NS398 can partially reverse TPA induction of COX-2.  
MDA-MB-231 were treated with TPA (10 nM) or TPA (10nM) with NS398 (20 µM) for 18 hours 
and the mRNA of A.ST3Gal-I; B.COX-2; C.C2GnT1 determined by RT-q-PCR. The histograms 
represent the mean of two biological experiments. n.s. p>0.05. 
 
 
MDA-MB-231 cells were also treated with TPA in presence or absence of Celecoxib. 
Celecoxib is another selective COX-2 inhibitor used in chronic inflammation and 
management of acute pain in adults. It is also used to reduce the number of polyps in 
patients with familial adenomatous polyposis (FAP) (European Medicine Agency 
website) and in some clinical trials for breast cancer (see section 1.9.5). 
Celecoxib did not inhibit the TPA effect on COX-2 and ST3Gal-I, rather unexpectedly it 
enhanced their mRNA expression (see figure 5.3). 
MDA-MB-231 were incubated with TPA and different concentrations of Celecoxib (1, 5, 
10, 20 µM).  COX-2 mRNA showed a small progressive increase in expression of 
27, 36, 41 fold with 1, 5, 10 µM of Celecoxib. However at 20 µM of  Celecoxib, 
COX-2 mRNA increased by a massive 403 fold (see figure 5.4). The induction of 
ST3Gal-I mRNA increased by 3 fold with 1, 5, 10 µM of Celecoxib, but increased to 9 
fold with 20 µM. In order to check if the production of PGE2 was also enhanced by 
Celecoxib, the concentration of PGE2 was measured in the media by ELISA. 
 ST3Gal-I       COX-2 
 C2GnT1 
  TPA               -                       +                        + 







































































  TPA               -                       +                       + 
NS398              -                        -                       + 
  TPA               -                      +                      + 
NS398              -                       -                      + 












Figure 5.3: Celecoxib can enhance TPA induced expression of COX-2 and ST3Gal-I.  
MDA-MB-231 were treated with TPA (10 nM) on its own and TPA (10nM) and Celecoxib (20 µM) 
for 18 hours and the mRNA of A.ST3Gal-I; B.COX-2; C. C2GnT1 determined by RT-q-PCR. The 
histograms represent the mean of three biological experiments. *p<0.05, **p<0.01, n.s.p>0.05. 
 
 
The concentration of PGE2 in the supernatant of MDA-MB-231 treated with TPA or 
different concentration of Celecoxib in the presence of TPA was higher compared to the 
control, ie. medium (DMEM without FCS and glutamine) from cells after 18 hours 
incubation (sample number 1). As can be seen in figure 5.5, Celecoxib can inhibit the 
TPA induced production of PGE2, with maximum inhibition being seen at 5 
µM.  Paradoxically, 20 µM Celecoxib (the concentration that induced a massive 
increase in COX-2 mRNA, see figure 5.4) still reduced PGE2 secretion by about one 
third, but still less than 5 µM. The increase of COX-2 and ST3Gal-I expression and the 
decrease in inhibition of PGE2 production after treatment with Celecoxib 20 µM	  can be 





   COX-2  
  TPA                 -                     +                      + 







  TPA               -                        +                        + 
















































  TPA                -                        +                       + 






























	   122 
 
Figure 5.4: Celecoxib increases TPA induced expression of COX-2 and ST3Gal-I. 
MDA-MB-231 cells were treated with TPA (10nM) and Celecoxib (1, 5, 10, 20 µM) for 18 hours 
and the mRNA of COX-2; ST3Gal-I and C2GnT1 measured by RT-q-PCR. The histograms 
represent only one biological experiment. Cel stands for celecoxib. 
 
                             
 
Figure 5.5: PGE2 concentration in the medium of MDA-MB-231 treated with TPA and 
Celecoxib. MDA-MB-231 cells were incubated with TPA in the presence of increased 
concentration of Celecoxib (1, 5, 10, 20 µM) and the media was collected after 18 hours of 




5.3.2 The effect of Celecoxib on the product of ST3Gal-I. 
 
The results with COX-2 in the presence of TPA and Celecoxib showed that 
determination of mRNA expression cannot always predict enzyme activity. Therefore 
the formation of ST3Gal-I product was measured to determine if Celecoxib could inhibit 
the glycosyltransferase activity. MDA-MB-231 were treated with TPA in the presence or 
absence of Celecoxib (20 µM) for 92 hours to allow turn-over of surface proteins, and 
cells were analysed for PNA staining by flow cytometry. As shown in figure 5.6, TPA 
decreases PNA staining (red) compared to the control (light green), but this effect could 
be reverted by Celecoxib (dark green). Thus when cells were treated with both TPA and 
Celecoxib the shift went back to the same level of the binding observed in the absence 
of TPA. This means that even if the mRNA of COX-2 and ST3Gal-I increases after TPA 
and Celecoxib treatment, Celecoxib is able to restore the TPA effect on ST3Gal-I 
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product. Figure 5.6 represents two independent biological experiments. However the 
experiment should be repeated using other concentrations of Celecoxib (like 5 µM, 
concentration) that was more effective at inhibiting PGE2 production. 
The use of inhibitors is always open to criticism due to their potential non-specificity. 
Moreover, the results obtained here with Celecoxib on COX-2 and ST3Gal-I expression 
were totally unexpected. Therefore to confirm that the increase of ST3Gal-I expression 
after TPA treatment was going via COX-2, COX-2 was knocked down after TPA 




Figure 5.6: Celecoxib reversed the TPA effect 
on ST3Gal-I activity. MDA-MB-231 cells were 
treated with TPA in the presence (dark green) or 
absence(red) of the COX-2 inhibitor celecoxib 
and then analysed for PNA binding. Grey, dark 
blue, light blue are control cells incubated 







5.3.3 Knock down of COX-2 in MDA-MB-231 and determination of 
ST3Gal-I mRNA expression. 
 
A) Characterization of the COX-2 antibody.  
 
To determine the efficacy of siRNA the best way is to look at the protein by Western 
blot. The antibody to COX-2 was therefore tested on Western Blots. The expected 
molecular weight of COX-2 is 72 kDa. MDA-MB-231 incubated for 5 hours with TPA, 
were lysed in RIPA buffer according to materials and methods (see chapter 2.4.1) and 
run on 7.5% SDS PAGE gels. 
The positive control used was MDA-MB-231 transfected for 24 hours with COX-2, lane 
number 3 of figure 5.7 A and B (see section 5.4). MDA-MB-231, treated with TPA for 5 
hours showed a band at the same molecular weight as the positive control, that was not 
present in MDA-MB-231 treated with the vehicle (lane 1 of figure 5.7 A). This 
experiment was repeated using the same conditions and in parallel lysates for mRNA 
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were collected. Unfortunately a further series of western blots did not show any band 
after blotting with the COX-2 antibody, apart from the transfected COX-2 MDA-MB-231 
(Figure 5.7 B). The loading control β-actin showed the band at the appropiate molecular 
weight (42 kb) indicating that the same amount of protein was used and that the 








       
 
Figure 5.7: Induction of COX-2 expression in response to 5 hours of TPA treatment of 
MDA-MB-231. Lysates were immunoblotted with COX-2 antibody followed by HRP-conjugated 
goat anti-mouse IgG (Dako). Both blots were stripped and reprobed with Mouse Anti- β−actin 
followed by HRP-goat antimouse IgG (Dako). Membranes were developed with the ECL system 
(Amersham) according to the manufacturer’s instructions. Lane 1, MDA-MB-231 treated with 
vehicle, lane 2, MDA-MB-231 treated with TPA and lane 3, MDA-MB-231 transfected with COX-
2 for 24 hours (positive control). A and B are two biological replicates. 
 
 
Another antibody against human COX-2 was used (Oxford Biomedical) and cells were 
lysed differently. In this case Laemli SDS PAGE sample buffer 1x (1 ul/10000 cells 
determined by counting a parallel well) was used directly on the cell layer. The 
concentration of antibody used was raised to 10 ug/ml. The western blot showed non-
specific bands, and no difference between the different conditions.  
 
 
B) Assessment of COX-2 mRNA knock down in MDA-MB-231. 
 
Since it was not possible to consistently see endogenous expression of COX-2 in MDA-
MB-231 by Western blot, the level of knock down for COX-2 was measured at the 
mRNA by RT-qPCR. MDA-MB-231 only express low levels of COX-2 at the mRNA 
level, hence the knock down was evaluated after TPA treatment (see figure 5.8, 5.9, 
5.10). 
Three different pairs of siRNA oligos were used to knock down COX-2 together with 
siRNA control. The first pair of primers from Santa Cruz Biotecnology (called siRNA 
COX-2 SC in figure 5.8) knocked down COX-2 only by 50% compared to the control. 24 
COX-2  
  β-actin  
      72 kb 
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Figure 5.8: siRNA knock-down of 
COX-2 with Santa Cruz oligos 
(siRNA COX-2 SC) reduced COX-2 
mRNA by 50% in MDA-MB-231 
compared to si-RNA control.  
Cells were transfected with siRNA and 
24 hours after transfection, treated for 
5 hours with TPA  (10 and 100 nM). 
COX-2 mRNA expression was then 










Another two oligos for siRNA silencing of COX-2 were used (see figure 5.9). They are 
called 1siRNA COX-2 and 2’ siRNA COX-2. They were designed by Stasinopoulos et 
al. (2007) and produced by Dharmacon. In this case both siRNA oligos could knock 
down COX-2 in three biological experiments (Figure 5.9). Having an efficient knock 




Figure 5.9: Two pairs of siRNA 
targeting COX-2 knocked down 
COX-2 in MDA-MB-231 by 70%. Cells 
were transfected with siRNA and 24 
hours after transfection, treated for 5 
hours with TPA 10 nM. COX-2 mRNA 
expression was then determined by 
RT-q-PCR. In 2’ COX-2 siRNA, 1siRNA 
and 2siRNA described in materials and 
methods were pooled. Data represent 
three independent experiments. 
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The expression of ST3Gal-I was determined after COX-2 had been knocked-down 
using the siRNA shown in figure 5.9. Figure 5.10 shows that when COX-2 was 
knocked-down by 70%, ST3Gal-I mRNA decreased by 50 % for both siRNA oligos in 
three biological experiments.  
 
Figure 5.10: The two siRNA that 
knocked down COX-2 by 70% in 
MDA-MB-231 (figure 5.9) reverted 
TPA effect on ST3Gal-I by 50%. 
MDA-MB-231 were transfected with 1 
and 2’ siRNA and 24 hours after 
transfection, treated for 5 hours with 
TPA 10 nM. ST3Gal-I mRNA 
expression was then determined by 
RT-qPCR. In 2’ COX-2 siRNA, 1siRNA 
and 2siRNA described in materials and 
methods were pooled. Data represent 
three independent experiments. 





Moreover two pooled siRNA to COX-2, that gave a knock down of 53% in two other 
biological experiments (figure 5.11), were also able to decrease ST3Gal-I mRNA 











Figure 5.11: 2’ siRNA, targeting COX-2, knocked down COX-2 in MDA-MB-231 by 53% in 
another two biological experiments and reverted TPA effect on ST3Gal-I. Cells were 
transfected and treated as descrive in figure 5.9 and 5.10. COX-2 mRNA expression was then 
determined by RT-q-PCR. Data represent two independent experiments. Asterisks denote a 
statistically significant difference from control: *p<0.05, ** p<0.01. In the specific case of p=0.07 
the value is reported since it is very close to be significant. 
 
In summary, two pairs of siRNA that could knock down COX-2 by 70%, could revert the 
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siRNA were used and COX-2 expression was only decreased by 50%, ST3Gal-I 
expression was still decreased (see figure 5.11). These data provide evidence that the 
increase of ST3Gal-I mRNA induced by TPA is working through COX-2. 
 
 
5.3.4 Transfection of COX-2 in MDA-MB-231 and determination of 
ST3Gal-I mRNA expression. 
 
A)Determination of COX-2 plasmid authenticity. 
 
To confirm the involvement of COX-2 in regulating ST3Gal-I expression, COX-2 was 
overexpressed by transient transfection in MDA-MB-231. 
The vector containing the cDNA for COX-2 (called pCMV6-AC) was purchased from 
Origene. The vector includes a strong CMV promoter, a neomycin selectable marker 
and the COX-2 cDNA (also called with the gene name: PTGS2) cloned into the vector 
at EcoRI and NotI sites. To check the authenticity of the construct, the plasmid was cut 
with restriction enzymes and an antibody against human COX-2 was used for staining 
transiently transfected cells.  
Two plasmid maxipreps were prepared and the purified plasmid cut with EcoRI and NotI 
and run on a 1% agarose gel. Figure 5.12 shows that digesting the samples with EcoRI 
and NotI resulted in two bands of around 6 and 3.5 kb agreeing with the manufacturer’s 




Figure 5.12: Restriction endonuclease 
digest of hPTGS2 vector (pCMV6-AC). 
Lanes 1 to 4 and 5 to 8 are two different 
batches derived by Maxiprep of the same 
vector. Lanes 1 and 5 are Not I and EcoRI 
digested, lane 2 and 6 Not I digested, lane 
3 and 7 EcoR I digested and lane 4 and 8 
are uncut. The ladder used was 1 kb 






COS cells were transiently transfected with the COX-2 plasmid and after 24 hours 
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between wild type COS cells (figure 5.13 a), COX-2 transfected COS cells stained only 
with secondary Alexa Fluor® 546 Goat Anti-Rabbit IgG (H+L) (figure 5.13b), and with 
COX-2 antibody (figure 5.13 c). The staining of COX-2 appeared to be located in the 
endoplasmic reticulum and around the nuclear envelope as it is expected for this 
enzyme (Morita et al.1995). In conclusion the plasmid pCMV6-AC was verified to 
express COX-2 and could be used to express COX-2 in the cell line MDA-MB-231.                                                                                                                                         
 
a)                                               b)                                                c) 
    
                 
Figure 5.13 COX-2 staining in COX-2 transfected COS cells. Cells (1x105) were plated the 
day prior to staining. Cells were fixed in 4% paraformaldehyde at 4°C for 10 min and blocked 
with 100% FCS. After three washes wild type COS cells were stained with anti-COX-2 antibody 
(Oxford Biomedical) followed by Alexa Fluor® 546 Goat Anti-Rabbit IgG (a); COX-2 transfected 
COS cells stained with the second antibody Alexa Fluor® 546 Goat Anti-Rabbit IgG (b); COX-2 




B) Transfection of COX-2 for 72 hours induced ST3Gal-I expression 
in MDA-MB-231 
 
MDA-MB-231 cells were transfected with pCMV6-AC and tested after 72 hours for 
COX-2 and ST3Gal-I mRNA expression. COX-2 transfected MDA-MB-231 showed an 
increase in COX-2 and ST3Gal-I mRNA expression by RT-qPCR. Figure 5.14 shows  
histograms of the mean of mRNA fold change in expression of COX-2 and ST3Gal-I 
compared to the mock transfected cells. 
 
 
5.3.5 Correlation of COX-2 and ST3Gal-I in vivo in breast cancers. 
 
To investigate the clinical significance of our findings we determined the expression of 
COX-2 and ST3Gal-I mRNA by RT-PCR on 78 primary breast cancers (52 ER positive, 
14 ER negative, rest unknown classification) obtained from the Guy’s and St Thomas’ 
Research Breast Tissue Bank. Before RNA extraction, sections were taken from the 
tissue to confirm that each sample contained at least 70% carcinoma cells (performed 
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by the Tissue Bank Lab). PUM1 was used as the reference gene and the level of 
ST3Gal-I normalized to PUM1 (see table 5.1 for the results). Figure 5.15 shows the plot 
of –log of the expression of COX-2 against –log of expression of ST3Gal-I. 
We applied two statistical tests to the data. Firstly, Spearman’s rank correlation which 
gave a correlation of 0.309 with a p value of 0.00593, and secondly Pearson’s 
correlation which gave a correlation coefficient of 0.274 with a p value of 0.015. Thus 
both tests confirmed the presence of moderate but statistically significant correlation in 
the expression of the two enzymes. The statistics were calculated by Dr. Brian Burford 
(Breakthrough Breast Cancer, Research Oncology, King’s College London, Guy’s 










Figure 5.14: COX-2 transfection of MDA-MB-231 enhances ST3Gal-I mRNA expression by 
two fold. MDA-MB-231 were transfected with COX-2 cDNA and RNA extracted 72 hours past 
transfection. The expression of COX-2 and ST3Gal-I were determined by RT-q-PCR. The 
histograms represent mean of three independent experiments. Asterisks denote a statistically 
significant difference from control: *p<0.05.  
 
 
Figure 5.15: The expression of COX-2 and 
ST3Gal-I are correlated in primary breast 
cancers. RNA was extracted from 78 primary 
breast cancers and the expression of COX-2 
and ST3Gal-I was determined by RT-PCR. 
The -log of the DCT was plotted and the 
correlation determined by the Spearman’s test, 
correlation coefficient was 0.309, p=0.00593 
and the Pearson test, correlation coefficient 
0.274 p=0.0150. Table 5.1 (below) lists the 
data for all the 78 primary tumours. 
Table 5.1: Relative expression to PUM1 of 
COX-2 and ST3Gal-I mRNAs in 78 
specimens of primary breast cancer 
COX-2 
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In chapter 4, it was demonstrated that in the breast cancer cell line MDA-MB-231, TPA 
could increase ST3Gal-I and COX-2 mRNA expression and the product of both 
enzymes (see PNA staining by FACS and PGE2 production by ELISA). Therefore to 
investigate if ST3Gal-I induction was via COX-2, NS398 and Celecoxib, selective 
inhibitors of COX-2 were used. NS398 could revert the TPA effect on COX-2 and 
slightly decrease ST3Gal-I expression. However, Celecoxib unexpectedly increased 
ST3Gal-I and COX-2 mRNA expression. Upon searching the literature it was found that 
induction of COX-2 mRNA by Celecoxib has been reported by others. Indeed 
Niederberger et al. (2001) showed that Celecoxib increases COX-2 mRNA and protein 
expression in a concentration between 10 and 50 µM. We also found that Celecoxib 
can increase COX-2 and ST3Gal-I mRNA and slightly decrease C2GnT1 mRNA 
expression (see figure 5.4). Thus ST3Gal-I and COX-2 mRNA expression move in 
parallel, even with Celecoxib treatment. It was totally unexpected that NSAIDs 
extensively used in clinic and in clinical trials for cancer, could increase COX-2 mRNA. 
However, the results from the ELISA quantifying PGE2 secretion in the samples treated 
for 18 hours with TPA and Celecoxib showed there was less PGE2 secretion than when 
the cells were treated with TPA alone. This result means that even if Celecoxib 
increases COX-2 mRNA, it was inhibiting its activity. Furthermore, Celecoxib was 
inhibiting ST3Gal-I activity. As said in the introduction, PNA (peanut agglutinin) binds 
specifically the T structure (Core1) and this binding is inhibited by the presence of sialic 
acid (Novogrodsky et al. 1975). Celecoxib could inhibit ST3Gal-I activity since it was 
able to revert the PNA binding seen after TPA treatment back to the TPA untreated 
cells.  
To confirm the ST3Gal-I mRNA was being induced by COX-2, COX-2 was silenced or 
over-expressed in MDA-MB-231 and ST3Gal-I expression measured by RT-qPCR. 
Stasinopoulos et al. (2007) showed that COX-2 expression could be knocked down in 
MDA-MB-231 using COX-2 targeting small interfering RNA (siRNA). The same oligos 
were used and they also showed a knock down of COX-2 by 70% after TPA treatment. 
This resulted in ST3Gal-I expression, after TPA induction, being decreased by 50% in 
three independent experiments. Moreover, when COX-2 was transfected into MDA-MB-
231, ST3Gal-I mRNA expression increased by 2 fold. Thus, ST3Gal-I expression is 
affected after silencing and transfection of COX-2. 
To relate these findings in breast cancer cell lines to clinical samples, the expression of 
COX-2 and ST3Gal-I were analyzed in 78 breast cancer samples. The statistical 
correlation between COX-2 and ST3Gal-I was moderate but statistically significant. 
However, the level of mRNA expression of an enzyme does not give us information on 
its activity or the possible influence of the cell environment and of competing 
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glycosyltransferases. This means that a moderate correlation may allow COX-2 to have 
even more influence on ST3Gal-I. Given all the data presented in this thesis we can 
conclude that ST3Gal-I expression is controlled by COX-2 in breast cancer cell lines 
and possibly in primary breast cancers. 
 
 
               
Figure 5.16 Effect of TPA and PGE2 on ST3Gal-I in breast cancer cells. TPA binds directly 
PKC and upregulates COX-2 expression and consequently increases PGE2 secretion. PGE2 
binds EP receptors and upregulates ST3Gal-I expression and SialylT expression. 
 
 
From the literature it is evident that COX-2 expression is turned on in many cancers. 
Increased expression has been reported in colon (Eberhart et al. 1994), bladder (Eltze 
et al. 2005) and breast cancers (Ristimaki et al. 2002), the same cancers that show 
increased expression of ST3Gal-I (Burchell et al. 1999, Potapenko et al.2010, Higai et 
al. 2006, Videira et al. 2009). In particular COX-2 was found overexpressed in about 
40% of cases of invasive breast carcinoma (associated with unfavorable distant 
disease-free survival) (Ristimaki et al. 2002) and ST3Gal-I has been found over-
expressed in breast carcinomas, and in primary breast cancers its increase is 
correlated with tumour grade (Burchell et al. 1999). 
COX-2 expression has been associated with lymph node metastasis (Costa et al. 
2002), distant metastasis (Larkins et al. 2006), angiogenesis (Davies et al. 2003), 
processes that all involve glycan interactions (Ono et al. 2004).  
COX-2 is important in lymph node metastasis and distant metastasis. Lymph node 
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β1-3 
SialylT 
	   133 
and EP4 receptors are involved in COX-2 mediated VEGF-C up-regulation (Su et al. 
2004, Xin et al. 2012). Moreover COX-2 up-regulates, via EP2 and EP4 receptors, 
CCR7 expression in breast cancer cells, a chemokine receptor associated with breast 
cancer metastasis. COX-2 also regulates matrix metalloproteinase expression that can 
digest the extracellular matrix and the basement membrane (Pan et al. 2008). Gene 
expression analyses and mouse model systems have also revealed correlations 
between COX-2 overexpression and breast cancer metastasis to the lung, bone, and 
brain (Bos et al. 2009; Singh et al. 2007; Minn et al. 2005). ST3Gal-I expression is 
associated with grade and therefore an association with lymph node expression is 
inferred.Julien et al. (2007) showed that when monocyte derived dendritic cells are 
induced to mature and migrate to the lymph nodes, the composition of their O-linked 
glycans changes in a way that mirrors the change in breast cancer. Upon maturation of 
DCs, C2GnT1 is down regulated and the sialyltransferase ST3Gal-I is up-regulated 
resulting in the change from core 2 based glycans to sialylated core 1 glycans. When 
breast cancer cells metastasize to the lymph nodes, like dendritic cells, they migrate 
from the tissue to the lymph nodes and it is possible that the O-linked glycans changes 
could be involved. Interestingly, PGE2 changed the expression of ST3Gal-I and 
C2GnT1 on dendritic cells (Julien et al. 2007).  
It was shown that in transgenic mice overexpressing the human COX-2 gene in the 
mammary glands resulted in reduced levels of the proapoptotic proteins Bax and Bcl-xL 
and an increase in Bcl-2, that can inactivate the apoptotic caspase cascade upstream 
of the mitochondria, suggesting that enhanced COX-2 expression is sufficient to inhibit 
apoptosis and induce mammary gland tumorigenesis. Therefore, inhibition of Cox-2 
may represent a mechanism-based chemopreventive approach for carcinogenesis (Liu 
et al. 2001).  
ST3Gal-I is important in tumorigenesis. In this lab, Picco et al. showed that ST3Gal-I 
promotes mammary gland carcinogenesis. Transgenic mice were developed that 
overexpressed ST3Gal-I from the MUC1 promoter to allow upregulation in mammary 
gland. ST3Gal-I transgenic mice did not show obvious change in the development of 
the mammary gland, but they showed increased activity and expression of the enzyme 
in the pregnant and lactating mammary glands, the stomach, lungs and intestine. These 
mice were then crossed with Polyoma middle T mice (a model of spontaneous breast 
cancer) running from the MMTV promoter and showed a significant increase in the 
speed of mammary tumour development compared to the controls (Picco et al. 2010). 
The findings reported here maybe useful for the development of specific therapeutics 
targeting COX-2 and changes in glycosylation in breast cancer. NSAIDs (non-steroidal 
anti-inflammatory drug) are important in chemoprevention and are used as adjuvant for 
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patients under chemotherapy/radiation regimens with COX-2 expressing breast 
cancers. The Randomised European Celecoxib Trial (REACT) is a phase III clinical trial 
(now underway) based on the use of Celecoxib (and Adjuvant endocrine therapy on 
hormone receptor (ER and PgR) positive patients) for women with breast cancers. 
Moreover there are other clinical trials underway using Celecoxib for breast cancer and 
other types of cancer: Neoexel study, (phase III Neoadjuvant trial of pre-operative 
exemestane or letrozole +/- celecoxib in the treatment of ER positive postmenopausal 
early breast cancer);2) NCI/MSKCC (phase II study of celecoxib and herceptin in 
women with HER2+ metastatic breast cancer refractory to herceptin); 3) NCI phase I 
randomised study of 6 weeks neoadjuvant celecoxib for localised prostate cancer; 4) 
NCI/UCSF randomised phase II study of two years celecoxib for prevention of basal cell 
carcinoma in patients with basal cell naevus syndrome. However, as described in 
section 1.9.5, COXIBs (as well as NSAIDs) have several side effects like cardiovascular 
complications, which is why all patients under these clinical trials receive a 
cadiovascular assessment throughout the treatment (REACT PROTOCOL– version 34, 
28.09.2009). 
Further studies are needed on the influence of COX-2 activity on glycosylation. 
Eventual discoveries could overcome side effects of NSAIDs as glycosylation enzymes 
may be suitable therapeutic targets for cases of breast cancer that have become 
resistant to other therapies.  
As said in section 1.2.2 Curtis et al. described a novel molecular classification of breast 
cancer based on the acquired somatic copy number aberrations and gene expression 
profiling. On a cohort of 2000 breast tumours ten groups were identified and a cohort of 
ER positive luminal epithelial cancers have been identified with a very bad outcome 
(Curtis et al. 2012). According to Gluck, Chin and other datasets ST3Gal-I is found 
more in invasive breast cancer (Chin et al. 2006, Gluck et al. 2012). It would be 
interesting to determine COX-2 and ST3Gal-I expression in the ER+ve cluster identified 
by Curtis et al  (Curtis et al. 2012) as having a poor prognosis with the aim of 
developing new targeted therapies. 
Chen et al. developed an inhibitor, lithocholic acid, that could block the action of 
different sialyltransferases, including ST3Gal-I, by lysosomal degradation. One 
limitation to this kind of approach is that ST3Gal-I is expressed by mature T cells and so 
a selective  inhibitor would face multivalent and low-affinity interactions in vivo (Chen et 
al. 2011).  
In this chapter we saw how two selective COX-2 inhibitors could affect ST3Gal-I mRNA 
expression and activity. It would be interesting to measure the expression of ST3Gal-I 
in tumours from the patients of the Clinical trials investigating the efficacy of the 
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selective COX-2 inhibitor, celecoxib, and see if the outcome of the patients that do 
express high levels of ST3Gal-I, differs from patients expressing moderate or lower 
levels. 
The results described here suggest the intriguing possibility that some of the malignant 
characteristics associated with COX-2 expression may by via the influence that COX-2 





























As discussed in the previous chapter, ST3Gal-I mRNA expression is induced by COX-
2, which results in increased ST3Gal-I activity, as demonstrated by the increased 
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formation of sialylated core 1, the ST3Gal-I product. The aim of this chapter is to 





1. Identify the phosphoprotein activated by TPA, using a Human Phospho-Kinase Array 
kit. 
2. Treat cells with EGF and investigate possible role in ST3Gal-I induction. 
3. Use of statistic website for investigating CREB binding sites on ST3Gal-I promoter 
and usage of forskolin to determine any possible influence on ST3Gal-I expression. 
4. Determine the effect of PKC inhibitors on ST3Gal-I and COX-2 expression after TPA 
and PGE2 treatment, in MDA-MB-231 and T47D, respectively. 
5. Chromatin Immunoprecipitation qPCR for histone marks (H3K4Me2 and H3K4Me3) 















6.3.1 Phosphorylation assay after TPA treatment in MDA-MB-231. 
 
The aim of the experiment was to analyze the phosphorylation profiles of some kinases 
and protein substrates in MDA-MB-231 after TPA treatment, to identify and see if any of 
them are involved in the upregulation of ST3Gal-I. To do so, a phosphoarray kit was 
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used. As explained in the materials and methods (section 2.4.4), the kit consists of 46 
capture antibodies of different kinases and proteins and control antibodies that have 
been spotted in duplicate on nitrocellulose membranes. Figure 6.1 shows a table with 
all the kinases and their disposition on the membranes. The Human Phospho-Kinase 
Array is divided in A and B as shown in figure 6.1. The membranes are incubated with 
cell lysates, probed with a cocktail of antibodies and developed as western blots.                                      







Figure 6.1: a) Human Phospho-Kinase Array 
Coordinates on the membranes. b) Table 
documenting  the 46 different kinase and 
proteins and their coordinates on the arrays. 
 
 
MDA-MB-231 was treated for 5 minutes with 
10 nM TPA or vehicle. Protein lysates were collected and parallel cultures were 
incubated for 5 hours with TPA for RNA extraction, in order to confirm overexpression 
of ST3Gal-I and COX-2. RT-qPCR confirmed the upregulation of ST3Gal-I and COX-2 
mRNA after 5 hours of TPA treatment (data not shown). The membranes of the array 
were incubated overnight with the protein lysate and the assay was run according to 
materials and methods. ERK 1/2, JNK, CREB, Chk-2, FAK (Spots A 5-6, A 7-8, C 3-4, F 
3-4, F 5-6 squared in red in figure 6.2), showed increased phosphorylation after 
www.RnDSystems.com 13
Membrane/Coordinate  Target/Control Phosphorylation Site Cell Source/Treatment
A-E1, E2 Fyn Y420 Daudi/Pervanadate*
A-E3, E4 Yes Y426 K562/Pervanadate*
A-E5, E6 Fgr Y412 K562/Pervanadate
A-E7, E8 STAT3 Y705 LNCap/rhIL-6
A-E9, E10 STAT5b Y699 Daudi/rhIFN-α2A*
B-E11, E12 p70 S6 Kinase T229 MCF-7/CPT*
B-E13, E14 RSK1/2 S221/S227 U937/PMA + rhIL-4
B-E15, E16 c-Jun S63 HeLa/PMA*
B-E17, E18 Pyk2 Y402 K562/Pervanadate*
A-F1, F2 Hck Y411 Daudi/Pervanadate
A-F3, F4 Chk-2 T68 HeLa/CPT*
A-F5, F6 FAK Y397 HepG2/Pervanadate
A-F7, F8 STAT6 Y641 U937/PMA + rhIL-4
A-F9, F10 STAT5a/b Y694/Y699 Daudi/rhIFN-α2A
B-F11, F12 STAT1 Y701 Daudi/rhIFN-α2A
B-F13, F14 STAT4 Y693 NC-37/Pervanadate
B-F15, F16 eNOS S1177 Jurkat/H2O2*
B-F17, F18 PBS (Negative Control) ___ ___
A-G1, G2 Reference Spot ___ ___
A-G5, G6 PBS (Negative Control) ___ ___
*A change in phosphorylation for this protein was detected in multiple cell sources.
For research use only. Not for use in diagnostic procedures.12
APPENDIX
Refer to the table below for the Human Phospho-Kinase Array coordinates.
Membrane/Coordinate  Target/Control Phosphorylation Site Cell Source/Treatment
A-A1, A2 Reference Spot ___ ___
A-A3, A4 p38α T180/Y182 MCF-7/UV*
A-A5, A6 ERK1/2 T202/Y204, T185/Y187 HeLa/PMA*
A-A7, A8 JNK pan T183/Y185, T221/Y223 MCF-7/UV*
A-A9, A10 GSK-3α/β S21/S9 MCF-7/rhIGF-I
B-A13, A14 p53 S392 MCF-7/CPT*
B-A17, A18 Reference Spot ___ ___
A-B3, B4 MEK1/2 S218/S222, S222/S226 MCF-7/UV*
A-B5, B6 MSK1/2 S376/S360 HeLa/PMA*
A-B7, B8 AMPKα1 T174 Jurkat/H2O2*
A-B9, B10 Akt S473 MCF-7/rhIGF-I*
B-B11, B12 Akt T308 K562/Pervanadate
B-B13, B14 p53 S46 MCF-7/CPT*
A-C1, C2 TOR S2448 MCF-7/UV*
A-C3, C4 CREB S133 Jurkat/H2O2*
A-C5, C6 HSP27 S78/S82 HeLa/PMA*
A-C7, C8 AMPKα2 T172 HepG2/Metformin*
A-C9, C10 β-Catenin ___ HeLa/PMA*
B-C11, C12 p70 S6 Kinase T389 MCF-7/CPT*
B-C13, C14 p53 S15 MCF-7/CPT*
B-C15, C16 p27 T198 Jurkat/H2O2*
B-C17, C18 Paxillin Y118 K562/Pervanadate
A-D1, D2 Src Y419 COLO 205/SFM*
A-D3, D4 Lyn Y397 Daudi/Pervanadate*
A-D5, D6 Lck Y394 Jurkat/Pervanadate
A-D7, D8 STAT2 Y689 Dau i/rhIFN-α2A
A-D9, D10 STAT5a Y694 U937/PMA + rhIL-4
B-D11, D12 p70 S6 Kinase T421/S424 MCF-7/UV*
B-D13, D14 RSK1/2/3 S380/S386/S377 HeLa/PMA*
B-D15, D16 p27 T157 K562/Pervanadate
B-D17, D18 PLCγ-1 Y783 Jurkat/H2O2*
*A change in phosphorylation for this protein was detected in multiple cell sources.
For research use only. Not for use in diagnostic procedures.8
DATA ANALYSIS
The positive signals seen on developed !lm can be quickly identi!ed by placing the 
transparency overlay on the array image and aligning it with the pairs of reference spots in the 
corners of each membrane (two pairs on the left side of Part A and one pair on the right side of 
Part B). The stamped identi!cation numbers on the membranes should be placed on the left 
hand side. The location of controls and capture antibodies is listed in the Appendix. It may be 
necessary to adjust the position of the transparency overlay template if the two parts of the 
membrane are not aligned.
Note: Reference spots are included to align the transparency overlay template and to demonstrate 
that the array has been incubated with Streptavidin-HRP during the assay procedure.
Pixel densities on developed X-ray !lm can be collected and analyzed using a transmission-
mode scanner and image analysis software.
1. Create a template to analyze pixel density in each spot of the array.
2. Export signal values to a spreadsheet !le for manipulation in a program such as Microsoft 
Excel.
3. Determine the average signal (pixel density) of the pair of duplicate spots representing 
each phosphorylated kinase protein.
4. Subtract an averaged background signal from each spot. Use a signal from a clear area of 
the array or negative control spots as a background value.
5. Compare corresponding signals on di"erent arrays to determine the relative change in 
phosphorylated kinase proteins between samples.








1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18
This image is not to scale. It is for coordinate reference only. 
Please use the transparency overlay for analyte identi!cation.
   Array A         Array B 
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Figure 6.2: Treatment of MDA-MB-231 with TPA results in increased phosphorylation of 
ERK 1/2, JNK, CREB, Chk-2, FAK. MDA-MB-231 were treated with 10 nM TPA or vehicle for 5 
minutes. Membranes were incubated with the lysates as described in materials and methods 




To confirm the results of the arrays, cells were treated again with 10 nM TPA for 5 
minutes and lysates run on SDS-PAGE and the Western blots probed with antibodies to 
FAK, CREB and ERK. Figure 6.3 shows the results and confirms that TPA induces 
phosphorylation of FAK, CREB and ERK in MDA-MB-231 (see figure 6.3).  
According to the literature (Wen-Sheng and Jun-Ming, 2005, Li et al. 2006), we found 
that TPA enhanced ERK and CREB phosphorylation.  The involvement of these two 
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Figure 6.3: TPA increases phospho-FAK, phospho-CREB and phospho-ERK in MDA-MB-
231 after 5 minutes of treament. Lysates were run on a 7.5% SDS-PAGE and the Western 
blots probed with antibodies to the protein or with phosphospecific antibodies. The loading 
control antibody used for each blot was β-actin. Membranes were developed with the ECL 
system according to the manufacturer’s instructions. 
 
 
6.3.2 ERK is not involved in ST3Gal-I and C2GnT1 activation of 
transcription. 
 
The activation of EGFR (epidermal growth factor receptor) is involved in breast cancer, 
in particular in the process of metastasis and invasion (Nickerson et al. 2012). ERK is a 
downstream molecule activated by EGF–EGFR signalling. EGF binding results in the 
phosphorylation of EGFR and consequent activation of ERK1/2. So, exogenous EGF 
was used as an alternative way to TPA, to activate ERK and see if it could also induce 
ST3Gal-I mRNA expression. MDA-MB-231 cell line was treated with EGF (50 ng/ml and 
100 ng/ml) for 2, 5 and 8 hours and ST3Gal-I and C2GnT1 mRNA expression was 
determined. In parallel, to confirm that ERK was phosphorylated, MDA-MB-231 were 
treated for 5 minutes with EGF and the phosphorylation of ERK determined by western 
blot (see figure 6.4). 
The expression of ST3Gal-I and C2GnT1 mRNA in EGF treated cells was determined 
by RT-qPCR. ST3Gal-I and C2GnT1 mRNA expression did not change more than 2 
fold in expression over the time course (shown in figure 6.5). However, as after 2 hours 
there was a two fold increase in ST3Gal-I expression, this time point was repeated a 
further three times.  
The results showed that the induction of ST3Gal-I by EGF after 2 hours of incubation 
was inconsistent (figure 6.5 B) and therefore, it was concluded that EGF could not 
induce ST3Gal-I expression and that ERK is not involved in TPA induction of 
expression of ST3Gal-I. 
 
Figure 6.4: EGF treatment of MDA-MB-231 
for 5 minutes can increase the 
phosphorylation of ERK.  
MDA-MB-231 were treated with PBS 
(vehicle) (Lane 1) or with 50 ng/ml or 100 
ng/ml EGF(Lanes 2 and 3). Lysates were run 
on 7.5% SDS-PAGE and the Western blots 
   44 kb 
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              ERK 
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probed with ERK and phosphoERK antibodies. The loading control antibody used was β−actin. 












Figure 6.5: EGF does not change the expression of ST3Gal-I or C2GnT1 consistently. A. 
MDA-MB-231 cells were treated with EGF for the times indicated and the expression of ST3Gal-
I and C2GnT1 was determined by RT-qPCR. The graphs show the average for two biological 
experiments. B. MDA-MB-231 cells were treated with EGF for 2 hours and the expression of 




6.3.3 CREB involvement on ST3Gal-I and C2GnT1 activation of 
transcription. 
 
The cAMP responsive element binding protein is a phosphorylation activated 
trascription factor (Mayr et al. 2001). CREB can be activated by different kinases, like 
Protein Kinase C, Protein Kinase A, calmodulin kinases (CaMKs), Akt and pp90 
ribosomal S6 kinase (pp90 RSK; also known as RSK2) (Sakamoto et al. 2009). When 
one of these protein kinases is activated, it translocates to the nucleus and 
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bound by a CBP (CREB-binding protein) that works as a cofactor for the transcription of 
other genes (Carlezon et al. 2005). 
Bioinformatic tools like Gene2promoter, MatInspector, ElDorado and FrameWorker 
were used to study the ST3Gal-I and C2GnT1 promoter to analyze the presence of 
CREB binding sites. The promoter region C2GnT1 is complex and in humans four 
different 5’ untranslated regions have been identified, consistent with the presence of 
multiple tissue specific promoters for the C2GnT1 gene (Falkenberg et al. 2003). As 
can be seen from figure 6.6, all four promoter regions of C2GnT1 contain CRE 
consensus sites. The promoter region of the ST3Gal-I is less complex and although two 
possible promoter regions have been identified, only one appears to be in the region 
important for the transcriptional activity of ST3Gal-I (Taniguchi et al. 2001). However, 
according to Softberry (predictive transcription binding site program), the only CREB 
binding site on ST3Gal-I promoter has a very low affinity to CREB. 
As forskolin is the most potent activator of CREB (Seternes et al.1999), it was used to 





Figure 6.6: Identification of CRE sequence (blue) in the alternative promoters of human 




MDA-MB-231 were treated with forskolin for 1, 3, 5 and 20 hours. The time point at 3, 5 
and 20 hours in figure 6.7 represent the mean±SD of two biological experiments. 
ST3Gal-I mRNA did not show any significant change in expression. On the other hand, 
C2GnT1 seemed to increase by about two fold. Around a three fold increase in COX-2 
mRNA was observed and this increase was much lower than that seen with TPA. 
Moreover, the major increase in expression was seen after 20 hours, suggesting that 
forskolin indirectly induces COX-2 mRNA expression. The data were not suggestive of 
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any positive response of ST3Gal-I to forskolin. Given that the CREB binding site on the 
ST3Gal-I promoter is of low affinity (Softberry data base), the possible correlation with 
this transcription factor was not further investigated.  
 
 
Figure 6.7: Forskolin does significantly not change ST3Gal-I mRNA expression. MDA-MB-
231 were treated with forskolin (20 µM) for 1, 3, 5 and 20 hours and ST3Gal-I, C2GnT1 and 
COX-2 mRNA were determined by RT-qPCR. The data represent two biological experiments for 
the time point of 90 minutes, 3 and 8 hours. 
 
 
6.3.4 Involvement of PKC in ST3Gal-I expression. 
 
TPA is a phorbol diester that resembles the structure and the activity of diacylglycerol and so 
binds to Protein Kinase C (Castagna et al. 1982). It was demonstrated that TPA increased the 
PKC activity more than the unsaturated diacylglycerol, and decreased in the Ca2+ concentration 
that was necessary for enzyme activation (Castagna et al. 1982).  
The PKC family consists of 12 isoenzymes classified in 3 subfamilies depending on their 
mechanism of activation and on structural characteristics: 1) conventional or classic PKCs (PKC 
α, β, γ) that require DAG and Ca2+ for activation; 2) non-classic or novel PKCs (PKC δ, ε, η, θ) 
that require DAG but not Ca2+ for activation and 3) atypical PKCs that do not require either DAG 
or Ca2+(PKC ι, ζ, µ, λ) (Newton et al. 2001).  
TPA can only bind classic and novel PKC. Gö6976 inhibits PKCα, β (conventional PKC), and 
PKCµ (atypical PKCs). Gö6983 inhibits PKCα, PKCβ, PKCγ, (conventional PKCs), PKCδ (non-
classic PKC), PKCζ, and PKCµ (atypical PKC).  
ST3Gal-I in T47D responded to PGE2 but not to TPA and ST3Gal-I in MDA-MB-231 responded 
to TPA but not to PGE2. Thus we wanted to determine if this could be explained by differential 
expression of PKC isoenzymes. 
MDA-MB-231 was incubated with TPA in the presence or absence of the two inhibitors Gö 6983 
(6 µM) and Gö6976 (2 µM) for 5 hours, while T47D was treated for 4 hours with PGE2 (100 nM) 
in the presence or absence of the same PKC inhibitors. The time point used for the two cell lines 
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inhibitors blocked the TPA effect on ST3Gal-I and COX-2. This result was expected, as TPA 
exerts its action through the isoforms of PKC.  
Unexpected was the effect that the PKC inhibitors had on the PGE2 upregulation of ST3Gal-I in 
T47D. Both inhibitors (Gö6983 and Gö6976) reversed the PGE2 effect on ST3Gal-I in two 
biological experiments (figure 6.9 A and B). COX-2 level of expression was very low and, as 
observed in chapter 4, PGE2 did not increase its expression (data not shown). Thus PGE2 
appears to be inducing the expression of ST3Gal-I via PKC in T47D.  
 
 
Figure 6.8 TPA effect on ST3Gal-I and COX-2 in MDA-MB-231 can be reverted by the PKC 
inhibitors A. Gö 6976, B. Gö 6983. MDA-MB-231 were treated with TPA or TPA and A)Gö 
6976 B) Gö 6983 for 5 hours. ST3Gal-I and COX-2 mRNA expression was then determined by 
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Figure 6.9 PGE2 effect on ST3Gal-I in T47D can be reverted by the PKC inhibitors Gö 6976 
and Gö 6983. T47D cells were treated with PGE2 or PGE2 and A)Gö 6983 B) Gö 6976. 
ST3Gal-I RNA expression was then determined by RT-qPCR. Data represent the mean of three 
independent experiments. *p<0.05.  
 
 
6.3.5 Histone marks H3K4Me3 and H3K4Me2 change on ST3Gal-I 
promoter region after TPA treatment. 
 
Histones are responsible for the structure of chromatin, since the DNA is wound around 
them, forming nucleosomes. There are five classes of histones: H1/H5, H2A, H2B, H3, 
and H4. H1 and H5 are the linker histones while H2A, H2B, H3 and H4 are known as 
the core histones since they form the nucleosome core (two H2A-H2B dimers and a H3-
H4 tetramer). Dependent upon the post-translation modifications of histones, chromatin 
can be condensed or more open and this will influence the expression of genes.  
Histones undergo a number of posttranslational modifications and this includes lysine 
methylation, arginine methylation, lysine acetylation, serine/threonine/tyrosine 
phosphorylation and even glycosylation (O-GlcNAc). Among the lysine methylation, 
trimethylation and dimethylation of H3 on lysine 4 (H3K4Me3), within promoter regions, 
are associated with active transcription. The H3K4Me3 mark sits near the 
transcriptional start site of many promoters, very close to polymerase II and TFIID 
(transcription factor II D that binds the TATA box in the promoter gene) sites 
(Heintzman et al. 2007).  
The methyl marks on H3K4 on the promoter of the ST3Gal-I gene was, therefore, 
investigated after transcription was induced by TPA, using ChIP Real Time PCR (RT-
qPCR). ChIP is defined as Chromatin Immuno-Precipitation and it is a method to 
examine in vivo protein-DNA interactions with transcription factors, modified histones 
and other nuclear factors. ChIP-qPCR is Chromatin Immunoprecipitation with qPCR 
detection and quantification. Using the dataset http://genome.ucsc.edu/ENCODE/, we 
were able to confirm the presence of H3K4Me3 sites around the transcriptional start site 
of ST3Gal-I and primers were designed. GAPDH was used as a positive control and the 
primers were provided by Qiagen in their  Epitect ChIP assay kit. Ten million MDA-MB-
231 cells were treated for 5 hours with 10 nM TPA. The chromatin was extracted and 
immunoprecipitated with antibodies to H3K4Me2 and H3K4Me3, as described in 
material and methods. To determine any change in the H3K4Me3 and Me2 marks, the 
results, obtained from qPCR of the chromatin immunoprecipitate with antibodies to 
H3K4Me3 or Me2, were normalized to the input results and the result with the IgG 
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control antibody deducted. In table 6.1, the Cts of the input, treated and not treated with 
TPA, was subtracted from the Cts of the immunoprecipitated chromatin treated and 
untreated with TPA respectively. These values were then normalized against the IgG 
ΔCts and these values were then converted to 2 −ΔΔ
Cts. 
The results obtained were totally unexpected (see figure 6.11). The H3K4Me3 and Me2 
marks on ST3Gal-I promoter both decreased after TPA treatment. However, the 
H3K4Me3 and Me2 marks on GAPDH, used as a positive control, decreased as well. 
Unexpectively, the H3K4Me2 and H3K4Me3 marks of active transcription decreased by 
5 fold on the ST3Gal-I promoter after TPA treatment, when ST3Gal-I transcription 
increased. The experiment was repeated, but the same result was obtained. Additional 
positive controls should be used to confirm that the decrease of the histone marks 
expression is not happening to all the control genes within the cell due to the action of 
TPA. 
 
Table 6.1: H3K4Me3 and Me2 decreased after TPA treatment. The sixth row is the fold 












































Ct ∆Ct ∆∆Ct Fold Enrichment
(Ct[IP]-Ct[InputxDF]) (∆Ct[IP]-∆Ct[NIS]) (2-∆∆Ct)
ST3Gal-I Input TPA(-) 30.22
Input TPA(+) 31.16
IgG TPA(-) 36.85 13.27
IgG TPA(+) 35.58 11.07
H3K4Me2 TPA(-) 26.70 3.12 -10.2 1141.5
H3K4Me2 TPA(+) 27.69 3.18 -7.9 237.3
H3K4Me3 TPA(-) 28.65 5.07 -8.2 295.3
H3K4Me3 TPA(+) 29.66 5.14 -5.9 60.6
GAPDH Input TPA(-) 29.37
Input TPA(+) 30.35
IgG TPA(-) 36.06 13.33
IgG TPA(+) 33.88 10.17
H3K4Me2 TPA(-) 26.22 3.49 -9.8 916.5
H3K4Me2 TPA(+) 27.13 3.42 -6.8 107.6
H3K4Me3 TPA(-) 27.59 4.86 -8.5 354.6
H3K4Me3 TPA(+) 28.52 4.81 -5.4 41.1
Samples
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TPA. Ten million MDA-MB-231 cells were treated for 5 hours with 10 nM TPA and the chromatin 
extracted and immunoprecipitated according to materials and methods. H3K4Me3 and Me3 are 






The aim of this chapter was to investigate the downstream pathways involved in 
ST3Gal-I induction after TPA or PGE2 treatment. The results showed that inhibition of 
different isoforms of PKCs leads to inhibition of the TPA and PGE2 effect on ST3Gal-I. 
On the other hand, ERK signalling and the transcription factor CREB do not seem to be 
involved in ST3Gal-I induction.  
TPA is a well known phorbol esther that binds specifically PKC and therefore triggers 
numerous pathway. Activated PKC isoforms generally transduce through either protein 
kinases (MAPK) pathways, usually p44/42 MAPK and c-Jun NH2-terminal kinase (JNK) 
and p38, or via MAPK-independent pathways, for example the phosphatidylinositol 3-
kinase (PI3-kinase). Downstream targets of phorbol esters can be transcription factors, 
such as AP-1, CREB, nuclear factor (NF)κ-B, or Sp1 (Chio et al. 2004). As expected, 
TPA treatment of MDA-MB-231 for 5 minutes triggered the phosphorylation of different 
transcription factors like ERK and CREB, but also FAK. The possible influence of ERK 
and CREB was further studied. However, treatment of MDA-MB-231 with EGF, which 
induces signaling of EGFR and activation of ERK, did not increase ST3Gal-I mRNA, 
suggesting that ERK is not involved in stimulating ST3Gal-I expression. 
PGE2 (the production of which can be increased by TPA) can bind to four receptors 
(EP): EP1 is a Gq coupled receptor with phospholipase C signalling through Ca2+; EP2 
and EP4 are Gs coupled receptors to protein kinase A (PKA) signaling through elevation 
of cAMP level; EP3 is mainly a coupled Gi protein and is linked to a decrease of cAMP. 
Thus, the two possible pathways, that can be trigerred, are PKA or PKC. Forskolin was 
used to activate the PKA pathway and consequently activate CREB, but no effect was 
obtained on ST3Gal-I expression. 
Chen et al. showed that Lith-O-Asp, an inhibitor of different sialyltransferases, including 
ST3Gal-I, suppressed cancer cell metastasis and one of the mechanism involved was 
by inhibiting FAK/paxillin signalling. Lith-O-Asp decreased the ST3Gal-I protein level by 
20% to 25%, inhibited migration and invasion abilities in the lung cancer cells H1299, 
CL1-5, and A549 cells and it delayed cancer cell metastasis in experimental metastasis 
assays in animal models. Importantly, Lith-O-Asp decreased the expression of 
phospho-FAK and phospho-paxillin in the lung cancer cell lines, H1299, CL1-5, and 
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A549. Inhibition of FAK activity and transwell invasion ability were similar in ST3Gal-I 
knocked down and Lith-O-Asp–treated cells (Chen et al. 2011). However, our study did 
not focus on the interaction of ST3Gal-I and FAK. 
The possible role of histone marks on ST3Gal-I expression was also investigated. 
H3K4Me3 and H3K4Me2 are associated with active transcription, so, since TPA 
induced ST3Gal-I over expression, we expected an enrichment of histone marks on the 
TSS of ST3Gal-I gene. Unfortunately, the result obtained was totally the opposite: 
H3K4Me3 and Me2, marks associated with active transcription, decreased on the 
ST3Gal-I transcription start site after TPA treatment. These histone marks also 
decreased on GAPDH. Freyschuss et al. reported that TPA can vary GAPDH level of 
expression (Freyschuss et al. 1994), so the choice of this gene was not advantageous. 
It would be interesting to look at other genes and to see if they change after TPA 
treatment. Moreover, cells were treated only for 5 hours, so, additional time points are 
needed to see any possible variation in histone marks. Until these further investigations 
will been done, we cannot draw any conclusion.  
As discussed in section 1.6.4, the promoter of ST3Gal-I has not been widely studied. 
Taniguchi et al. found the transcription factor binding sites for Sp1 and USF1 on the 
promoter of ST3Gal-I (Taniguchi et al. 2001). Higai et al. suggested the involvement of 
NF-κb in ST3Gal-I expression, since NF-κb knockdown, in two human colon 
adenocarcinoma cell line and one leukaemia cell line, inhibited the increase of ST3Gal-I 
expression after TNF-α treatment (Higai et al. 2006).  
PKC inhibition reverted the TPA or PGE2 induction of ST3Gal-I in MDA-MB-231 and 
T47D. TPA binds directly PKC, so, the effect of PKC inhibitors on ST3Gal-I was 
expected after TPA treatment in MDA-MB-231, but not after PGE2 treatment in T47D. 
PGE2 can trigger PKC via EP1 and EP3. According to our results of chapter 3, EP1 and 
EP3 are the receptors not certainly expressed by T47D. However, Barclay et al. 
demonstrated that T47D cell line expresses the EP3 receptor, but not the EP1 (Barclay 
et al. 2007). Further investigation on the role of the EP (PGE2) receptors on ST3Gal-I 
will be needed to define PGE2 role in glycosylation. Moreover, it would be interesting to 
find out the specific PKC isoforms involved in ST3Gal-I expression. 
To our knowledge this is the first study investigating the interaction between PKC and 
ST3Gal-I in breast cancer. In the last years it has been established that PKC 
isoenzymes are important in cell proliferation, migration, adhesion, and cancer cell 
metastasis and different isoforms expression are altered in various types of cancers 
(Schmitz et al. 2000). Also, some PKC inhibitors have been developed with significant 
anti-cancer activity, so, correlation of ST3Gal-I with PKC can be considered as a 
possible coadjuvant to PKC inhibitors in the cure and prevention of breast cancer.  



























Chapter 7. Summary of results and conclusion. 
 
To our knowledge, this is the first study investigating the interaction between COX-2, 
ST3Gal-I and C2GnT1 in breast cancer.  
We have shown that in two breast cancer cell lines, T47D and MDA-MB-231, 
transcription of ST3Gal-I is increased by COX-2 via PGE2. In T47D cells, PGE2 could 
induce expression of ST3Gal-I mRNA, but not in MDA-MB-231 cells. TPA, which 
induces COX-2 expression among its many effects, could also induce mRNA 
expression of ST3Gal-I in MDA-MB-231, but not in T47D cells. Investigation of the 
PGE2 receptors in MDA-MB-231 and T47D has shown that T47D expressed EP2 and 
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EP4 and MDA-MB-231 expressed the EP4 receptor, but extremely low levels of EP2. EP2 
and EP4 differ in their sensitivity to PGE2. EP4 is desensitized after short-term exposure 
to PGE2 and this, coupled with the rapid metabolism of PGE2 (Nishigaki et al. 1996), 
may explain the lack of response to exogenous PGE2 of MDA-MB-231 cells. On the 
other hand, TPA only induced COX-2 overexpression in MDA-MB-231, the only cell line 
with the highest amount of COX-2 compared to the other breast cancer cell lines. 
In both cell lines, induction of ST3Gal-I mRNA has led to increased activity of this 
sialyltransferase, as demonstrated by decreased binding of the lectin PNA (which binds 
to the substrate of ST3Gal-I -T antigen). Celecoxib inhibited ST3Gal-I activity, since it 
was able to revert the PNA binding. A knock down of COX-2 by 70%, after TPA 
treatment, resulted in a 50% decrease of ST3Gal-I expression. When COX-2 was 
transfected into MDA-MB-231, ST3Gal-I mRNA expression increased by 2 fold. Thus, 
ST3Gal-I expression is affected after silencing and transfection of COX-2. Moreover, it 
was found that there is a significant correlation between COX-2 and ST3Gal-I 
expression in primary breast cancers, indicating that our findings have clinical 
significance (Sproviero et al. 2012).  
Dendritic cells (DCs) are the most potent APC (antigen presenting cells) in the 
organism. The model that dendritic cell (DC) “maturation” describes the change from an 
immature, antigen-capturing cell to a mature, antigen-presenting cell is well-established. 
Dendritic cells (DC) migrate from the tissue to the lymph nodes during “maturation” and 
this process describes the change from an immature, antigen-capturing cell, to a 
mature, antigen presenting cell (Tan & O’Neill, 2005). Mature DCs are responsible for 
antigen presentation and stimulation of T cells. Bax et al. and Julien et al. showed that, 
when monocyte derived dendritic cells are induced to mature, the composition of their 
O-linked glycans changes in a way that mirrors the change in breast cancer: mature 
dendritic cells showed an up-regulation of the glycosyltransferases involved in the 
expression of core 1 and sialylated structures (upregulation of ST3Gal-I) and a down-
regulation of genes involved in the synthesis of core 2 O-glycans (down-regulation of 
C2GnT1)  (Julien et al. 2007, Bax et al. 2003). This is similar to the change seen in 
breast cancer cells. 
As said in the introduction, DCs express C-type lectins (CLR), like DC-SIGN, MGL and 
dectin-1.  Several carbohydrate structures (such as Tn, sialyl Tn, T (Thomsen-
Friedenreich disaccharide), (sialylated) Lewis antigens) are highly upregulated in 
tumour cells and have been widely used as diagnostic and prognostic markers. Tn 
epitopes on MUC-1 is associated with poor prognosis in several types of cancer 
(Hakomori, 2002). Tn glycans on MUC-1 bind MGL on iDC (immature dendritic cells)  
and induce a Th2-mediated responses, which, unlike Th1, do not contribute to tumor 
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eradication (Aarnoudse et al. 2006, Saeland et al. 2007). MGL expressed on iDCs is an 
optimal receptor for the internalization of short GalNAcs, carrying immunogens to be 
delivered into HLA class I and II compartments. For this reason MGL-Tn-MUC1 has 
possible implications in designing cancer vaccines (Napoletano et al. 2007). 
During maturation of DCs, often loss of CLR expression occurs (Figdor et al. 2002). 
Interestingly, it was noticed that during dendritic cells maturation there was up-
regulation of sialic acid expression by mDC, correlated with an increased binding of 
siglec-1, -2, and -7 (Bax et al. 2007). The metastatic potential of some tumor cells has 
been correlated with increased sialylation of cell surface glycoproteins and 
consequently with an increase of sialic acid-binding lectins, such as selectins that 
mediate cell adhesion and extravasation during the metastatic process (Passaniti & 
Hart, 1988, Varki NM & Varki A., 2007, Babál et al. 2006). 
The change of glycosylation that occurs during the maturation of DCs may increase the 
efficacy of DCs migration and possibly of breast cancer cells. 
Julien et al. showed that in dendritic cells prostaglandin E2 alone was sufficient to 
induce the upregulation of ST3Gal-I and the down regulation of C2GnT1 (Julien et al. 
2009). Moreover, it was shown that PGE2 can induce the expression of CCR7 in breast 
cancer cell lines and that expression of this cytokine receptor is associated with lymph 
node metastasis (Pan et al. 2008). We demonstrated that PGE2 and TPA can change 
the glycosylation of the breast cancer cell lines T47D and MDA-MB-231, so there is a 
real possibility that the change of glycosylation that occurs in dendritic cells and in 
breast cancer cells is responsible for the migration from the tissue to the lymph nodes 
and is central in metastasis.  
 
Glycosylation is one of the most frequent form of posttranslation modifications and is 
essential for many protein and cellular functions. Changes in glycosylation are common 
events in malignancy and these changes can affect the course of the disease, since 
they play a key role in the induction of invasion, metastasis and tumorigenesis 
(Hakomori et al. 2002, Mungul et al. 2004, Julien, Ivetic ,Grigoriadis, QiZe, Burford, 
Sproviero et al. 2011). 
In breast cancer overexpression of ST3Gal-I leads to the overexpression of truncated 
sialylated glycans, which could change the immune response and allow the progression 
of cancer. Picco et al. showed that over-expressing ST3Gal-I in the mammary gland 
promotes the early development of spontaneous mammary tumours in a murine model 
(Picco et al. 2010).  
ST3Gal-I revealed essential roles in immune system homeostasis. Van Dyken 
demonstrated that deletion of the ST3Gal-I locus yields unsialylated core 1 O-glycans, 
	   151 
which were found to be associated with increased CD8+ T cell apoptosis (Van Dyken et 
al. 2007). Moreover Moody et al. showed that sialic acid addition to core1 of mature 
CD8 single-positive thymocytes decreases CD8 binding to MHCI (Moody et al. 2001). 
Hence, sialylation of cell surface glycoproteins can control the immune cell 
responsiveness or tolerance (Daniels et al. 2002).  
Until now, very little has been known about the control of expression of ST3Gal-I in 
breast cancer cells. Analysis of the promoter region of ST3Gal-I identified binding sites 
for the transcription factors SP1, USF, NF-kB (Taniguchi et al. 2001, Higai et al. 2006). 
We have shown that increased expression of ST3Gal-I in breast cancer cells can be 
induced by COX-2 through PGE2. Further studies will be required to demonstrate the 
transcription factors involved. 
COX-2 is induced by inflammation and is turned on in many cancers. Increased 
expression of COX-2 has been reported in colon, bladder and breast cancers,  (Legler 
et al. 2006, Eltze et al. 2005, Ristimaki et al. 2002), the same cancers that overexpress 
ST3Gal-I. It would be interesting to measure the expression of ST3Gal-I in tumours 
from the patients on the Clinical trials investigating the efficacy of the selective COX-2 
inhibitor, celecoxib, and seeing if the outcome of the patients that express high levels of 
ST3Gal-I, differs from the patients expressing moderate or lower levels. 
The results described in this thesis suggest that COX-2 could affect the glycosylation of 
tumour cells, increasing the tumorigenesis and metastasis. Recent efforts have 
highlighted essential roles of glycan-binding proteins or lectins (galectins, C-type lectins 
and siglecs) in cancer, metastasis, host-pathogen interactions, initiation of innate 
immunity. This has created interest in its potential biotechnological and pharmaceutical 
applications. Knowing that COX-2, target of well established NSAIDs, can control the 
expression of ST3Gal-I, it opens up the possibility of designing new drugs.  
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